

OM of: US-10-031-904-8 to: N_Geneseq_032802.* out_format: pfs

Date: Oct 9, 2002 6:42 PM

About: Results were produced by the GenCore software, version 4.5,
Copyright (c) 1993-2000 CompuGen Ltd.

Command line parameters:

-MODE=frame+model -DEV=xlh
-Q=/cgn2_1/USPPO_Spool/US10031904/runat_09102002_084257_23681/app-query.fasta_1.232
-DB=N_Geneseq_032802 -QFWT=fastcap -SUFFIX=p2n.rng -GAPOP=12.000
-GAPEXT=4.000 -MINMATCH=0.100 -LOOPCL=0.000 -LOOPEXT=0.000
-GAPOP=6.000 -GAPEXT=0.050 -GAPOP=10.000 -XGAPEXT=0.500
-FGAPOP=6.000 -DELEXT=7.000 -STAR=1 -MATRIX=blom62
-TRANS=human10.cdi -LIST=45 -DOCLIGN=200 -THR_SCORE=pct
-THR_MAX=100 -THR_MIN=0 -ALIGN=15 -MODE=LOCAL -OUTFWT=pfs
-NORM_ext -HEAPSIZE=500 -MINLEN=0 -MAXLEN=200000000
-USER=US10031904 -CGN1_1.481 -NCPU=6 -ICPU=3 -LONGLOC
-DEV_TIMEOUT=120 -WARN_TIMEOUT=30 -NO_XLPHY -WAIT -THREADS=1

Search information block:

Query: US-10-031-904-8
Query length: 174
Database: N_Geneseq_032802.*
Database sequences: 176436
Database length: 858457221
Search time (sec): 175.470000

Score_list:

Sequence	Strd Orig	ZScore	Escore	len	Documentation
/SIDSI/gcgdata/geneseq/geneseqn-emb1/NA2001A.DAT:AAFS6602 +	946.00	1870.05	8.2e-96	6	
/SIDSI/gcgdata/geneseq/geneseqn-emb1/NA2001B.DAT:AAFS64474 +	649.50	1253.09	1.9e-61	7	
/SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1989.DAT:AAV91477 +	649.50	1252.37	2.1e-61	69	
/SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1991.DAT:AAQ11642 +	649.50	1252.37	2.1e-61	69	
/SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1999.DAT:AAZ38150 +	649.50	1251.82	2.2e-61	7	
/SIDSI/gcgdata/geneseq/geneseqn-emb1/NA2001A.DAT:AAQ09026 +	636.50	1226.31	5.9e-60	7	
/SIDSI/gcgdata/geneseq/geneseqn-emb1/NA2001A.DAT:AAI60166 +	635.00	1220.09	2.8e-61	59	
/SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1998.DAT:AAV53262 +	635.00	1250.09	2.8e-61	59	
/SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1998.DAT:AAV53269 +	635.00	1250.09	2.8e-61	59	
/SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1998.DAT:AAV53270 +	635.00	1250.09	2.8e-61	59	
/SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1998.DAT:AAV53271 +	635.00	1250.09	2.8e-61	59	
/SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1998.DAT:AAV53272 +	635.00	1250.09	2.8e-61	59	
/SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1998.DAT:AAV53273 +	635.00	1250.09	2.8e-61	59	
/SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1993.DAT:AAQ41867 +	513.00	989.83	8.7e-47	2	
/SIDSI/gcgdata/geneseq/geneseqn-emb1/NA2001B.DAT:AAFS64473 +	487.00	937.94	5.8e-44	2	
/SIDSI/gcgdata/geneseq/geneseqn-emb1/NA2001B.DAT:AAFS64289 +	456.00	867.39	5.8e-40	2	
/SIDSI/gcgdata/geneseq/geneseqn-emb1/NA2001B.DAT:AAFS64290 +	442.00	840.99	1.7e-38	54	
/SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1991.DAT:AAO11643 +	442.00	840.99	1.7e-38	54	
/SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1999.DAT:AAZ38151 +	380.00	592.31	2.0e-22	11	
/SIDSI/gcgdata/geneseq/geneseqn-emb1/NA2001A.DAT:AAO11504 +	289.00	552.59	2.0e-22	11	
/SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1996.DAT:AAI17595 +	289.00	552.59	2.0e-22	11	
/SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1996.DAT:AAI17597 +	289.00	551.59	2.2e-22	12	
/SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1991.DAT:AAO14919 +	289.00	549.74	2.8e-22	14	
/SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1997.DAT:AAI90306 +	289.00	549.36	3.0e-22	15	
/SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1995.DAT:AAO93106 +	289.00	549.36	3.0e-22	15	
/SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1995.DAT:AAO103339 +	289.00	549.24	3.0e-22	15	
/SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1991.DAT:AAO10864 +	289.00	548.88	3.0e-22	16	
/SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1991.DAT:AAO14915 +	289.00	547.31	3.9e-22	1	
/SIDSI/gcgdata/geneseq/geneseqn-emb1/NA2001A.DAT:AAO20355 +	289.00	547.31	3.9e-22	1	
/SIDSI/gcgdata/geneseq/geneseqn-emb1/NA2001A.DAT:AAO20370 +	289.00	547.14	4.0e-22	18	
/SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1996.DAT:AAI46065 +	289.00	546.51	4.3e-22	19	
/SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1991.DAT:AAO14919 +	289.00	541.04	8.7e-22	3	
/SIDSI/gcgdata/geneseq/geneseqn-emb1/NA2001A.DAT:AAI83433 +	289.00	541.04	8.7e-22	3	
/SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1996.DAT:AAI18270 +	287.00	538.60	3.3e-22	11	
/SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1996.DAT:AAI17596 +	287.00	538.60	3.3e-22	11	
/SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1999.DAT:AAV08935 +	272.50	519.55	1.4e-20	17	
/SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1999.DAT:AAV08935 +	272.50	516.69	3.0e-20	14	
/SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1987.DAT:AAV08935 +	272.50	513.45	3.0e-20	20	

/SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1999.DAT:AAV87914 + 272.50 513.00 3.2e-20
/SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1989.DAT:AAV91043 + 272.50 512.93 3.2e-20
/SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1995.DAT:AAQ79863 + 272.50 512.93 3.2e-20
/SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1987.DAT:AAV00048 + 272.50 512.34 3.4e-20
/SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1989.DAT:AAV91044 + 272.50 512.34 3.4e-20

seq_name: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA2001A.DAT:AAFS6602

seq_documentation_block:

ID AAF58602 standard; cDNA: 627 BP.

AAFS6602;

24-APR-2001 (first entry)

Human RECAP polynucleotide, SEQ ID NO: 30.

Human; RECAP: receptors and associated proteins; cerebroprotective;

neurotrophic; neuroprotective; anticonvulsant; antiparkinsonian; anti-HIV;

antidiabetic; immunostimulant; immunomodulator; anti-inflammatory;

antithyroid; immunosuppressive; nephrotropic; antigout; thyromimetic;

cytostatic; antibacterial; virucide; fungicide; protozoacide;

antiartherosclerotic; hepatotropic; gene therapy; infection; cancer; ss.

Homo sapiens.

WO200107612-A2.

01-FEB-2001.

21-JUL-2000; 2000MO-US20035.

21-JUL-1999; 99US-0145232.

07-OCT-1999; 99US-0138578.

12-NOV-1999; 99US-0165192.

(INCY-) INCYTE GENOMICS INC.

An-Young J, Bandman O, Tang YT, Yue H, Azimzal Y, Burford N;

Baughn MR, Lu DM, Hillman JL, Patterson C, Lal P;

WPI: 2001-168554/17.

P-PSDB; AAB8878.

Novel receptors and associated proteins for diagnosis and treatment of

neurological disorders, immunological disorders including autoimmune/

inflammatory disorders and cell proliferative disorders such as cancer

-

Claim 5: Page 120; 128pp. English.

The present sequence encodes a human RECAP (receptors and associated

proteins) polypeptide. RECAP polynucleotides and polypeptides are useful

in the diagnosis, treatment and prevention of neurological disorders

such as stroke, Alzheimer's disease, Pick's disease, Huntington's

disease, dementia, Parkinson's disease, Down's syndrome, amyotrophic

lateral sclerosis, multiple sclerosis, bacterial and viral meningitis,

CJD (Creutzfeldt-Jakob disease), GSS (Gerstmann-Strausner-Scheinker

syndrome), immunological disorders, including autoimmune/inflammatory

disorders such as AIDS, Digeorge's syndrome, severe combined

immunodeficiency disease (SCID), Chediak-Higashi syndrome, Cushing's

disease, Addison's disease, autoimmune thyroiditis, Crohn's disease,

diabetes mellitus, Good pasture's syndrome, gout, Grave's disease,

Hashimoto's thyroiditis, Sjogren's syndrome, Werner's syndrome, viral,

bacterial, fungal, parasitic, protozoal, and helminthic infections; and

cell proliferation disorders such as arteriosclerosis, atherosclerosis,

celiacitis, hepatitis and cancer.

Sequence 627 BP; 142 A; 173 C; 128 G; 184 T; 0 other;

alignment_scores: Quality: 946.00 Length: 174

```

Percent Similarity: 100.000      Gaps: 0
Ratio: 5.437
Percent Identity: 100.000
Alignment block:
US-10-031-904-8 x AAF58602  ..

Align seg 1/1  to: AAF58602  from: 1  to: 627

1  MetaLabProVal1ArgLeuGlnArgProPheSerArgPhePr 17
|||||
87  ATGGCGGCTCCCGTCCGCTCCAGCGGTCCCTTCCCTCCGCGGCTTTC 136
|||||
17  OG1LeuLeuLeuAlaLeuValLeuLeuLeuSerSerPheSerAsp 34
|||||
137  TGGGTCTCTTCTGGCGGCGCTGCTGTCTCTCTCTCTCTCTCTCTCGAATC 186
|||||
34  IncysaenValProGluTrpLeuProPheAlaArgProThrAsnLeuThr 50
|||||
187  AATCAATATGTCGGAGATGGCTTCATTTGGCAAGCCTTACCAACTTAAT 236
|||||
51  AspaSpheGluPheProIleGlyThrThrLeuAsnArgIleLucySarpr 67
|||||
237  GATGACTTTGAGTTTCCATTTGGGACATCTGAATCTGAATGAATGAGCGGCC 286
|||||
67  OG1TyrSerGlyArgProPheSerIleIleCysLeuLeuAsnSerValT 84
|||||
287  TGGTTATTCGGAGAGACCTTTTTCATCATCTGCTTAAATACTCAAGTCT 336
|||||
84  rprhrSerAlaLysAspLysCysLysArgLysSerCysArgAsnProPro 100
|||||
337  GGAACTGCTAAAGGCAAGTCCAAAGCTAATATCATGTCTTAATCTCTCA 386
|||||
101  AspProValAsnGlyMetaIahIleValIleLysAspIleGlnPheGlySe 117
|||||
387  GATCTCTGTGATGGCATGGCACATCATGTGATCAAAAGCATTCACAGTTCGATC 436
|||||
117  rGllIleLysTyrSerCysProLysGlyTyrArgLeuIleGlySerSerS 134
|||||
437  CCAATTAATATATTCTTGTCCTTAAAGGATACCGACATCATGTTCTCTGCT 486
|||||
134  eraIahTrCysIleIleSerGlyAsnThrValIleTrpAspAsnLysThr 150
|||||
487  CTGGCAATGATCATCATCTAGGACACACTGTCAATTTGGGATATTAAMAACA 536
|||||
151  ProValCysAspSerGluLeuLysTyrAlaPheLeuPheLeuLeuProI1 167
|||||
537  CCGTGTGTGACAGTGAAGTTGAATATCATTCCTATTCTTTTACCAGT 586
|||||
167  ehIserAspPheSerLeuGln 174
|||||
587  ACATTCATATTTTCTCTGGAG 608
|||||

seq_name: /stids1/gcgdata/geneseq/geneseq-emb1/NA001B.DAT:AA564474
doc_id: 1
documentation_block:
ID  AA564474  standard; cDNA; 7821 BP.
XX
XX  AA564474;
XX
13-FEB-2002  (first entry)
XX
DNA encoding novel human diagnostic protein #278.
XX
Human; chromosome mapping; gene mapping; gene therapy; forensic;
XX  food supplement; medical imaging; diagnostic; genetic disorder; ss
OS  Homo sapiens.
XX
XX  WO200175067-A2.
XX
11-OCT-2001.
XX
30-MAR-2001; 2001WO-US08631.
XX

```

XX PR 31-MAR-2000; 2000US-0540217.
PR 23-AUG-2000; 2000US-0649167.
XX PA (HYSE-) HYSBO INC.
XX PI Drmanac RT, Liu C, Tang YT;
XX DR WPI, 2001-639362/73.
XX P-PDB: ABG00287.

New isolated polynucleotide and encoded polypeptides, useful in diagnostics, forensics, gene mapping, identification of mutations responsible for genetic disorders or other traits and to assess biodiversity -

PS Claim 1; SEQ ID No 278; 103pp; English.
XX
XX
CC The invention relates to isolated polynucleotide (I) and
CC polypeptide (II) sequences. (I) is useful as hybridisation probes,
CC polymerase chain reaction (PCR) primers, oligomers, and for chromosome
CC and gene mapping, and in recombinant production of (II). The
CC polynucleotides are also used in diagnostics as expressed sequence tags
CC for identifying expressed genes. (I) is useful in gene therapy technique
CC to restore normal activity of (II) or to treat disease states involving
CC (II). (II) is useful for generating antibodies against it, detecting or
CC quantitating a polypeptide in tissue, as molecular weight markers and as
CC a food supplement. (II) and its binding partners are useful in medical
CC imaging of sites expressing (II). (I) and (II) are useful for treating
CC disorders involving aberrant protein expression or biological activity.
CC The polypeptide and polynucleotide sequences have applications in
CC diagnostics, forensics, gene mapping, identification of mutations
CC responsible for genetic disorders or other traits to assess biodiversity
CC and to produce other types of data and products dependent on DNA and
CC amino acid sequences. AAS64197-AA934564 represent novel human
CC diagnostic coding sequences of the invention.
CC Note: The sequence data for this patent did not appear in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences.
XX
XX Sequence 7821 BP; 1986 A; 1904 C; 1883 G; 2046 T; 2 other;

```

Alignment_scores:                                Length:      149
          Quality:    650.50                      Gaps:        2
          Ratio:     4.854                          Percent Identity: 81.208
Percent Similarity:   89.933

```

alignment_block:
US-10-031-904-8 x AAS64474 ..

Align seg 1/1 to: AAS64474 From: 1 to: 7821

9	AATProPheProSerArGrPh.....	ProGlyLeuLeuAlaLl 23
:	: :	: :
497	CAGCGGGGCCGCCTCCCCCTTCGTGCGAGAGAANCCCTGTCGGCCT	546
23	aLeuValleuLeu..LeuSerSerPheSArgInCysAsnValPrOG 39	
:	::::: :	: :: :
547	GCTGTCTCTCTCGCGCTCGGTGGCTTGGGGCAATGAACAAAGCCCACG 596	
39	IutPrLeuProPheAlaArGrProThrAsnLeuThrAsPaSPheGlupHe 55	
597	AATGGCTTCCATTGGCCAGGCTACCAACAATACTATGATGATTTGAGTTT 646	
56	ProlieclYthrTyrlleuasntyrClucyArgrProgLyISerClYar 72	
:	:	: :
647	CCCATTTGGACATATCTGAATGAATGAACGCCCGCTGATTATTCGGAGG 696	
72	gPropheSerlleleCyLeuLyAsnSerValTrpThSerAlatylSA 89	
:	:	: :
697	ACCSTTTTATCATCTGCCTAAAAAATCAGTGTGACTGGTGCTAAGG 746	


```

320 3693CAGACGCTAAATATATGTGTATATCTCTCCAAATCTCTGTGATGGCATG 3692
90 yscYslsYsArGlySerCYsArGAsnProProAspProValAsnGlyMet 1066
270 GTTTCATCATATCTGCTATAAAACTAGTCTGAGCTAGGTGTAAAGGCA 3193
73 oPhSeTleIleCYsLeuLYsAsnSerValTTrpThrSerAlaIysAspL 90
220 ATTGGGCAATATCTACATATGATGCGCCGCTGGTATTATCCGAGAGACC 265
57 lIeIlyThyTleuAsnTrpGluCYsArGProGlyTYrSerGlyArgP 73
170 GGCATTCATTGGCAGGCGCTACCAACTACTATGAGTTAGATTGCC 219
40 rPleuProPheAlaArGProPheAsnLeuThrAspAspHeIuPhePro 56
120 GGTCTCTCTTGCCCTCCGCGTGGCGCTGGGGTCAATGCATGCCCCAGAT 169
24 uValIleLeu...LeuSerSerPheSerAspGlyGlyCysAsnValProGlyT 40
10 ProPheProSerTrpArgPhe.....ProGlyLeuLeuLeuAlaIle 24
70 CCGGCGCCGCGGTCTCCCTCTTCGTGCGGAGAGACCCCTCTGCGGCTGTCT 116

```

sequence 09-

[illegible]

Sequence 6951 BP; 1802 A; 1680 C; 1661 G; 1808 T; 0 other;

alignment_scores:
 Quality: 649.50 Length: 148
 Ratio: 4.883 Gaps: 2
 Percent Similarity: 89.865 Percent Identity: 81.757

alignment_block:
 US-10-031-904-8 x AA158380

Align seg 1/1 to: AA158380 from: 1 to: 6951

```

10 ProPheProSerArgArgPhe.....ProGlyLeuLeuLeuAlaLale 24
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
70 CCGGCGCCCGGCTCCCTTCTGCTGCGGAGAGATCCCTGCTGCGGTTGT 119
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
24 uValLeuLeu...LeuSerSerPheSerAspGlnCysAsnValProGluT 40
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
120 GGTGCTGCTTGGCTGCGGCTGCGGCTGCGGCTGCGGCTGCGGCTGCGG 169
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
40 rPLeuProPheAlaArgProThrAsnLeuThrAspAspPheGluPhePro 56
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
170 GGTTCATCATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 219
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
57 lIleGlyThrTyrLeuAsnTyrGlnCysArgProGlyTyrSerGlyArgPr 73
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
220 ATGGGACATATCTGAAATGAAATGAAATGAAATGAAATGAAATGAAATG 269
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
73 oPheSerTlelleCysLeuLysAsnSerValTPrPThrSerAlaLysAspL 90
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
270 GTTTCATCATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 319
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
90 yAcGlyAsnArgLysSerCysArgAsnProProAspProValAsnGlyMet 106
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
320 GGTGAGACGTAATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 369
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
107 AlaHisValIleLysAspIleGlnPheGlySerGlnIleLysTyrSerCy 123
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
370 GGTGATGATGATCAAGCATCAAGCATCAAGCATCAAGCATCAAGCATCA 419
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
123 sProlGlyTyrArgLeuIleGlySerSerSerAlaThrCysIleIle 140
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
420 TACTTAAGATACCGACTCATGTTGCTGCTGCTGCTGCTGCTGCTGCTG 469
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
140 eRGLAsnThrValIleTPrPAspAsnLysThrProValCysAsp 154
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
470 CAGGTGATGATGATCAATGATGATGATGATGATGATGATGATGATGAT 513
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

```

seq_name: /SIDSL/gcgdata/geneseg/genesegn-emb1/NM2001A.DAT:AA158380

seq_documentation_block:

ID AA158380 standard; CDNA; 7313 BP.

AA158380;

22-OCT-2001 (first entry)

Human polynucleotide SEQ ID NO 583.

Human; nocotropic; immunosuppressant; cytostatic; gene therapy; cancer;
 Peripheral nervous system; neuropathy; central nervous system; CNS;
 Alzheimer's; Parkinson's disease; Huntington's disease; haemostatic;
 amyotrophic lateral sclerosis; Shy-Drager Syndrome; chemotactic;
 chemokinetic; thrombolytic; drug screening; arthritis; inflammation;
 leukaemia; ss.

OS Homo sapiens.

PN WO200153312-A1.

PD 26-JUL-2001.

PF 26-DEC-2000; 2000WO-US34263.

XX

21-JAN-2000; 2000US-0488725.
 25-APR-2000; 2000US-0552317.
 09-JUL-2000; 2000US-0598042.
 19-JUL-2000; 2000US-0620312.
 03-AUG-2000; 2000US-0653450.
 14-SEP-2000; 2000US-0662191.
 19-OCT-2000; 2000US-0693036.
 29-NOV-2000; 2000US-0727344.
 (HSE-) HYSEQ INC.
 Tang YF, Liu C, Asundi V, Chen R, Ma Y, Qian XB, Ren F, Wang D;
 Wang J, Wang Z, Wehrman T, Xu C, Xue AJ, Yang Y, Zhang J;
 Zhao Q, Zhou P, Georrich R, Demanac RT;
 WPI: 2001-44253/47.
 P-PSDB: AAM39224.

Novel nucleic acids and polypeptides, useful for treating disorders
 such as central nervous system injuries -
 Claim 1; SEQ ID NO 583; 10078bp; English.

The invention relates to human nucleic acids (AA157798-AA161369) and
 the encoded polypeptides (AA38642-AA42213) with nocotropic,
 immunosuppressant and cytostatic activity. The polynucleotides are useful
 in gene therapy. A composition containing a polypeptide or polynucleotide
 of the invention may be used to treat diseases of the peripheral nervous
 system, such as peripheral nervous injuries, peripheral neuropathy and
 localized neuropathies and central nervous system diseases, such as
 Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic
 lateral sclerosis, and Shy-Drager Syndrome. Other uses include the
 utilisation of the activities such as: immune system suppression,
 activation/inhibition activity, chemotactic/chemokinetic activity,
 CC and thrombolytic activity, cancer diagnosis and therapy, drug screening,
 assays for receptor activity, arthritis and inflammation, leukaemia and
 CC, C.N.S disorders.
 Note: The sequence data for this patent did not form part of the printed
 specification.

Sequence 7313 BP; 1903 A; 1770 C; 1733 G; 1907 T; 0 other;

alignment_scores:
 Quality: 649.50 Length: 148
 Ratio: 4.883 Gaps: 2
 Percent Similarity: 89.865 Percent Identity: 81.757

alignment_block:

US-10-031-904-8 x AA158380

Align seg 1/1 to: AA158380 from: 1 to: 7313

```

10 ProPheProSerArgArgPhe.....ProGlyLeuLeuLeuAlaLale 24
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
70 CCGGCGCCCGGCTCCCTTCTGCTGCGGAGAGATCCCTGCTGCGGTTGT 119
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
24 uValLeuLeu...LeuSerSerPheSerAspGlnCysAsnValProGluT 40
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
120 GGTGCTGCTTGGCTGCGGCTGCGGCTGCGGCTGCGGCTGCGGCTGCGG 169
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
40 rPLeuProPheAlaArgProThrAsnLeuThrAspAspPheGluPhePro 56
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
170 GGTTCATCATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 219
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
57 lIleGlyThrTyrLeuAsnTyrGlnCysArgProGlyTyrSerGlyArgPr 73
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
220 ATGGGACATATCTGAAATGAAATGAAATGAAATGAAATGAAATGAAATG 269
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
73 oPheSerTlelleCysLeuLysAsnSerValTPrPThrSerAlaLysAspL 90
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
270 GTTTCATCATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 319
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

```

```

90 yscyslysarqlyssercysarqanproproaspvalalasnlymet 106
   ::::::::::::::::::::::::::::::::::::::::::::::::::::
320 GGTCAACACGTATATCATCTGCTATCTCCATCATCTCTGAAAGGCAATG 369
   ::::::::::::::::::::::::::::::::::::::::::::::::::
107 ALAHISVALLIELYSAPLIEGLNPHGLYSERGLNILELYTYRSERCY 123
   ::::::::::::::::::::::::::::::::::::::::::::::::::
370 GTGCATGTGATCAAGGACATCCAGTTCGGATCCCAATTAATATCTTG 419
   ::::::::::::::::::::::::::::::::::::::::::::::::::
123 SPRLVSGLYTYRARGLEULIEGLYSERSESERALATHRCYSILIELES 140
   ::::::::::::::::::::::::::::::::::::::::::::::::::
420 TACCAAGAGATACGACATCATCTGCTCTGCTGCCACATGACATCACT 469
   ::::::::::::::::::::::::::::::::::::::::::::::::::
140 erglysanthrvalilietrpaspasnlythrprovalcysasp 154
   ::::::::::::::::::::::::::::::::::::::::::::::::::
470 CAGGTGATCTGCTCATTTGGATATATGAAACACCTATTGTGTAC 513

seq_name: /sids1/gcgdata/geneseq/geneseqn-emb1/NA2001A.DAT:ABA09026
seq_documentation_block:
ID   ABA09026 standard; cDNA; 7028 BP.
AC   ABA09026;
XX
XX
XX   11-JAN-2002 (first entry)
XX
XX   Human CR1 protein homologue-encoding cDNA, SRQ ID NO:802.
XX
XX   Human; cytokine; cell proliferation; cell differentiation; growth factor;
XX   haematopoiesis regulation; tissue growth; immunomodulator; activin;
XX   inhibin; chemotaxis; chemokinesis; thrombolysis; oncogenesis;
XX   proliferation; metastasis; cancer; tumour; haemotopoietic disorder;
XX   myeloid cell disorder; lymphoid cell disorder; asthma; arthritis;
XX   chronic inflammatory condition; proliferative retinopathy;
XX   atherosclerosis; coronary heart disease; arterial ischaemia;
XX   bone disorder; osteoporosis; vascular growth disorder;
XX   tissue regeneration; wound healing; infection; immune disorder;
XX   cell culture; drug screening; gene therapy; antiinflammatory;
XX   antiasthmatic; antiarthritis; haemostatic; antiarteriosclerosis;
XX   cytostatic; osteopathic; vasotropic; cardianc; virucide; antibacterial;
XX   antifungal; vulnereary; antituber; ss.
XX
XX   Homo sapiens.
XX
XX   WO200157188-A2.
XX
XX   09-AUG-2001.
XX
XX   05-FEB-2001; 2001WO-0503800.
XX
XX   03-FEB-2000; 2000US-0496914.
XX
XX   27-APR-2000; 2000US-0560875.
XX
XX   (HYSE-) HYSEQ INC.
XX
XX   Tang YF, Liu C, Drmanac RT;
XX
XX   WPI: 2001-457740/49.
XX
XX   P-PSDB: ABB11782.
XX
XX   Human proteins and DNA encoding sequences useful for preventing,
XX   treating or ameliorating a medical condition in a mammalian subject
XX   e.g. arthritis and cancer -
XX
XX   Claim 1; Page 707-709; 1963pp; English.
XX
XX   Sequences ABB10981-ABB12330 represent 1350 novel human polypeptides, and
XX   sequences ABA08225-ABA09574 represent nucleic acids encoding them. The
XX   invention also relates to vectors and recombinant host cells comprising a
XX   nucleotide of the invention, methods of producing the novel polypeptides,
XX   antibodies against the polypeptides, methods of detecting the nucleotides,
XX   or polypeptides in a sample, and methods of identifying compounds which
XX   bind to polypeptides of the invention. Although novel, many of the
XX   polypeptides of the invention have homology to known proteins, thereby

```

```

CC   giving an insight into their probable biological activities, and hence
CC   potential therapeutic applications. The polypeptides of the invention may
CC   have various activities, including cytokine, cell proliferation or cell
CC   differentiation activities; stem cell growth factor activity;
CC   haematopoiesis regulatory activity; tissue growth factor activity;
CC   immunomodulatory activity; activin- or inhibin-related activities;
CC   chemotactic or chemokinetic activities; haemostatic, thrombotic or
CC   thrombolytic activities; receptor or ligand activities; or may be
CC   involved in oncogenesis, cancer cell proliferation or metastasis.
CC   The invention on their biological activities, polypeptides and nucleotides of
CC   conditions, e.g., by protein or gene therapy. Such conditions include
CC   cancers, haematopoietic disorders (e.g., myeloid or lymphoid cell
CC   disorders), chronic inflammatory conditions (e.g., asthma or arthritis),
CC   proliferative retinopathy, atherosclerosis, coronary heart disease,
CC   arterial ischaemia, bone disorders (e.g., osteoporosis), and abnormal
CC   vascular growth. Polypeptides involved with tissue regeneration and
CC   repair (or nucleic acids encoding them) may be used to promote wound
CC   healing (e.g., of burns, incisions and ulcers), while those with
CC   immunomodulatory activities may be used in the treatment of viral,
CC   bacterial and fungal infections in addition to immune disorders.
CC   Polypeptides with growth factor activity may be used in cell cultures to
CC   promote cell growth. For example, such polypeptides may be used to
CC   manipulate stem cells in culture to give rise to neuroepithelial cells
CC   that can be used to augment or replace cells damaged by illness,
CC   autoimmune disease or accidental damage. The polypeptides and nucleotides
CC   may also be used in the diagnosis of the above conditions, and in drug
CC   screening techniques. The present sequence represents a cDNA encoding a
CC   novel human polypeptide of the invention.
XX
XX   SO   Sequence 7028 BP; 1819 A; 1704 C; 1681 G; 1824 T; 0 other;

```

```

alignment_scores:
Quality: 636.50      Length: 149
Percent Similarity: 4.786      Gaps: 3
Percent Identity: 89.262      Percent Identity: 81.208

```

alignment_block:

US-10-031-904-8 x ABA09026 ..

Align seg 1/1 to: ABA09026 from: 1 to: 7028

```

10 ProPheProSerArgArgPhe.....ProGlyLeuLeuAlaAlaLe 24
   ||| |||::: ||| ||| ||| |||:::
70 CCGGCCCGCCGGTCCTCCCTCTGCTCGGAGGATCCCGCGGGGTGT 119
   ::::::::::::::::::::::::::::::::::::::::::
24 uValleuLeu...LeuSerSerPheSerAspGlnCysAsnValProGluT 40
   :::::::::: ||| ||| ||| ||| ||| ||| ||| |||
120 GGGCTGCTGCTGCGCTGCCGCTGCGGCTCAATGCAATGCCCAAT 169
   :::::::::: ||| ||| ||| ||| ||| ||| ||| |||
40 rp LeuProPheAlaArgProThrAsnLeuThrAspAspPheGluThr 56
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
170 GGGCTTCCATTTGCGAGGCTACCACTCACTGATGAGTTGATCTTC 219
   :::::::::: ||| ||| ||| ||| ||| ||| ||| |||
56 oIleGlyThrTyrlLeuAsnTyrlGluCysArgProGlyTYRSerLYAR 73
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
220 CATGGACATATCTGATCAATGAATGCGCCCTGGTATATTCGGAAGC 269
   :::::::::: ||| ||| ||| ||| ||| ||| ||| |||
73 roPheSerIleIleCysLeuLYASnSerValTYrThrSerAlaValAsp 89
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
270 CGTTTCTATCATCTGCTAAATAACTGATGAGTGGTGTAGAGAC 319
   :::::::::: ||| ||| ||| ||| ||| ||| ||| |||
90 lysCyslysarqlyssercysarqanproproaspvalalasnlyme 106
   :::::::::: ||| ||| ||| ||| ||| ||| ||| |||
320 AGGTGACAGCTAATATCATCTGATCTCCAGATCTCTGAAATGGAT 369
   :::::::::: ||| ||| ||| ||| ||| ||| ||| |||
106 lAlaHisValIleLYsAspLIEGLNPHGLYSERGLNILELYTYRSERC 123
   :::::::::: ||| ||| ||| ||| ||| ||| ||| |||
370 GTGCATGTGATCAAGGACATCCAGTTCGGATCCCAATTAATATCTT 419
   :::::::::: ||| ||| ||| ||| ||| ||| ||| |||
123 SPRLVSGLYTYRARGLEULIEGLYSERSESERALATHRCYSILIELE 139
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

```


PF 05-MAR-1998; 98WO-GB00727.
 XX
 PR 05-MAR-1997; 97GB-0004519.
 XX
 PA (ADPR-) ADPROTECH PLC.
 XX
 PI Cox VF, Mossakowska DEI, Smith RAG;
 DR WPI: 1998-506358/43.
 DR P-PSDB; AAW79237.
 XX
 PF Soluble polypeptide comprising short consensus repeats from LHR-A -
 PF used to treat disorders and diseases associated with inflammation or
 PF inappropriate complement activation
 XX
 PS Claim 22; Page 42-43; 67pp; English.
 CC This DNA sequence encodes CM7 (see AAW79236), a protein that consists
 CC of the short consensus repeats (SCR) 1 and 2 from the complement
 CC receptor type 1 (CRI) fused to the SCR3 of CRI-1-like pseudogene (see
 CC AAW79247). CM7 DNA was constructed using plasmid pDB1013-5, which
 CC codes for SCR1-3 of CRI, by site-directed mutagenesis using 3 pairs
 CC of oligonucleotides (see AAW53263-65) that introduced 10 amino acid
 CC changes to the native SCR3 sequence corresponding to changes
 CC observed in the CRI-1-like pseudogene (Cr1pse). ProSCR1-3CM7
 CC carrying the CM7 DNA construct was used to transform *Escherichia*
 CC coli BL21(DE3), and CM7 was purified from solubilised inclusion
 CC bodies. The invention provides DNA sequences (see AAW53262 and
 CC AAW53269-79) encoding novel soluble engineered CRI polypeptides (see
 CC functional complement inhibitor, including anti-haemolytic,
 CC activity. These can be used to treat a disease or disorder
 CC associated with inflammation or inappropriate complement activation,
 CC such as neurological disorders (e.g. multiple sclerosis and
 CC Parkinson's disease), disorders of inappropriate or undesirable
 CC complement activation (e.g. xenograft rejection), inflammatory
 CC disorders (e.g. Crohn's disease, asthma, and acute pancreatitis),
 CC post-ischaemic reperfusion conditions, infection or sepsis,
 CC immune complex disorders and autoimmune diseases (e.g. rheumatoid
 CC arthritis, proliferative nephritis and myasthenia gravis), and
 CC reproductive disorders.
 XX
 XX Sequence 591 BP; 132 A; 159 C; 148 G; 152 T; 0 other;

alignment_scores:
 Quality: 635.00 Length: 121
 Ratio: 5.336 Gaps: 0
 Percent Similarity: 98.347 Percent Identity: 90.909

alignment_block:
 US-10-031-904-8 x AAW53262 ..

Align seg 1/1 to: AAW53262 from: 1 to: 591

34 GlnCysAnValProGluTrpLeuProPheAlaArgProThrAsnLeuTh 50
 |||||
 4 CAGGCAACGCTCCGGAATGCTGCTCCGCGCCGACCAACCACTGAC 53
 |||||
 50 AspAspPheGluPheProIleGlyThrTyrlleuAsnTyrlleuGlyAsnPro 67
 |||||
 54 TGATGAAATTGAGTCCGATCGGACCTACTACTAGCAATGCCGCC 103
 |||||
 67 rogllytYrserGlyArpProPheSerIleIleCysLeuYAsnSerVal 83
 |||||
 104 CGGGTTATACGGCCGCCGTTTATCAATCTGCCGAAACCACTCTGTC 153
 |||||
 84 TrpIleSerAlaLysAspLysCysLysArgLysSerCysArgAsnPro 100
 |||||
 124 TGAGCTGATGCTAAGACCGCTTCCGACGTAATCTGTGCTAATCGGCC 203
 |||||
 100 cAspPrivaLAsnGlyMetAlaHisValIleuAspIleGlnPheGlyS 117
 |||||

204 AGATCCGGTTAACGGCAATGTCATGATCAAGGCAATCCAGTCCGTT 253
 117 ergInIleuYsTrSerCysProLysGlyTrArgLeuIleGlySerSer 133
 |||||
 254 CCCAAATTAATATCTTCTACTAAGGTTACCGCTGATGGTTCTCC 303
 |||||
 134 SerIleThrCysIleIleSerGlyAsnThrValIleTrpAspAsnLysSer 150
 |||||
 304 AGCGCTACATGCATCTCTGATGATATCTGATTTGGGATTAAGAAC 353
 150 rProValCysAsp 154
 |||||
 354 ACCGATTGTGAC 366
 seq_name: /SIDSI/gcdata/geneseq/geneseqn-emb1/NA1998.DAT:AAW53269
 seq_documentation_block:
 ID AAW53269 standard; DNA; 591 BP.
 XX
 AC AAW53269;
 XX
 DT 18-JAN-1999 (first entry)
 XX
 DE Complement receptor type 1-like sequence CM1 DNA.
 XX
 KW Complement receptor type-1; CRI; CM1; complement; inhibitor;
 KW anti-haemolytic; multiple sclerosis; Parkinson's disease;
 KW xenograft rejection; inflammation; Crohn's disease; asthma;
 KW pancreatitis; post-ischaemic reperfusion; infection; sepsis;
 KW autoimmune disease; rheumatoid arthritis; proliferative nephritis;
 KW myasthenia gravis; reproductive disorder; therapy; ss.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN W09839433-A1.
 XX
 PD 11-SEP-1998.
 XX
 PF 05-MAR-1998; 98WO-GB00727.
 XX
 PR 05-MAR-1997; 97GB-0004519.
 XX
 PA (ADPR-) ADPROTECH PLC.
 XX
 PI Cox VF, Mossakowska DEI, Smith RAG;
 DR WPI: 1998-506358/43.
 DR P-PSDB; AAW79237.
 XX
 PF Soluble polypeptide comprising short consensus repeats from LHR-A -
 PF used to treat disorders and diseases associated with inflammation or
 PF inappropriate complement activation
 XX
 PS Claim 22; Page 44; 67pp; English.
 CC This DNA sequence encodes CM1 (see AAW79237), a protein that consists
 CC of the short consensus repeats (SCR) 1 and 2 from complement
 CC receptor type 1 (CRI) fused to an SCR3 (see AAW79242) in which 5 amino
 CC acids were altered to those found in the SCR3 of the CRI-1-like
 CC pseudogene (Cr1pse) putative product. CM1 DNA was constructed by
 CC site-directed mutagenesis (see AAW53263) of plasmid pDB1013-5, which
 CC codes for SCR1-3 of CRI. ProSCR1-3CM1 carrying CM1 DNA was used
 CC to transform *Escherichia coli* BL21(DE3), and CM1 was purified from
 CC solubilised inclusion bodies. The invention provides DNA sequences
 CC (see AAW53262 and AAW53269-79) encoding novel soluble engineered CRI
 CC polypeptides (see AAW53263-47) such as CM1 that act as complement
 CC inhibitors with functional complement inhibitory, including
 CC anti-haemolytic, activity. These can be used to treat a disease or
 CC disorder associated with inflammation or inappropriate complement
 CC activation, such as neurological disorders (e.g. multiple sclerosis
 CC and Parkinson's disease), disorders of inappropriate or undesirable
 CC complement activation (e.g. xenograft rejection), inflammatory

CC	alignement_block:	US-10-031-904-x	AAV53271	..
CC	complement activation (e.g. xenograft rejection), inflammatory			
CC	disorders (e.g. Crohn's disease, asthma, and acute pancreatitis),			
CC	post-ischemic reperfusion conditions, infection or sepsis,			
CC	immune complex disorders and autoimmune diseases (e.g. rheumatoid			
CC	arthritis, proliferative nephritis and myasthenia gravis), and			
CC	reproductive disorders.			
XX	Sequence 591 BP: 131 A; 160 C; 149 G; 151 T; 0 other;			
SQ				
	alignment_scores:			
	Quality: 635.00		Length: 121	
	Ratio: 5.336		Gaps: 0	
	Percent Similarity: 98.347		Percent Identity: 90.909	
	Align seq 1/1 to: AAV53271 from: 1 to: 591			
34	GlucyAsnValProGluTrpLeuProPheAlaArgProThrAsnLeuTh 50			
4	CAAGTGCACGCGCCGAAATGGCTGCCTGCGCGCCGACCAACCTAC 53			
50	IAAPAspPheGluPheProIleGlyThrTyrlAsnArgTylGlyCysArg 67			
54	TGATGAATTTGAGTTCCCGATTCGTACCTACCTGAACCTAGAAATCCGCC 103			
67	roLylrSerGlyAArgProPheSerIleIleCysLeuLysAsnSerVal 83			
104	CGGGTTATAGCGCGCGCCGCTTTCTATACATCTCCGAAAAACCTCTC 153			
84	TrpThrSerAlaLysAspLysCysLysArgLysSerCysArgAspProPr 100			
154	TGAGATCGTGCTAAGAGACCGCTTCACAGTAACTCTGCGTAACCCGC 203			
100	CAAPProValAsnGlyMetAlaHisValIleLysAspIleGlnPheGly 117			
204	AGATCGGTTAACGGCATGGTGTGATGTGATCAAAAGCATCAGTTCCGTT 253			
117	erGlnIleLysTyrSerCysProLysGlyTyrArgLeuIleGlySerSer 133			
254	CCGAATTTAAATATTCTTGTAACAAAGTTACCGCTGATGGTTCCTCC 303			
134	SerAlaThrCysIleIleSerGlyAsnThrValIleThrAspAsnLysTh 150			
304	AGCGCTACATGATCATCTCGGTGATGTGATGTGGATTAAGAAC 353			
150	rProValCysasp 154			
354	ACCGATTGTGTGAC 366			
seq_name:	/SIDS1/gcdata/geneseq/geneseqn-emb1/NA1998.DAT:AAV53272			
seq_documentation_block:				
ID	AAV53272 standard; DNA: 591 BP.			
AC	AAV53272;			
XX	18-JAN-1999 (first entry)			
DE	Complement receptor type 1-like sequence C5b DNA.			
XX				
KW	Complement receptor type-1; CRL; C5b; complement; inhibitor;			
KW	anti-hemolytic; multiple sclerosis; Parkinson's disease;			
KW	xenograft rejection; inflammation; Crohn's disease; asthma;			
KW	pancreatitis; post-ischemic reperfusion; infection; sepsis;			
KW	autoimmune disease; rheumatoid arthritis; proliferative nephritis			
KW	myasthenia gravis; reproductive disorder; therapy; ss.			
XX	Homo sapiens.			
XX	Synthetic.			

PN W09839433-A1.
 XX 11-SEP-1998.
 PD 05-MAR-1998: 98WO-GB00727.
 XX 05-MAR-1997: 97GB-0004519.
 XX (ADPR-) ADPROTECH PLC.
 XX Cox VF, Mossakowska DEL, Smith RAG;
 XX MPI: 1998-506358/43.
 XX P-PSDB: AAW79240.
 PT Soluble polypeptide comprising short consensus repeats from LHR-A -
 PT used to treat disorders and diseases associated with inflammation or
 PT inappropriate complement activation
 PS Claim 22: Page 47; 67pp; English.
 XX This DNA sequence encodes CM5 (see AAW79240), a protein that consists
 CC of the short consensus repeats (SCR) 1 and 2 from complement
 CC receptor type 1 (CRI) fused to an SCR3 (see AAW79240) in which 5 amino
 CC acids were altered to those found in the SCR3 of the CRI-like
 CC pseudogene (Cripse) putative product. CM5 DNA was constructed by
 CC site-directed mutagenesis (see AAV53264-65) of PDB1013-5 which
 CC codes for SCR1-3 of CRI. pProSCR1-3CM5 carrying CM5 DNA was used
 CC to transform *Escherichia coli* BL21(DE3), and CM5 was purified from
 CC solubilized inclusion bodies. The invention provides DNA sequences
 CC (see AAV53262 and AAV53269-79) encoding novel soluble engineered CRI
 CC polypeptides (see AAW53236-47) such as CM5 that act as complement
 CC inhibitors with functional complement inhibitory, including
 CC anti-hemolytic, activity. These can be used to treat a disease or
 CC disorder associated with inflammation or inappropriate complement
 CC activation, such as neurological disorders (e.g. multiple sclerosis
 CC and Parkinson's disease), disorders of inappropriate or undesirable
 CC complement activation (e.g. xenograft rejection), inflammatory
 CC disorders (e.g. Crohn's disease, asthma, and acute pancreatitis),
 CC post-ischemic reperfusion conditions, infection or sepsis,
 CC immune complex disorders and autoimmune diseases (e.g. rheumatoid
 CC arthritis, proliferative nephritis and myasthenia gravis), and
 CC reproductive disorders.
 SO Sequence 591 BP: 128 A; 160 C; 151 G; 152 T; 0 other;
 alignment_scores: Length: 121
 Quality: 635.00 Gaps: 0
 Ratio: 5.336 Percent Identity: 90.909
 Percent Similarity: 98.347
 alignment_block:
 US-10-031-904-8 x AAW53272 ..
 Align seg 1/1 to: AAW53272 from: 1 to: 591
 34 GlnCysAsnValProGluTrpLeuProPheAlaArgProThrAsnLeuTh 50
 4 CAGTGCAGCGTCGCGAATGCTCGCTTCGCCGCCACCAACCTGAC 53
 50 TASPAPPhagLupheProIleGlyTrpTyrLeuAsnTyrGluCysArgP 67
 54 TGAATGAATTGAGTCCGATCGGTACCTGACCTGACCTGACCTGACCTG 103
 67 rolyIyrsSerGlyArProPheSerIleIleCysLeuAsnSerVal 83
 104 CGGGTATATAGCGCGCCCGCTTTCTATCATCTGCTGAAAAAATCTGTG 153
 84 TrpThrSerAlaLysAspLysCysLysArgLysSerCysArgAsnProP 100
 154 TGACATGTCGTATAGGACCGTTGCCGACGTAATCTTGTCTGAATCCGCC 203

100 oAsProValAsnGlyMetAlaHisValIleLysAspIleGlnPheGlys 117
 204 AGATCGGCTTAACGCGCATGGGTCATGATCAAGCATCCAGTCCGCTT 253
 117 erGlnIleLysTyrSerCysProLysGlyTyrArgLeuIleGlySerSer 133
 254 CCAAAATTAATATCTTGTACTTAAGGTACCGCTGCTGATGGTCTCC 303
 134 SerAlaThrCysIleIleSerGlyAsnThrValIleTrpAspAsnLysTh 150
 304 AGCGGTACATGCATCATCTCTGGTACTGATTCATTTGGATGAATGAAC 353
 150 rProValCysasp 154
 354 ACCGATTTGTGAC 366
 seq_name: /SIDS1/gcdata/geneseq/geneseqn-emb1/NA1998.DAT:AAV53273
 seq_documentation_block:
 ID AAV53273 standard: DNA; 591 BP.
 AC AAV53273:
 XX 18-JAN-1999 (first entry)
 DT Complement receptor type 1-like sequence CM6 DNA.
 DE
 XX
 XX Complement receptor type-1; CRI; CM6; complement; inhibitor;
 KW anti-hemolytic; multiple sclerosis; Parkinson's disease;
 KW xenograft rejection; inflammation; Crohn's disease; asthma;
 KW pancreatitis; post-ischemic reperfusion; infection; sepsis;
 KW autoimmune disease; rheumatoid arthritis; proliferative nephritis;
 KW myasthenia gravis; reproductive disorder; therapy; ss.
 OS Homo sapiens.
 OS Synthetic.
 PN W09839433-A1.
 PD 11-SEP-1998.
 PF 05-MAR-1998: 98WO-GB00727.
 XX 05-MAR-1997: 97GB-0004519.
 XX (ADPR-) ADPROTECH PLC.
 XX Cox VF, Mossakowska DEL, Smith RAG;
 XX MPI: 1998-506358/43.
 XX P-PSDB: AAW79241.
 PT Soluble polypeptide comprising short consensus repeats from LHR-A -
 PT used to treat disorders and diseases associated with inflammation or
 PT inappropriate complement activation
 PS Claim 22: Page 48; 67pp; English.
 XX This DNA sequence encodes CM6 (see AAW79241), a protein that consists
 CC of the short consensus repeats (SCR) 1 and 2 from complement
 CC receptor type 1 (CRI) fused to an SCR3 (see AAW79246) in which 6 amino
 CC acids were altered to those found in the SCR3 of the CRI-like
 CC pseudogene (Cripse) putative product. CM6 DNA was constructed by
 CC site-directed mutagenesis (see AAV53263 and AAV53265) of PDB1013-5,
 CC which codes for SCR1-3 of CRI. pProSCR1-3CM6 carrying CM6 DNA was used
 CC to transform *Escherichia coli* BL21(DE3), and CM6 was purified from
 CC solubilized inclusion bodies. The invention provides DNA sequences
 CC (see AAV53262 and AAV53264-47) encoding novel soluble engineered CRI
 CC polypeptides (see AAW53236-47) such as CM6 that act as complement
 CC inhibitors with functional complement inhibitory, including
 CC anti-hemolytic, activity. These can be used to treat a disease or
 CC disorder associated with inflammation or inappropriate complement
 CC activation, such as neurological disorders (e.g. multiple sclerosis

CC and Parkinson's disease), disorders of inappropriate or undesirable
 CC complement activation (e.g. xenograft rejection), inflammatory
 CC disorders (e.g. Crohn's disease, asthma, and acute pancreatitis),
 CC post-ischemic reperfusion conditions, infection or sepsis,
 CC immune complex disorders and autoimmune diseases (e.g. rheumatoid
 CC arthritis, proliferative nephritis and myasthenia gravis), and
 CC reproductive disorders.

Sequence 591 BP; 135 A; 159 C; 146 G; 151 T; 0 other;

alignment_scores:
 Quality: 635.00 Length: 121
 Ratio: 5.336 Gaps: 0
 Percent Similarity: 98.347 Percent Identity: 90.909

alignment_block:

US-10-031-904-8 x AAV53273 ..

Align seq 1/1 to: AAV53273 from: 1 to: 591

```

34 GlnCysAsnValProGluTrpLeuProPheAlaArgProThrAspLeuTh 50
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
4 CAGTGCACGCTCCGGAATGGCTGCCGCTGCCGCGCCGACCACTGAC 53
50 TASPAPhpeGluPheProGluLeuGlyTrpLeuAsnTrpGluCysArgP 67
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
54 TGAATGATTTGATCCGATCGGATCGACTGACCTGAACCTGAGATGCCGC 103
67 roGlyTrpSerGlyArgProPheSerIleLeuCysLeuAsnSerVal 83
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
104 CGGGTTATAGCGCGCCGCTTTCTATCATCTGCTGAAAAAATCTCTGC 153
84 TrpThrSerAlaIleAspLysCysLysArgLysSerCysArgAspProPr 100
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
154 TGGACGTGGTCTAGAGACCGTTGCCGACGTAAATCTTGTCGTAATCCGC 203
100 oASPProValAsnGlyMetAlaHisValIleLysAspIleGlnPheGly 117
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
204 AGATCCGCTTACGGATGATGATGATGATGATGATGATGATGATGATG 253
117 erGlnIleLysTrpSerCysProLysGlyTrpArgLeuIleGlySerSer 133
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
254 CCAATTTAAATATCTTGTACTAAAGGTACCGTCTGATGTTGCTCTCC 303
134 SerAlaThrCysIleIleSerGlyAsnThrValIleTrpAspAsnLysTh 150
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
304 AGCGCTACATGCATCTCTGATGATGATGATGATGATGATGATGATG 353
150 rProValCysAsp 154
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
354 ACCGATTTGTGAC 366

```

seq_name: /SIDSL/9cdata/geneseq/geneseq-emb1/NA1993.DAT:AAQ41867

seq_documentation_block:

ID AAQ41867 standard; DNA; 6951 BP.

AC AAQ41867:

DT 14-SEP-1993 (first entry)

DE CRI coding region.

KW C3b/C4b receptor; CRI, erythrocyte; monocyte; macrophage; granulocyte;
 KW IC3b; T cell; splenic follicular dendritic cell; soluble; complement;
 KW glomerular podocyte; B cell; C3b; C4b; inactivated C3b; phagocytosis;
 KW plasma; ligand binding activity; immune complex; activator; allotype;
 KW endocytosis; lymphocyte; classical; alternative; pathway; cofactor; F
 KW C3/C5 convertase; liver; cleavage; factor I; regulation; glycoprotein;
 KW S; A; B; glycosylation; duplication; repetitive intervening sequence;
 KW endoglycosidase F; ss.

OS Homo sapiens.

XX Key Location/Qualifiers
 XX CDS 28..6147
 XX sig_peptide /*tag= a
 XX mat_peptide /*tag= b
 XX misc_RNA 151..6144
 XX /*tag= c
 XX /*tag= d
 XX /*tag= e
 XX /*tag= f
 XX /*tag= g
 XX /*tag= h
 XX /*tag= i
 XX /*tag= j
 XX /*tag= k
 XX /*tag= l
 XX /*tag= m
 XX /*tag= n
 XX /*tag= o
 XX /*tag= p
 XX /*tag= q
 XX /*tag= r
 XX /*tag= s
 XX /*tag= t
 XX /*tag= u
 XX /*tag= v
 XX /*tag= w
 XX /*tag= x
 XX /*tag= y
 XX /*tag= z
 XX /*tag= AA
 XX /*tag= AB
 XX /*tag= AC
 XX /*tag= AD
 XX /*tag= AE
 XX /*tag= AF
 XX /*tag= AG
 XX /*tag= AH
 XX /*tag= AI
 XX /*tag= AJ
 XX /*tag= AK
 XX /*tag= AL
 XX /*tag= AM
 XX /*tag= AN
 XX /*tag= AO
 XX /*tag= AP
 XX /*tag= AQ
 XX /*tag= AR
 XX /*tag= AS
 XX /*tag= AT
 XX /*tag= AU
 XX /*tag= AV
 XX /*tag= AW
 XX /*tag= AX
 XX /*tag= AY
 XX /*tag= AZ
 XX /*tag= BA
 XX /*tag= BB
 XX /*tag= BC
 XX /*tag= BD
 XX /*tag= BE
 XX /*tag= BF
 XX /*tag= BG
 XX /*tag= BH
 XX /*tag= BI
 XX /*tag= BJ
 XX /*tag= BK
 XX /*tag= BL
 XX /*tag= BM
 XX /*tag= BN
 XX /*tag= BO
 XX /*tag= BP
 XX /*tag= BQ
 XX /*tag= BR
 XX /*tag= BS
 XX /*tag= BT
 XX /*tag= BU
 XX /*tag= BV
 XX /*tag= BW
 XX /*tag= BX
 XX /*tag= BY
 XX /*tag= BZ
 XX /*tag= CA
 XX /*tag= CB
 XX /*tag= CC
 XX /*tag= CD
 XX /*tag= CE
 XX /*tag= CF
 XX /*tag= CG
 XX /*tag= CH
 XX /*tag= CI
 XX /*tag= CJ
 XX /*tag= CK
 XX /*tag= CL
 XX /*tag= CM
 XX /*tag= CN
 XX /*tag= CO
 XX /*tag= CP
 XX /*tag= CQ
 XX /*tag= CR
 XX /*tag= CS
 XX /*tag= CT
 XX /*tag= CU
 XX /*tag= CV
 XX /*tag= CW
 XX /*tag= CX
 XX /*tag= CY
 XX /*tag= CZ
 XX /*tag= DA
 XX /*tag= DB
 XX /*tag= DC
 XX /*tag= DD
 XX /*tag= DE
 XX /*tag= DF
 XX /*tag= DG
 XX /*tag= DH
 XX /*tag= DI
 XX /*tag= DJ
 XX /*tag= DK
 XX /*tag= DL
 XX /*tag= DM
 XX /*tag= DN
 XX /*tag= DO
 XX /*tag= DP
 XX /*tag= DQ
 XX /*tag= DR
 XX /*tag= DS
 XX /*tag= DT
 XX /*tag= DU
 XX /*tag= DV
 XX /*tag= DW
 XX /*tag= DX
 XX /*tag= DY
 XX /*tag= DZ
 XX /*tag= EA
 XX /*tag= EB
 XX /*tag= EC
 XX /*tag= ED
 XX /*tag= EE
 XX /*tag= EF
 XX /*tag= EG
 XX /*tag= EH
 XX /*tag= EI
 XX /*tag= EJ
 XX /*tag= EK
 XX /*tag= EL
 XX /*tag= EM
 XX /*tag= EN
 XX /*tag= EO
 XX /*tag= EP
 XX /*tag= EQ
 XX /*tag= ER
 XX /*tag= ES
 XX /*tag= ET
 XX /*tag= EU
 XX /*tag= EV
 XX /*tag= EW
 XX /*tag= EX
 XX /*tag= EY
 XX /*tag= EZ
 XX /*tag= FA
 XX /*tag= FB
 XX /*tag= FC
 XX /*tag= FD
 XX /*tag= FE
 XX /*tag= FF
 XX /*tag= FG
 XX /*tag= FH
 XX /*tag= FI
 XX /*tag= FJ
 XX /*tag= FK
 XX /*tag= FL
 XX /*tag= FM
 XX /*tag= FN
 XX /*tag= FO
 XX /*tag= FP
 XX /*tag= FQ
 XX /*tag= FR
 XX /*tag= FS
 XX /*tag= FT
 XX /*tag= FU
 XX /*tag= FV
 XX /*tag= FW
 XX /*tag= FX
 XX /*tag= FY
 XX /*tag= FZ
 XX /*tag= GA
 XX /*tag= GB
 XX /*tag= GC
 XX /*tag= GD
 XX /*tag= GE
 XX /*tag= GF
 XX /*tag= GG
 XX /*tag= GH
 XX /*tag= GI
 XX /*tag= GJ
 XX /*tag= GK
 XX /*tag= GL
 XX /*tag= GM
 XX /*tag= GN
 XX /*tag= GO
 XX /*tag= GP
 XX /*tag= GQ
 XX /*tag= GR
 XX /*tag= GS
 XX /*tag= GT
 XX /*tag= GU
 XX /*tag= GV
 XX /*tag= GW
 XX /*tag= GX
 XX /*tag= GY
 XX /*tag= GZ
 XX /*tag= HA
 XX /*tag= HB
 XX /*tag= HC
 XX /*tag= HD
 XX /*tag= HE
 XX /*tag= HF
 XX /*tag= HG
 XX /*tag= HH
 XX /*tag= HI
 XX /*tag= HJ
 XX /*tag= HK
 XX /*tag= HL
 XX /*tag= HM
 XX /*tag= HN
 XX /*tag= HO
 XX /*tag= HP
 XX /*tag= HQ
 XX /*tag= HR
 XX /*tag= HS
 XX /*tag= HT
 XX /*tag= HU
 XX /*tag= HV
 XX /*tag= HW
 XX /*tag= HX
 XX /*tag= HY
 XX /*tag= HZ
 XX /*tag= IA
 XX /*tag= IB
 XX /*tag= IC
 XX /*tag= ID
 XX /*tag= IE
 XX /*tag= IF
 XX /*tag= IG
 XX /*tag= IH
 XX /*tag= II
 XX /*tag= IJ
 XX /*tag= IK
 XX /*tag= IL
 XX /*tag= IM
 XX /*tag= IN
 XX /*tag= IO
 XX /*tag= IP
 XX /*tag= IQ
 XX /*tag= IR
 XX /*tag= IS
 XX /*tag= IT
 XX /*tag= IU
 XX /*tag= IV
 XX /*tag= IW
 XX /*tag= IX
 XX /*tag= IY
 XX /*tag= IZ
 XX /*tag= JA
 XX /*tag= JB
 XX /*tag= JC
 XX /*tag= JD
 XX /*tag= JE
 XX /*tag= JF
 XX /*tag= JG
 XX /*tag= JH
 XX /*tag= JI
 XX /*tag= JJ
 XX /*tag= JK
 XX /*tag= JL
 XX /*tag= JM
 XX /*tag= JN
 XX /*tag= JO
 XX /*tag= JP
 XX /*tag= JQ
 XX /*tag= JR
 XX /*tag= JS
 XX /*tag= JT
 XX /*tag= JU
 XX /*tag= JV
 XX /*tag= JW
 XX /*tag= JX
 XX /*tag= JY
 XX /*tag= JZ
 XX /*tag= KA
 XX /*tag= KB
 XX /*tag= KC
 XX /*tag= KD
 XX /*tag= KE
 XX /*tag= KF
 XX /*tag= KG
 XX /*tag= KH
 XX /*tag= KI
 XX /*tag= KJ
 XX /*tag= KK
 XX /*tag= KL
 XX /*tag= KM
 XX /*tag= KN
 XX /*tag= KO
 XX /*tag= KP
 XX /*tag= KQ
 XX /*tag= KR
 XX /*tag= KS
 XX /*tag= KT
 XX /*tag= KU
 XX /*tag= KV
 XX /*tag= KW
 XX /*tag= KX
 XX /*tag= KY
 XX /*tag= KZ
 XX /*tag= LA
 XX /*tag= LB
 XX /*tag= LC
 XX /*tag= LD
 XX /*tag= LE
 XX /*tag= LF
 XX /*tag= LG
 XX /*tag= LH
 XX /*tag= LI
 XX /*tag= LJ
 XX /*tag= LK
 XX /*tag= LL
 XX /*tag= LM
 XX /*tag= LN
 XX /*tag= LO
 XX /*tag= LP
 XX /*tag= LQ
 XX /*tag= LR
 XX /*tag= LS
 XX /*tag= LT
 XX /*tag= LU
 XX /*tag= LV
 XX /*tag= LW
 XX /*tag= LX
 XX /*tag= LY
 XX /*tag= LZ
 XX /*tag= MA
 XX /*tag= MB
 XX /*tag= MC
 XX /*tag= MD
 XX /*tag= ME
 XX /*tag= MF
 XX /*tag= MG
 XX /*tag= MH
 XX /*tag= MI
 XX /*tag= MJ
 XX /*tag= MK
 XX /*tag= ML
 XX /*tag= MN
 XX /*tag= MO
 XX /*tag= MP
 XX /*tag= MQ
 XX /*tag= MR
 XX /*tag= MS
 XX /*tag= MT
 XX /*tag= MU
 XX /*tag= MV
 XX /*tag= MW
 XX /*tag= MX
 XX /*tag= MY
 XX /*tag= MZ
 XX /*tag= NA
 XX /*tag= NB
 XX /*tag= NC
 XX /*tag= ND
 XX /*tag= NE
 XX /*tag= NF
 XX /*tag= NG
 XX /*tag= NH
 XX /*tag= NI
 XX /*tag= NJ
 XX /*tag= NK
 XX /*tag= NL
 XX /*tag= NO
 XX /*tag= NP
 XX /*tag= NQ
 XX /*tag= NR
 XX /*tag= NS
 XX /*tag= NT
 XX /*tag= NU
 XX /*tag= NV
 XX /*tag= NW
 XX /*tag= NX
 XX /*tag= NY
 XX /*tag= NZ
 XX /*tag= OA
 XX /*tag= OB
 XX /*tag= OC
 XX /*tag= OD
 XX /*tag= OE
 XX /*tag= OF
 XX /*tag= OG
 XX /*tag= OH
 XX /*tag= OI
 XX /*tag= OJ
 XX /*tag= OK
 XX /*tag= OL
 XX /*tag= OM
 XX /*tag= ON
 XX /*tag= OO
 XX /*tag= OP
 XX /*tag= OQ
 XX /*tag= OR
 XX /*tag= OS
 XX /*tag= OT
 XX /*tag= OU
 XX /*tag= OV
 XX /*tag= OW
 XX /*tag= OX
 XX /*tag= OY
 XX /*tag= OZ
 XX /*tag= PA
 XX /*tag= PB
 XX /*tag= PC
 XX /*tag= PD
 XX /*tag= PE
 XX /*tag= PF
 XX /*tag= PG
 XX /*tag= PH
 XX /*tag= PI
 XX /*tag= PJ
 XX /*tag= PK
 XX /*tag= PL
 XX /*tag= PM
 XX /*tag= PN
 XX /*tag= PO
 XX /*tag= PP
 XX /*tag= PQ
 XX /*tag= PR
 XX /*tag= PS
 XX /*tag= PT
 XX /*tag= PU
 XX /*tag= PV
 XX /*tag= PW
 XX /*tag= PX
 XX /*tag= PY
 XX /*tag= PZ
 XX /*tag= QA
 XX /*tag= QB
 XX /*tag= QC
 XX /*tag= QD
 XX /*tag= QE
 XX /*tag= QF
 XX /*tag= QG
 XX /*tag= QH
 XX /*tag= QI
 XX /*tag= QJ
 XX /*tag= QK
 XX /*tag= QL
 XX /*tag= QM
 XX /*tag= QN
 XX /*tag= QO
 XX /*tag= QP
 XX /*tag= QQ
 XX /*tag= QR
 XX /*tag= QS
 XX /*tag= QT
 XX /*tag= QU
 XX /*tag= QV
 XX /*tag= QW
 XX /*tag= QX
 XX /*tag= QY
 XX /*tag= QZ
 XX /*tag= RA
 XX /*tag= RB
 XX /*tag= RC
 XX /*tag= RD
 XX /*tag= RE
 XX /*tag= RF
 XX /*tag= RG
 XX /*tag= RH
 XX /*tag= RI
 XX /*tag= RJ
 XX /*tag= RK
 XX /*tag= RL
 XX /*tag= RM
 XX /*tag= RN
 XX /*tag= RO
 XX /*tag= RP
 XX /*tag= RQ
 XX /*tag= RR
 XX /*tag= RS
 XX /*tag= RT
 XX /*tag= RU
 XX /*tag= RV
 XX /*tag= RW
 XX /*tag= RX
 XX /*tag= RY
 XX /*tag= RZ
 XX /*tag= SA
 XX /*tag= SB
 XX /*tag= SC
 XX /*tag= SD
 XX /*tag= SE
 XX /*tag= SF
 XX /*tag= SG
 XX /*tag= SH
 XX /*tag= SI
 XX /*tag= SJ
 XX /*tag= SK
 XX /*tag= SL
 XX /*tag= SM
 XX /*tag= SN
 XX /*tag= SO
 XX /*tag= SP
 XX /*tag= SQ
 XX /*tag= SR
 XX /*tag= SS
 XX /*tag= ST
 XX /*tag= SU
 XX /*tag= SV
 XX /*tag= SW
 XX /*tag= SX
 XX /*tag= SY
 XX /*tag= SZ
 XX /*tag= TA
 XX /*tag= TB
 XX /*tag= TC
 XX /*tag= TD
 XX /*tag= TE
 XX /*tag= TF
 XX /*tag= TG
 XX /*tag= TH
 XX /*tag= TI
 XX /*tag= TJ
 XX /*tag= TK
 XX /*tag= TL
 XX /*tag= TM
 XX /*tag= TN
 XX /*tag= TO
 XX /*tag= TP
 XX /*tag= TQ
 XX /*tag= TR
 XX /*tag= TS
 XX /*tag= TT
 XX /*tag= TU
 XX /*tag= TV
 XX /*tag= TW
 XX /*tag= TX
 XX /*tag= TY
 XX /*tag= TZ
 XX /*tag= UA
 XX /*tag= UB
 XX /*tag= UC
 XX /*tag= UD
 XX /*tag= UE
 XX /*tag= UF
 XX /*tag= UG
 XX /*tag= UH
 XX /*tag= UI
 XX /*tag= UJ
 XX /*tag= UK
 XX /*tag= UL
 XX /*tag= UM
 XX /*tag= UN
 XX /*tag= UO
 XX /*tag= UP
 XX /*tag= UQ
 XX /*tag= UR
 XX /*tag= US
 XX /*tag= UT
 XX /*tag= UV
 XX /*tag= UW
 XX /*tag= UX
 XX /*tag= UY
 XX /*tag= UZ
 XX /*tag= VA
 XX /*tag= VB
 XX /*tag= VC
 XX /*tag= VD
 XX /*tag= VE
 XX /*tag= VF
 XX /*tag= VG
 XX /*tag= VH
 XX /*tag= VI
 XX /*tag= VJ
 XX /*tag= VK
 XX /*tag= VL
 XX /*tag= VM
 XX /*tag= VN
 XX /*tag= VO
 XX /*tag= VP
 XX /*tag= VQ
 XX /*tag= VR
 XX /*tag= VS
 XX /*tag= VT
 XX /*tag= VU
 XX /*tag= VV
 XX /*tag= VW
 XX /*tag= VX
 XX /*tag= VY
 XX /*tag= VZ
 XX /*tag= WA
 XX /*tag= WB
 XX /*tag= WC
 XX /*tag= WD
 XX /*tag= WE
 XX /*tag= WF
 XX /*tag= WG
 XX /*tag= WH
 XX /*tag= WI
 XX /*tag= WJ
 XX /*tag= WK
 XX /*tag= WL
 XX /*tag= WM
 XX /*tag= WN
 XX /*tag= WO
 XX /*tag= WP
 XX /*tag= WQ
 XX /*tag= WR
 XX /*tag= WS
 XX /*tag= WT
 XX /*tag= WU
 XX /*tag= WV
 XX /*tag= WW
 XX /*tag= WX
 XX /*tag= WY
 XX /*tag= WZ
 XX /*tag= XA
 XX /*tag= XB
 XX /*tag= XC
 XX /*tag= XD
 XX /*tag= XE
 XX /*tag= XF
 XX /*tag= XG
 XX /*tag= XH
 XX /*tag= XI
 XX /*tag= XJ
 XX /*tag= XK
 XX /*tag= XL
 XX /*tag= XM
 XX /*tag= XN
 XX /*tag= XO
 XX /*tag= XP
 XX /*tag= XQ
 XX /*tag= XR
 XX /*tag= XS
 XX /*tag= XT
 XX /*tag= XU
 XX /*tag= XV
 XX /*tag= XW
 XX /*tag= XX
 XX /*tag= XY
 XX /*tag= XZ
 XX /*tag= YA
 XX /*tag= YB
 XX /*tag= YC
 XX /*tag= YD
 XX /*tag= YE
 XX /*tag= YF
 XX /*tag= YG
 XX /*tag= YH
 XX /*tag= YI
 XX /*tag= YJ
 XX /*tag= YK
 XX /*tag= YL
 XX /*tag= YM
 XX /*tag= YN
 XX /*tag= YO
 XX /*tag= YP
 XX /*tag= YQ
 XX /*tag= YR
 XX /*tag= YS
 XX /*tag= YT
 XX /*tag= YU
 XX /*tag= YV
 XX /*tag= YW
 XX /*tag= YX
 XX /*tag= YY
 XX /*tag= YZ
 XX /*tag= ZA
 XX /*tag= ZB
 XX /*tag= ZC
 XX /*tag= ZD
 XX /*tag= ZE
 XX /*tag= ZF
 XX /*tag= ZG
 XX /*tag= ZH
 XX /*tag= ZI
 XX /*tag= ZJ
 XX /*tag= ZK
 XX /*tag= ZL
 XX /*tag= ZM
 XX /*tag= ZN
 XX /*tag= ZO
 XX /*tag= ZP
 XX /*tag= ZQ
 XX /*tag= ZR
 XX /*tag= ZS
 XX /*tag= ZT
 XX /*tag= ZU
 XX /*tag= ZV
 XX /*tag= ZW
 XX /*tag= ZX
 XX /*tag= ZY
 XX /*tag= ZZ

Clam 1; Fig 1; 90pp; English.

This sequence represents the entire coding region for the C3b/C4b receptor (CRI). CRI is present on erythrocytes, monocytes/macrophages, granulocytes, B cells, some T cells, splenic follicular dendritic cells and glomerular podocytes. CRI specifically binds C3b, C4b and inactivated C3b (iC3b). A soluble form of the receptor is found in plasma which has ligand binding activity and the same molecular weight as membrane-associated CRI. CRI binds C3b and C4b that have covalently attached to immune complexes and other complement activators. The consequences of these interactions depends on the type of bearing the receptor. Erythrocyte CRI binds immune complexes for transport to the liver. CRI on neutrophils and monocytes internalises bound complexes, either by adsorptive endocytosis or by phagocytosis. The function of CRI on B lymphocytes is less well defined. CRI can inhibit the classical and alternative pathway C3/C5 convertases and act as a cofactor for the cleavage of C3b and C4b by factor I, therefore CRI has a complement regulatory function as well as acting as a receptor. CRI is a glycoprotein composed of a single polypeptide chain. Four allotypic forms of CRI have been identified, differing by increments of approx. 40-50 kD. The two most common forms, the F and S allotypes, also termed A and B allotypes, have molecular weights of 250 and 290 kD respectively. The two latter forms have molecular weights of 210 and 290 kD. These differences represent differences in the polypeptide chain of CRI, rather than glycosylation state because they are not abolished by treatment of purified receptor protein with endoglycosidase F. The CRI gene has been shown to have repetitive intervening sequences which may have been duplicated in the formation of the larger allotypes.

Sequence 6951 BP; 1799 A; 1692 C; 1648 G; 1807 T; 5 other;

alignment_scores:

Quality: 634.50 Length: 146
Ratio: 4.844 Gaps: 2
Percent Similarity: 89.726 Percent Identity: 81.507

alignment_block:

US-10-031-904-8 x AAQ41867 ..

Align seg 1/1 to: AAQ41867 from: 1 to: 6951

```
10 ProphepSerArgArgphe.....ProglyLeuLeuAlaAla 24
   ||| |||:|:| ||| ||| ||| ||| ||| ||| ||| |||
70 CGGGGGCCGCTCCCTCTGCTGCGGAGATCCCTCTGCGGTTGT 119
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
24 uValLeuLeu...LeuSerSerPheSerAspGlnCysAsnValProGluT 40
   :||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
120 GGCTGCTGCTGCTGCGGCTGCGGCTGCGGCTCAATGCAATGCCAGAA 169
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
40 rPheuProPheAlaArgProThrAsnLeuThrAspAspPheGluPhePro 56
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
170 GGCTTCATTTGCCAGGCTACCACTACCTACATGAGTTGAGTTGCC 219
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
57 lIleGlyThrTyLeuAsnTyGluCysArgProGlyTySerGlyArgPr 73
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
220 ATTTGGACATATCTGAACATATGAATGCCGCCCTGTTATTCGGAAGACC 269
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
73 oPheSerIleIleCysLeuLysAsnSerValTTrPThrSerAlaLysAspL 90
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
270 GTTTTCTTCATCTGCCTTAATAAACTCAGTCTGACTGGTGCTAAGGACA 319
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
90 yScysLysArgLysSerCysArgAsnProProAspProValAsnGlyMet 106
   :||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
320 GGTCGACAGCTAAATCATGTCGTATCTCCAGATCTCTGTAATGGCANG 369
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
107 AlaHisValIleLysAspIleGlnPheGlySerGlnIleLysTySerCy 123
   :||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
370 GTTCATGTGATCAAGAAGCATTCAGTTCGATCCCAATTAATATCTCTG 419
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
123 sProLysGlyTyArgLeuIleGlySerSerSerAlaIleThrCysIleIle 140
   | ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
420 TACTAAAGGATACCGACTCATTTGTTCTGCTGCGCACATGCATCATCT 469
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
140 eRGlyAsnThrValIleTrpAspAsnLysThrProVal 152
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
470 CAGGTGATACGTGATTTGGGATATGAACACCTATAT 507
```


1

[illegible]

```

420 TACTAAGATACCGATCATTTGGTTCCTCGCTGCACATGCATCATCT 469
140 erg1YasnThrValIleTrpAspAsnLysTrpProValCysAsp 154
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
470 CAGGTGATCACTGCTCATTTGGATATGAACACACTATTGTGAC 513

seq_name: gb_pr:CHPCRIx

seq_documentation_block:
LOCUS CHPCRIx 1985 bp mRNA linear PRI 30-OCT-1994
DEFINITION Pan troglodytes alternatively spliced CRI (CRI) gene, partial cds.
ACCESSION L24921
VERSION L24921.1 GI:557726
KEYWORDS alternative splicing product; complement receptor 1.
SOURCE Pan troglodytes cDNA to mRNA.
ORGANISM Pan troglodytes
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homindae; Pan.
1 (bases 1 to 1985)
REFERENCE
AUTHORS Birmingham,D.J., Shen,X.P., Hourcade,D., Nickells,M.W. and
Atkinson,J.P.
TITLE Primary sequence of an alternatively spliced form of CRI. Candidate
for the 75,000 M(r) complement receptor expressed on chimpanzee
erythrocytes
JOURNAL J Immunol. 153 (2), 691-700 (1994)
MEDLINE 94292799
FEATURES
source
Location/Qualifiers
1..1985
/organism="Pan troglodytes"
/db_xref="taxon:9598"
/cell_line="EBV transformed"
/cell_type="B cell"
<1..50
/gene="CRI"
<1..>1985
/codon_start=3
/product="complement receptor 1"
/protein_id="AA51439.1"
/db_xref="GI:557727"
/translation="SILAVVYLALPVAMGOCNAPFWLPAPRTNLDFEFPPIGYTL
NYECPGYGPRPSITICKNSWMTGAKDRCKRSRNPDPVNGMVHVIKIDIGSQT
KYSCKGRIIGSSATCTISGDTVIMNENPIDRIPCGPPTTNDGFIETNRNF
HYGSVYTRCNMPSGGGRKVFELVEPSITCYTSDNDVYINGSPAPOCITRNKCTPPV
ENGILVSDNRSLFSLNEVERFCOPGVPMKPPRYKCAQALKMPELSPSCRVCOOP
DVLHAERTORDKNFSPGEVYFSCPEYDILGASALCTPOGMSPATPTCEKSCD
DFMGQLNGRYLFPVNIQLGAKVDFVCEGFLKSSASVCVLAMGSLNNSVAVCE
OIFCPNPAILNGRHTGTPFGDIPYKGIYSACDHPDRGMTFNLIGSSIRCTSDPO
GNGVSSPAPRCELSVPACPPHPKIQNGHDIGHSVLYLPGMTISYICDGYLAVGK
GRITCDGIMSDLHYCKEYKCSFPLPMNGISKLEMKVYHVGDTYLTKCEDGYTL
EGSPMSOCQADDRMPPLAKCTSRADALIVCTSGTIFILLIIFLSWILKKRKN
NAHEKPKVAHLHISGGSSVHPRTLQTNENSRVLP"
1..1985
/gene="CRI"
/mat_peptide
51..1985
/gene="CRI"
/product="complement receptor 1"
BASE COUNT 521 a 476 c 478 g 510 t
ORIGIN

alignment_scores:
Quality: 645.50 length: 136
Ratio: 5.043 Gaps: 1
Percent Similarity: 94.118 Percent Identity: 86.029

alignment_block:
US-10-031-904-8 x CHPCRIx ..
Align seg 1/1 to: CHPCRIx from: 1 to: 1985
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
20 LeuLeuAlaLeuValLeuLeu...LeuSerSerPheSerAspGlnCys 35
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

seq_name: gb_pr:CHPCRIWT

seq_documentation_block:
LOCUS CHPCRIWT 6044 bp mRNA linear PRI 30-OCT-1994
DEFINITION Chimpanzee complement receptor type one (CRI) mRNA, partial cds.
ACCESSION L24920
VERSION L24920.1 GI:551564
KEYWORDS complement receptor 1.
SOURCE Pan troglodytes cDNA to mRNA.
ORGANISM Pan troglodytes
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homindae; Pan.
1 (bases 1 to 6044)
REFERENCE
AUTHORS Birmingham,D.J., Shen,X.P., Hourcade,D., Nickells,M.W. and
Atkinson,J.P.
TITLE Primary sequence of an alternatively spliced form of CRI. Candidate
for the 75,000 M(r) complement receptor expressed on chimpanzee
erythrocytes
JOURNAL J Immunol. 153 (2), 691-700 (1994)
MEDLINE 94292799
FEATURES
source
Location/Qualifiers
1..6044
/organism="Pan troglodytes"
/db_xref="taxon:9598"
1..6044
/gene="CRI"
<1..>6044
/codon_start=3
/product="complement receptor 1"
/protein_id="AA51438.1"
/db_xref="GI:557725"
/translation="SILAVVYLALPVAMGOCNAPFWLPAPRTNLDFEFPPIGYTL
NYECPGYGPRPSITICKNSWMTGAKDRCKRSRNPDPVNGMVHVIKIDIGSQT
KYSCKGRIIGSSATCTISGDTVIMNENPIDRIPCGPPTTNDGFIETNRNF
HYGSVYTRCNMPSGGGRKVFELVEPSITCYTSDNDVYINGSPAPOCITRNKCTPPV
ENGILVSDNRSLFSLNEVERFCOPGVPMKPPRYKCAQALKMPELSPSCRVCOOP
DVLHAERTORDKNFSPGEVYFSCPEYDILGASALCTPOGMSPATPTCEKSCD
DFMGQLNGRYLFPVNIQLGAKVDFVCEGFLKSSASVCVLAMGSLNNSVAVCE

```


Align seg 1/1 to: HSCR18S from: 1 to: 2376

```

20 LeuLeuAlaLeuValLeuLeu...LeuSerSerPheSerAspGlnCys 35
   |||||.....|||
6  CTGCTGGCGGTTGGTGGCTGCTGGCTGCCGCTGGCTGGCTGGCTGAATG 55
35 sAsnValProGluTrpLeuProPheAlaArgProThrAsnLeuThrAspA 52
   |||||.....|||
56 CAATGCCGAGAAATGGCTTCATTTGCCAGGCTACCACTTAACCTGATG 105
52 sPheGluPheProIleGlyThrTyrLeuAsnTyrGlnCysArgProGly 68
   |||||.....|||
106 AGTTGAGTTCCCATTTGGGACATCTGAACATGATGATCCGCCCTGGT 155
69 TyrSerGlyArgProPheSerIleIleCysLeuLysAsnSerValTyrPth 85
   |||||.....|||
156 TATTCGGGAAGACCGTTTCTATCATCTGCCTAAATAAACTCAGCTGGAC 205
85 rSerAlaLysAspLysCysLysArgLysSerCysArgAsnProProAsp 102
   |||||.....|||
206 TGGTGGCTTAAGGACAGGTGACAGCTTAATCATGTCGTAATCTCCAGATC 255
102 roValAsnGlyMetAlaHisValIleLysAspIleGlnPheGlySerGln 118
   |||||.....|||
256 CTGGAATGGCATGGTGCATGTGATCAAGGACATCCAGTTCCGATCCCA 305
119 IleTyrTyrSerCysProLysGlyTyrArgLeuIleGlySerSerAla 135
   |||||.....|||
306 ATTAATAATCTCTGTACTAAAGATACGACTCATTTGCTTCCTGCTGTC 355
135 aThrCysIleIleSerGlyAsnThrValIleTyrPAsnLysThrProV 152
   |||||.....|||
356 CACATGGCATCATTCAGGTGATGTCATTTGGGATTAATGAACACCTTA 405
152 aLysAsp 154
   |||||
406 TTTGTGAC 413

```

seq_name: gb_sts:G28591

seq_documentation_block:

LOCUS G28591 2376 bp DNA linear STS 11-JUL-1996
 DEFINITION human STS SHGC-35372, sequence tagged site.
 ACCESSION G28591
 VERSION G28591.1 GI:1408406
 XREFS STS: STS sequence; primer: sequence tagged site.
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1 (bases 1 to 2376)
 AUTHORS Myers, R.M.
 JOURNAL Unpublished
 COMMENT Contact: Richard M. Myers
 Stanford Human Genome Center (SHGC)
 Stanford University School of Medicine
 Department of Genetics, M-344, Stanford, CA 94305, USA
 Tel: 415/259687
 Fax: 415/259689
 Email: myers@shgc.stanford.edu

Primer A: TGAGTTGGACGACATGTC
 Primer B: CATACTCTTATTTGCACTGCC
 STS size: 216
 PCR Profile:

Initial incubation: 94 degrees C for 90 seconds
 Denaturation: 94 degrees C for 15 seconds
 Annealing: 62 degrees C for 23 seconds
 Polymerization: 72 degrees C for 30 seconds
 PCR cycles: 30
 Thermal Cycler: Perkin Elmer 9600

Protocol:

Template: 25 ng
 Primer: each 1 uM
 dNTPs: each 200 uM
 Tag Polymerase: 0.05 units/ul
 Total Vol: 10 ul

Buffer:
 MgCl2: 2.5 mM
 KCl: 50 mM
 Tris-HCl: 20 mM
 pH: 8.3

Prepared with primer pairs provided by Sandoz, derived from X14362
 -- Washington University/Merck EST sequence.

FEATURES
 source
 1. .2376
 /organism="Homo sapiens"
 /db_xref="taxon:9606"

STS
 primer_bind 1680..1895
 primer_bind 1680..1899
 complement(1872..1895)
 BASE COUNT 633 a 549 c 568 g 626 t
 ORIGIN

alignment_scores:
 Quality: 644.50 Length: 136
 Ratio: 5.035 Gaps: 1
 Percent Similarity: 94.118 Percent Identity: 86.029

alignment_block:
 US-10-031-904-8 x G28591 ..

Align seg 1/1 to: G28591 from: 1 to: 2376

```

20 LeuLeuAlaLeuValLeuLeu...LeuSerSerPheSerAspGlnCys 35
   |||||.....|||
6  CTGCTGGCGGTTGGTGGCTGCTGGCTGCCGCTGGCTGGCTGGCTGAATG 55
35 sAsnValProGluTrpLeuProPheAlaArgProThrAsnLeuThrAspA 52
   |||||.....|||
56 CAATGCCGAGAAATGGCTTCATTTGCCAGGCTACCACTTAACCTGATG 105
52 sPheGluPheProIleGlyThrTyrLeuAsnTyrGlnCysArgProGly 68
   |||||.....|||
106 AGTTGAGTTCCCATTTGGGACATCTGAACATGATGATGCCCTGGT 155
69 TyrSerGlyArgProPheSerIleIleCysLeuLysAsnSerValTyrPth 85
   |||||.....|||
156 TATTCGGGAAGACCGTTTCTATCATCTGCCTAAATAAACTCAGTCTGGAC 205
52 rSerAlaLysAspLysCysLysArgLysSerCysArgAsnProProAsp 102
   |||||.....|||
206 TGGTGGCTTAAGGACAGGTGACAGCTTAATCATGTCGTAATCTCCAGATC 255
102 roValAsnGlyMetAlaHisValIleLysAspIleGlnPheGlySerGln 118
   |||||.....|||
256 CTGGAATGGCATGGTGCATGTGATCAAGGACATCCAGTTCCGATCCCA 305
119 IleTyrTyrSerCysProLysGlyTyrArgLeuIleGlySerSerAla 135
   |||||.....|||
306 ATTAATAATCTCTGTACTAAAGATACGACTCATTTGCTTCCTGCTGTC 355
135 aThrCysIleIleSerGlyAsnThrValIleTyrPAsnLysThrProV 152
   |||||.....|||
356 CACATGGCATCATTCAGGTGATGTCATTTGGGATTAATGAACACCTTA 405
152 aLysAsp 154
   |||||
406 TTTGTGAC 413

```

seq_name: gb_pat:A86593

seq_documentation_block:

LOCUS A86593 591 bp DNA linear PAT 21-JAN-2000

DEFINITION Sequence 2 from Patent WO9839433.

ACCESSION A86593

VERSION A86593.1 GI:6735168

KEYWORDS

SOURCE unidentified.

ORGANISM unidentified.

REFERENCE 1 (bases 1 to 591)

AUTHORS Smith, R.A. and Cox, V.F.

TITLE COMPLEMENT RECEPTOR TYPE 1 (CR1)-LIKE SEQUENCES

JOURNAL Patent: WO 9839433-A 2 11-SEP-1998;

SMITH RICHARD ANTONY GODWIN (GB); ADPROTECH PLC (GB)

FEATURES

source 1. 591

/organism="unidentified"

/db_xref="taxon:32644"

BASE COUNT 132 a 159 c 148 g 152 t

ORIGIN

alignment_scores:

	Quality:	635.00	Length:	121
	Ratio:	5.336	Gaps:	0
	Percent Similarity:	98.347	Percent Identity:	90.909

alignment_block:

US-10-031-904-8 x A86593 ..

Align seg 1/1 to: A86593 from: 1 to: 591

```
34 GlnCysAsnValProGluTrpLeuProPheAlaArgProThrAsnLeuTh 50
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
4 CAGTGCACACGCTCCGGAATGGCTGCCGTCGCCGCCCGACCAACCTGAC 53
50 rAspAspPheGluPheProIleGlyThrTyTrpLeuAsnTyrgLucysArgp 67
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
54 TGATGAATTTGAGTCCCGATCGGTACCTACCTGAACTACGAAATGCCGCC 103
67 roGlyTySerGlyArgProPheSerIleIleCysLeuLysAsnSerVal 83
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
104 CGGGTTAAGCGCCGCCGTTTCTATCATCTCCGTAAGAAACCTGTC 153
84 TrpThrSerAlaLysAspLysCysLysArgLysSerCysArgAsnProPr 100
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
154 TGGACTGGTGCTAAGAGACCGTTGCCGAGCTAAATCTGTCTATCCGCC 203
100 oAspProValAsnGlyMetAlaHisValIleLysAspIleGlnPheGlys 117
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
204 AGATCCGGTTAAGCGCATGGTGCATGATCAAAAGCATCCAGTTCGGTT 253
117 erGlnIleLysTySerCysProLysGlyTyArgLeuIleGlySerSer 133
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
254 CCCAAATTAATATTCTTGTACTAAAGCTTACCGCTGATTGGTCTCC 303
134 SerAlaThrCysIleIleSerGlyAsnThrValIleTrpAspAsnLysTh 150
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
304 AGCGCTACATCATCATCTGCTGTGATCATCTGTTGGGATATGAAC 353
150 rProValCysAsp 154
|||||:|||||:
354 ACCGATTTGTGAC 366
```

seq_name: gb_pat:A86601

seq_documentation_block:

LOCUS A86601 591 bp DNA linear PAT 21-JAN-2000

DEFINITION Sequence 10 from Patent WO9839433.

ACCESSION A86601

VERSION A86601.1 GI:6735175

KEYWORDS

SOURCE unidentified.

ORGANISM unidentified.

REFERENCE 1 (bases 1 to 591)

AUTHORS Smith, R.A. and Cox, V.F.

TITLE COMPLEMENT RECEPTOR TYPE 1 (CR1)-LIKE SEQUENCES

JOURNAL Patent: WO 9839433-A 10 11-SEP-1998;

SMITH RICHARD ANTONY GODWIN (GB); ADPROTECH PLC (GB)

FEATURES

source 1. 591

/organism="unidentified"

/db_xref="taxon:32644"

BASE COUNT 127 a 159 c 151 g 154 t

ORIGIN

alignment_scores:

	Quality:	635.00	Length:	121
	Ratio:	5.336	Gaps:	0
	Percent Similarity:	98.347	Percent Identity:	90.909

alignment_block:

US-10-031-904-8 x A86601 ..

Align seg 1/1 to: A86601 from: 1 to: 591

```
34 GlnCysAsnValProGluTrpLeuProPheAlaArgProThrAsnLeuTh 50
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
4 CAGTGCACACGCTCCGGAATGGCTGCCGTCGCCGCCCGACCAACCTGAC 53
50 rAspAspPheGluPheProIleGlyThrTyTrpLeuAsnTyrgLucysArgp 67
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
54 TGATGAATTTGAGTCCCGATCGGTACCTACCTGAACTACGAAATGCCGCC 103
67 roGlyTySerGlyArgProPheSerIleIleCysLeuLysAsnSerVal 83
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
104 CGGGTTAAGCGCCGCCGTTTCTATCATCTCCGTAAGAAACCTGTC 153
84 TrpThrSerAlaLysAspLysCysLysArgLysSerCysArgAsnProPr 100
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
154 TGGACTGGTGCTAAGAGACCGTTGCCGAGCTAAATCTGTGATCCGCC 203
100 oAspProValAsnGlyMetAlaHisValIleLysAspIleGlnPheGlys 117
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
204 AGATCCGGTTAAGCGCATGGTGCATGATCAAAAGCATCCAGTTCGGTT 253
117 erGlnIleLysTySerCysProLysGlyTyArgLeuIleGlySerSer 133
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
254 CCCAAATTAATATTCTTGTACTAAAGCTTACCGCTGATGTTGCCCTCC 303
134 SerAlaThrCysIleIleSerGlyAsnThrValIleTrpAspAsnLysTh 150
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
304 AGCGCTACATCATCTGCTGTGATCATCTGTTGGGATATGAAC 353
150 rProValCysAsp 154
|||||:|||||:
354 ACCGATTTGTGAC 366
```

seq_name: gb_pat:A86603

seq_documentation_block:

LOCUS A86603 591 bp DNA linear PAT 21-JAN-2000

DEFINITION Sequence 12 from Patent WO9839433.

ACCESSION A86603

VERSION A86603.1 GI:6735176

KEYWORDS

SOURCE unidentified.

ORGANISM unidentified.

REFERENCE 1 (bases 1 to 591)

AUTHORS Smith, R.A. and Cox, V.F.

TITLE COMPLEMENT RECEPTOR TYPE 1 (CR1)-LIKE SEQUENCES

JOURNAL Patent: WO 9839433-A 12 11-SEP-1998;
SMITH RICHARD ANTONY GODWIN (GB); ADPROTECH PLC (GB)

FEATURES
source 1. .591
Location/Qualifiers

BASE COUNT 134 a 158 c 146 g 153 t
ORIGIN

alignment_scores:

Quality: 635.00 Length: 121
Ratio: 5.336 Gaps: 0
Percent Similarity: 98.347 Percent Identity: 90.909

alignment_block:
US-10-031-904-8 x A86603 ..

Align seg 1/1 to: A86603 from: 1 to: 591

```

34 GlnCysAsnValProGluTrpLeuProPheAlaArgProThrAsnLeuTh 50
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
4 CAGTGAACGCTCCGGAATGGCTGCCGCGCCGACCAACCTGAC 53
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
50 TASPAPPhgGluPheProIleGlyThrTyrlleuAsnTyrlleuGlyArg 67
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
54 TGATGAATTGAGTCCCGATCGGATCGTACCTGAACTGCAATGCGCC 103
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
67 roGlyTyrSerGlyArgProPheSerIleleCysLeuLysAsnSerVal 83
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
104 CGGGTTATAGCGCGCCGCTTTCTATCATCTGCTGAATAACTGCTGTC 153
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
84 TrpThSerAlaLysAspLysCysLysArgLysSerCysArgAsnProPr 100
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
154 TGGACGGGCTAGAGACCGGTCGACGTAATCTTGCTGAATCCGCC 203
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
100 oAspProValAsnGlyMetAlaHisValIleLysAspIleGlnPheGly 117
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
204 AGATCGCGTTAAGCGATGGTGCATGATCAAGGATCCAGTTCCGTT 253
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
117 ergGlnIleLysTyrSerCysProLysGlyTyrArgLeuIleGlySer 133
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
254 CCCAAATTAATATCTTCTGACTAAAGGTTACCGCTGATGGTCCCTCC 303
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
134 SerAlaThrCysIleIleSerGlyAsnThrValIleTrpAspAsnLysTh 150
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
304 AGCGTACATGCATCATCTGCTGATGATCTGATTTGGGATATGAAC 353
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
150 rProValCysAsp 154
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
354 ACCGATTGTGAC 366

```

seq_name: gb_pat:A86605

seq_documentation_block:

LOCUS A86605 591 bp DNA linear PAT 21-JAN-2000
DEFINITION Sequence 14 from Patent WO9839433.
ACCESSION A86605
VERSION A86605.1 GI:6735177
KEYWORDS
ORGANISM unidentified.
SOURCE unidentified.
REFERENCE 1 (bases 1 to 591)
AUTHORS Smith,R.A. and Cox,V.F.
TITLE COMPLEMENT RECEPTOR TYPE 1 (CR1)-LIKE SEQUENCES
JOURNAL Patent: WO 9839433-A 14 11-SEP-1998;
SMITH RICHARD ANTONY GODWIN (GB); ADPROTECH PLC (GB)
FEATURES
source 1. .591
Location/Qualifiers
/organism="unidentified"
/db_xref="taxon:32644"

BASE COUNT 131 a 160 c 149 g 151 t

ORIGIN

alignment_scores:
Quality: 635.00 Length: 121
Ratio: 5.336 Gaps: 0
Percent Similarity: 98.347 Percent Identity: 90.909

alignment_block:
US-10-031-904-8 x A86605 ..

Align seg 1/1 to: A86605 from: 1 to: 591

```

34 GlnCysAsnValProGluTrpLeuProPheAlaArgProThrAsnLeuTh 50
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
4 CAGTGAACGCTCCGGAATGGCTGCCGCGCCGACCAACCTGAC 53
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
50 TASPAPPhgGluPheProIleGlyThrTyrlleuAsnTyrlleuGlyArg 67
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
54 TGATGAATTGAGTCCCGATCGGATCGTACCTGAACTGCAATGCGCC 103
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
67 roGlyTyrSerGlyArgProPheSerIleleCysLeuLysAsnSerVal 83
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
104 CGGGTTATAGCGCGCCGCTTTCTATCATCTGCTGAAATAACTGCTGTC 153
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
84 TrpThSerAlaLysAspLysCysLysArgLysSerCysArgAsnProPr 100
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
154 TGGACGGGCTAGAGACCGGTCGACGTAATCTTGCTGAATCCGCC 203
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
100 oAspProValAsnGlyMetAlaHisValIleLysAspIleGlnPheGly 117
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
204 AGATCGCGTTAAGCGATGGTGCATGATCAAGGATCCAGTTCCGTT 253
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
117 ergGlnIleLysTyrSerCysProLysGlyTyrArgLeuIleGlySer 133
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
254 CCCAAATTAATATCTTCTGACTAAAGGTTACCGCTGATGGTCCCTCC 303
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
134 SerAlaThrCysIleIleSerGlyAsnThrValIleTrpAspAsnLysTh 150
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
304 AGCGTACATGCATCATCTGCTGATGATCTGATTTGGGATATGAAC 353
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
150 rProValCysAsp 154
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
354 ACCGATTGTGAC 366

```

seq_name: gb_pat:A86607

seq_documentation_block:

LOCUS A86607 591 bp DNA linear PAT 21-JAN-2000
DEFINITION Sequence 16 from Patent WO9839433.
ACCESSION A86607
VERSION A86607.1 GI:6735178
KEYWORDS
ORGANISM unidentified.
SOURCE unidentified.
REFERENCE 1 (bases 1 to 591)
AUTHORS Smith,R.A. and Cox,V.F.
TITLE COMPLEMENT RECEPTOR TYPE 1 (CR1)-LIKE SEQUENCES
JOURNAL Patent: WO 9839433-A 16 11-SEP-1998;
SMITH RICHARD ANTONY GODWIN (GB); ADPROTECH PLC (GB)
FEATURES
source 1. .591
Location/Qualifiers
/organism="unidentified"
/db_xref="taxon:32644"

alignment_scores:
Quality: 635.00 Length: 121
Ratio: 5.336 Gaps: 0
Percent Similarity: 98.347 Percent Identity: 90.909

alignment_block:
US-10-031-904-8 x A86607

Align seg 1/1 to: A86607 from: 1 to: 591

```

34 GlnCysAsnValProGluTrpLeuProPheAlaArgProThrAsnLeuTh 50
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
4 CAGTGCACACGCTCCGGAATGGCTGCGCGCCGCCGCCACCAACCTGAC 53
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
50 rAspAspPheGluPheProIleGlyThrTyrLeuAsnTyrGluCysArgP 67
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
54 TGATGATTTGAGTTCGCCGATCGGTAACCTGACCTGAACTACCAATCCGCC 103
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
67 roGlyTyrSerGlyArgProPheSerIleIleCysLeuLysAsnSerVal 83
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
104 CGGGTTATAGCGCGCCCGCTTTTCATCATCTGCTCAAAAACCTGCTC 153
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
84 TrpThrSerAlaLysAspLysCysLysArgLysSerCysArgAsnProPr 100
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
154 TGACACTGGTCTAGACACCGCTGCCGACGTAATCTTGCTGTAATCCGCC 203
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
204 AGATCCGGTTAACGGCATGGTGCATGTGATCAAGGCATCCAGTTCGGTT 253
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
100 oAspProValAsnGlyMetAlaHisValIleLysAspIleGlnPheGly 117
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
117 ergInIleLysTyrSerCysProLysGlyTyrArgLeuIleGlySerSer 133
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
254 CCCAAATTAAATTTCTTGTACTAAAGTTACCGTCTGATTTGCTCTCC 303
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
134 SerAlaThrCysIleIleSerGlyAsnThrValIleTrpAspAsnLysTh 150
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
304 AGCGCTACATGCAATCATCTGTGTGATCTGATCTGATTTGGATTAAGAAC 353
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
150 rProValCysAsp 154
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
354 ACCGATTGTGAC 366

```

seq_name: gb_pat:A86609

seq_documentation_block:

```

LOCUS      A86609                      591 bp    DNA     linear     PAT 21-JAN-2000
DEFINITION Sequence 18 from Patent WO9839433.
ACCESSION  A86609
VERSION     A86609.1  GI:6735179
KEYWORDS
SOURCE      unidentified.
ORGANISM    unidentified.
REFERENCE   1 (bases 1 to 591)
AUTHORS    Smith, R.A. and Cox, V.F.
TITLE      COMPLEMENT RECEPTOR TYPE 1 (CR1)-LIKE SEQUENCES
JOURNAL    Patent: WO 9839433-A 18 11-SEP-1998;
          SMITH RICHARD ANTONIO GODWIN (GB); ADPROTECH PLC (GB)
FEATURES
  source     1..591
             /organism="unidentified"
             /db_xref="taxon:32644"
BASE COUNT  135 a      159 c      146 g      151 t
ORIGIN

```

alignment_scores:
Quality: 635.00 Length: 121
Ratio: 5.336 Gaps: 0
Percent Similarity: 98.347 Percent Identity: 90.909

alignment_block:

US-10-031-904-8 x A86609

Align seg 1/1 to: A86609 from: 1 to: 591

34 GlnCysAsnValProGluTrpLeuProPheAlaArgProThrAsnLeuTh 50

```

|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
4 CAGTGCACACGCTCCGGAATGGCTGCGCGCCGCCGCCACCAACCTGAC 53
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
50 rAspAspPheGluPheProIleGlyThrTyrLeuAsnTyrGluCysArgP 67
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
54 TGATGATTTGAGTTCGCCGATCGGTAACCTGACCTGAACTACCAATCCGCC 103
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
67 roGlyTyrSerGlyArgProPheSerIleIleCysLeuLysAsnSerVal 83
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
104 CGGGTTATAGCGCGCCCGCTTTTCATCATCTGCTCAAAAACCTGCTC 153
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
84 TrpThrSerAlaLysAspLysCysLysArgLysSerCysArgAsnProPr 100
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
154 TGACACTGGTCTAGACACCGCTGCCGACGTAATCTTGCTGTAATCCGCC 203
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
204 AGATCCGGTTAACGGCATGGTGCATGTGATCAAGGCATCCAGTTCGGTT 253
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
117 ergInIleLysTyrSerCysProLysGlyTyrArgLeuIleGlySerSer 133
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
254 CCCAAATTAAATTTCTTGTACTAAAGTTACCGTCTGATTTGCTCTCC 303
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
134 SerAlaThrCysIleIleSerGlyAsnThrValIleTrpAspAsnLysTh 150
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
304 AGCGCTACATGCAATCATCTGTGTGATCTGATCTGATTTGGATTAAGAAC 353
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
150 rProValCysAsp 154
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
354 ACCGATTGTGAC 366

```

seq_name: gb_pat:AR029199

seq_documentation_block:

```

LOCUS      AR029199                     605 bp    DNA     linear     PAT 29-SEP-1999
DEFINITION Sequence 33 from patent US 5859223.
ACCESSION  AR029199
VERSION     AR029199.1  GI:5941172
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unknown.
REFERENCE   1 (bases 1 to 605)
AUTHORS    Mosakowska, D. Ewa-Irena., Dodd, I., Freeman, A. Mary. and
          Smith, R. Anthony. Godwin.
TITLE      Soluble CR1 derivatives
JOURNAL    Patent: US 5859223-A 33 12-JAN-1999;
          Location/Qualifiers
FEATURES
  source     1..605
             /organism="unknown"
BASE COUNT  136 a      161 c      150 g      158 t
ORIGIN

```

alignment_scores:
Quality: 635.00 Length: 121
Ratio: 5.336 Gaps: 0
Percent Similarity: 98.347 Percent Identity: 90.909

alignment_block:

US-10-031-904-8 x AR029199

Align seg 1/1 to: AR029199 from: 1 to: 605

```

34 GlnCysAsnValProGluTrpLeuProPheAlaArgProThrAsnLeuTh 50
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
7 CAGTGCACACGCTCCGGAATGGCTGCGCGCCGCCGCCACCAACCTGAC 56
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
50 rAspAspPheGluPheProIleGlyThrTyrLeuAsnTyrGluCysArgP 67
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
57 TGATGATTTGAGTTCGCCGATCGGTAACCTGACCTGAACTACCAATCCGCC 106
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
67 roGlyTyrSerGlyArgProPheSerIleIleCysLeuLysAsnSerVal 83

```



```
|||||
107 CCGGTTATAGCGCGCCGGTTTCTATCATCTGCGTGAACCACTCTGTC 156
84 TTPThrSerAlaLysAspLysCysLysArgLysSerCysArgAspProp 100
|||||
157 TCGACTGGCTAGACCGCTGGCCGACGTAATCTTGTCTGTAACCCGCC 206
100 oAspProValAsnGlyMetAlaHisValIleLysAspIleGlnPheGly 117
|||||
207 AGATCCGGTTACGGCATGCTCATGTATCAAGGCAATCCAGTTCCGATT 256
117 eGlnIleLysTyrSerCysProLysGlyTyrArgLeuIleGlySerSer 133
|||||
257 CCCAATTAATAATCTGTACTAAGGTACCGCTGATGTTGTTCTCTCC 306
134 SerAlaThrCysIleLeSerGlyAsnThrValIleTrrPAspAsnLysTh 150
|||||
307 ACCGCTACATGCATCATCTGTGTATCATGTGCATTTGGGATGAAGAAC 356
150 rProValCysAsp 154
|||||
357 ACCGATTTCTGAC 369

seq_name: gb_pr:BABCORE
seq_documentation_block:
LOCUS BABCORE 1688 bp mRNA linear PRI 07-MAY-1996
DEFINITION Papio cynocephalus complement receptor mRNA, partial cds.
ACCESSION L77977
VERSION L77977.1 GI:1301608
KEYWORDS complement C3b; complement receptor;
glycophosphatidylinositol-linked protein.
SOURCE Papio cynocephalus cDNA to mRNA.
ORGANISM Papio cynocephalus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Cercopitheciidae;
Cercopithecinae; Papio.
1 (bases 1 to 1688)
REFERENCE
AUTHORS Birmingham,D.J., Logar,C.M., Shen,X.-P. and Chen,W.
TITLE The baboon erythrocyte complement receptor is a glycosphosphatidyl
inositol-linked protein encoded by a homologue of the human
CRI-like genetic element
JOURNAL Unpublished (1996)
FEATURES
location/Qualifiers
source
1..1688
/organism="Papio cynocephalus"
/db_xref="taxon:9536"
/cell_type="erythrocyte"
/tissue_type="bone marrow"
/dev_stage="adult"
<1..>1688
<1..1571
/note="homologue of human CRI-like genetic element"
/codon_start=3
/product="complement receptor"
/protein_id="AA99004.1"
/db_xref="GI:1301608"
/translacion="VVALQKAGASSPSPEVGPAPRLFFCCGSLAVVYLALPVA
WGOCNAPEQLPFAPIPLDASEFPVGTIKYKCLPGYHKKPSIICLNKSVTSKD
KCTRKSCRNPKDPVNGVAVHIDIOGSOYNVSCNGYRLIGSSATCIISGTVLMD
NETPIEIIICPGPIIANGDFISTSEYSPYSVYRNLSSGRKLELGEPSI
YCTSKDOVQIWSGPAPOCIIPNKRCMPNENVALSVNSLFSLNKVEEFCOPFI
MKGRHYCOALNKMEPELPSRCNVCOPREILAGHTBPESHOEPSPGOEYFSCBEGY
DLKGAASLHCTPGQDNKPEAPICTVYSCDFDLQLPHGRVLFPLNLQDLKAKSVCE
GFRKGRFASHCVIAGKALMNSVPCEDIFCPNPAILNGRHIAPIGLDIPYGEV
SYICDPHPRGMVNLIGESTIRCTSDPOGNSWSPAPRCLELSPAGANDALIVGTL
SGTIFVLEFIIFLS"
BASE COUNT 413 a 427 c 411 g 437 t
ORIGIN
alignment_scores:
Quality: 599.50 Length: 138
```

```
Ratio: 4.874 Gaps: 1
Percent Similarity: 89.130 Percent Identity: 81.159
alignment_block:
US-10-031-904-8 x BABCORE ..
Align seg 1/1 to: BABCORE from: 1 to: 1688
18 GlyLeuLeuLeuAlaIleValLeuLeu...LeuSerSerPheSerAs 33
|||||
90 GGATCCCTGTTGGCGGTGTGTCTGCTCGCTGCGGCTGGCCCTGGGG 139
33 pGlnCysAsnValProGluTrrPleuProPheAlaArgProThrAsnLeu 50
|||||
140 TCATATGCAATGCCCGGACAGCTTCATTTGCCAGGCCACCACTTA 169
50 hrAspAspPheGluPheProIleGlyThrTyrLeuAsnTyrGluCysArg 66
|||||
190 CTGATGCATCTGACGTTCCCGTTGGGACATATCTGAAGTATGATGCC 239
67 ProGlyTyrSerGlyArgProPheSerIleIleCysLeuLysAsnSerVa 83
|||||
240 CTTGCTTATCATGGAACCAATTTCTATCATCTGCTTAATAAACTAGT 289
83 ITrpThrSerAlaLysAspLysCysLysArgLysSerCysArgAsnProp 100
|||||
290 CTGACCAAGTCTCTAAGACACAAGTCACACGTAATATCATGCTAATCT 339
100 roAspProValAsnGlyMetAlaHisValIleLysAspIleGlnPheGly 116
|||||
340 AAGATCTGTGTAAGGATGGTGCATGTGATCAAGACATCCAGTTCCGGA 389
117 SerGlnIleLysTyrSerCysProLysGlyTyrArgLeuIleGlySerSe 133
|||||
390 TCCCAATTAATATTCTTGTGAATAAGATACCGATCATCTAGTTGTTCT 439
133 rSerAlaThrCysIleLeSerGlyAsnThrValIleTrrPAspAsnLysT 150
|||||
440 GTCCGCCACATGATCAATCTCAGGCAATGATGTCATTTGGGATATGAAA 489
150 hrProValCysAsp 154
|||||
490 CACCTATTGTGAG 503

seq_name: gb_pr:BABCR1A
seq_documentation_block:
LOCUS BABCR1A 6000 bp mRNA linear PRI 11-FEB-1995
DEFINITION Papio hamadryas complement component receptor type 1 (CRI) mRNA,
complete cds.
ACCESSION L39791
VERSION L39791.1 GI:662828
KEYWORDS C3b/C4b complement component receptor; complement component
receptor CRI; complement receptor 1.
SOURCE Papio hamadryas (clone SPC-CYT3NC) cDNA to mRNA.
ORGANISM Papio hamadryas
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Cercopitheciidae;
Cercopithecinae; Papio.
1 (bases 1 to 6000)
REFERENCE
AUTHORS Clemenz,L., Subramanian,B.V., Nickells,M.W., Hourcade,D.E. and
Atkinson,J.P.
TITLE Primary sequence of the baboon 200 kDa C3b/C4b receptor (CRI)
JOURNAL Unpublished (1995)
FEATURES
location/Qualifiers
source
1..6000
/organism="Papio hamadryas"
/db_xref="taxon:9557"
/clone="SPC-CYT3NC"
/cell_line="26CB-1"
/cell_type="lymphoblastoid"
1..6000
/gene="CRI"
gene
```



```

|||||
403 AACATATGACTTTGAGTTCCCATTTGGACATATCTAATATGATGATGCC 354
66 rprgcltyrserglyarpropheserlelleleuylsasnsr 82
353 GCCCTGCTTATTCGGAAGACCGTTTCTATCATCTGCCATTAATACTCA 304
83 ValTTPThrSerAlaLysAspLysCysLysArgLysSerCysArgAsnDr 99
303 GTCCTGACAAAGTCTTAAGACAACTGCAACGTAATCAATGCTGATATCC 254
99 oProAspProValAsnGlyMetAlaHisValIleLysAspIleGlnPheG 116
253 TCCAGATCCTGTGATGGCATGGCAGCATGTGATCAAAAGCATCATTCG 204
116 lYserGlnIleLysTyrSerCysProLysGlyTyrArgLeuIleGlySer 132
203 GATCCCAATTAATATTTCTGTCTTAAGGATACGACATGCTGATGCC 154
133 SerSerAlaThrCysIleIleSerGlyAsnThrValIleTyrAspAsnLys 149
153 TCGCTGCGCACATCATCATCTCAGCCACACATGATGGGATTAATA 104
149 sThrProValCysAspSerGlyLeuLysTyrAlaPheLeuPheLeuLeuP 166
103 AACACCTGTTTGTGACAGTGAATGTAATGATGATCTTCTTTTAC 54
166 rolleHisSerAspPheSerLeuGlu 174
53 CGATACATTCATTAATTTCTCTCGGAA 28
seq_name: gb_est1:A1240881

```

```

seq_documentation_block:
LOCUS A1240881 443 bp mRNA linear EST 28-JAN-1999
DEFINITION g194604.x1 NCI CGAP Kid3 Homo sapiens cDNA clone IMAGE:1867134 3'
similar to gb:Y00816.cd81 COMPLEMENT RECEPTOR TYPE 1 PRECURSOR
(HUMAN);, mRNA sequence.
ACCESSION A1240881
VERSION A1240881.1 GI:3836278
KEYWORDS EST.
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
1 (bases 1 to 443)
NCI CGAP http://www.ncbi.nlm.nih.gov/ncicgap.
National Cancer Institute, Cancer Genome Anatomy Project (CGAP),
Tumor Gene Index
Unpublished (1997)
Contact: Robert Strausberg, Ph.D.
Email: c9aps-r@mail.nih.gov
Tissue Procurement: Christopher Moskaluk, M.D., Ph.D., Michael R.
Emmert-Buck, M.D., Ph.D.
CDNA Library Preparation: M. Bento Soares, Ph.D.
DNA Library Arrayed by: Greg Lennon, Ph.D.
DNA Sequencing by: Washington University Genome Sequencing Center
clone distribution: NCI-CGAP clone distribution information can be
found through the I.M.A.G.E. Consortium/BLM at:
www-bio.liml.gov/bhrp/image/image.html
Insert Length: 625 Std Error: 0.00
Seq primer: -40UP from gibco
High quality sequence stop: 373.
Location/Qualifiers
1..443
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone="IMAGE:1867134"
/clone_lib="NCI CGAP_Kid3"
/lab_host="DH10B"
/note="Organ: Kidney; Vector: p773D-Pac (Pharmacia) with
a modified polylinker; Site:1: Not 1; Site_2: Eco RI; 1st
strand cDNA was primed with a Not I - oligo(dt) primer,"

```

double-stranded cDNA was ligated to Eco RI adaptors (Pharmacia), digested with Not I and cloned into the Not I and Eco RI sites of the modified p773 vector. MRNA source: 2 pooled kidneys. Library went through one round of normalization. Library constructed by Bento Soares and M. Patricia Bonaldo.

```

BASE COUNT      131 a      80 c      104 g      128 t
ORIGIN
alignment_scores:
Quality: 748.00 Length: 141
Ratio: 5.420 Gaps: 0
Percent Similarity: 97.872 Percent Identity: 97.163

```

alignment_block:
US-10-031-904-8 x A1240881/rev ..

Align seg 1/1 to reverse of: A1240881 from: 1 to: 443

```

34 GInCysAsnValProGluTyrPheProPheAlaArgProThrAsnLeuTh 50
|||||
442 CATGCTTATTCGGAAGACCGTTTCTATCATCTGCTTAATAAACTCAGTCC 393
50 rAspAspPheGluPheProIleGlyThrTyrLeuAsnTyrGluCysArgP 67
|||||
392 TGATGACTGTGAGTTCCCATGCGACATVTCGAACTATGAAATCCGCC 343
67 roGlyTyrSerGlyArgProPheSerIlelleCysLeuLysAsnSerVal 83
|||||
342 CTGGTTATTCGGAAGACCGTTTCTATCATCTGCTTAATAAACTCAGTCC 293
84 TrpThrSerAlaLysAspLysCysLysArgLysSerCysArgAsnProp 100
|||||
292 TGACAAAGTCTTAAGACAAAGTCAACGTAATCATCTGCTTAATCTCC 243
100 cAspProValAsnGlyMetAlaHisValIleLysAspIleGlnPheGlys 117
242 AGATCCTGTGAATGGCATGGCAGATGATGCAAAAGACATCGATCGGAT 193
117 ergGlnIleLysTyrSerCysProLysGlyTyrArgLeuIleGlySerSer 133
|||||
192 CCCAATTAATAATTTCTGTCTTAAGGATACCGACTATGCTGCTCG 143
133 SerAlaThrCysIleIleSerGlyAsnThrValIleTyrAspAsnLysTh 150
|||||
142 TCTGCCACATCATCATCTCAGCCACACGTCATTTGGGATTAATAAAC 93
150 rProValCysAspSerGlyLeuLysTyrAlaPheLeuPheLeuLeuProI 167
92 ACCTGTTGTGACAGTGAATGAAATATGCAATTCATTTCTTTACCGA 43
167 leHisSerAspPheSerLeuGlu 174
42 TACATTCATTAATTTCTCTCGGAA 20

```

seq_name: gb_est1:A1718588

```

seq_documentation_block:
LOCUS A1718588 444 bp mRNA linear EST 10-JUN-1999
DEFINITION a54601.x1 Barstead aorta HPIRB6 Homo sapiens cDNA clone
IMAGE:2220273 3' similar to gb:Y00816.cd81 COMPLEMENT RECEPTOR TYPE
1 PRECURSOR (HUMAN);, mRNA sequence.
ACCESSION A1718588
VERSION A1718588.1 GI:5035844
KEYWORDS EST.
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
1 (bases 1 to 444)
Hillier,L., Allen,M., Bowles,L., Dubuque,T., Geisels,G., Jost,S.,
Klitzman,D., Kucaba,T., Lacy,M., Le,N., Lennon,G., Marra,M., Martin

```

J., Moore, B., Schellenberg, K., Steptoe, M., Tan, F., Theising, B.,
White, Y., Wylie, T., Waterston, R. and Wilson, R.
WashU-MCI human EST Project
Unpublished (1997)
Contact: Wilson RK
Washington University School of Medicine
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
Tel: 314 286 1800
Fax: 314 286 1810
Email: est@wustl.wustl.edu

This clone is available royalty-free through LNL; contact the
IMAGE Consortium (info@image.llnl.gov) for further information.
Seq primer: -400P from Gldco.

FEATURES

source
1..444
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone_image="2320273"
/clone_lib="Barstead aorta HPLRB6"
/sex="male"
/dev_stage="adult, age 64"
/lab_host="DH10B (phage resistant)"
/note="Organ: aorta; Vector: pT73D-Pac (Pharmacia) with a
modified polylinker; Site_1: EcoRI, Site_2: NotI; 1st
strand cDNA was primed with a Not I - Oligo(dT) primer [5'
TGTTACGATCTGAGTGGAGCGCGCCCTTTTCTTTTCTTTTCTTTTCTTTT
3']; double-stranded cDNA was ligated to Eco RI adaptors
[5' ATTCGATCGAAC 3' and 5' GTTGGATCGG 3'], digested
with Not I and cloned into the Not I and Eco RI sites of
the modified pT73 vector. Library constructed by Bob
Barstead."

BASE COUNT 134 a 87 c 103 g 120 t

ORIGIN

alignment_scores:
Quality: 699.00 Length: 141
Ratio: 5.102 Gaps: 0
Percent Similarity: 97.163 Percent Identity: 90.780

alignment_block:

US-10-031-904-8 x A1718588/rev ..

Align seg 1/1 to reverse of: A1718588 from: 1 to: 444

```

34 GlnCysAsnValProGluTrpLeuProPheAlaArgProThrAsnLeuTh 50
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
441 CAATGCAATGCCAGATGGCTTCATTTGCCAGGCTTACCAACCTAAC 392
50 RAspAspPheGluPheProIleGlyThrTyrLeuAsnTyrGluCysArgP 67
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
391 TGAATGAGTTGAGTTCCCATTTGGACATATCTGACATATGATGACGCC 342
67 roGlyTyrSerGlyArgProPheSerIleIleCysLeuLysAsnSerVal 83
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
341 CTGCTATATCCGAGACGCTTTTCATCATCTGCTAAACCAACCACTC 292
84 TrpThrSerAlaLysAspLysCysLysArgLysSerCysArgAspProPr 100
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
291 TGGACATGCTGCTAAGACAGACAGCTAATCATCATCTGCAATCCCTCC 242
100 cAspProValAsnGlyMetAlaHisValIleLysAspIleGlnPheGlyS 117
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
241 AGATCCCTGTGAATGGATGGTGCATGTGATCAAGACATCCGATCCGAT 192
117 ergInIleLysTyrSerCysProLysGlyTyrArgLeuIleGlySerSer 133
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
191 CCCAAATTAATATATCTTGTACTAAGATACGACATCATCTGCTCCG 142
134 SerAlaThrCysIleIleSerGlyAsnThrValIleThrAspAsnLysTh 150
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
141 TC.GCCACATGCATCATCTCAGGTGATACGTCAATTTGGAGTAATGAAC 93

```

150 rProValCysAspSerGluLeuLysTyrAlaPheLeuPheLeuProI 167
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
92 ACCATATTTGTGACAGTGAATATCCCTTCTTCTTCTTCTTCTTACCGA 43
167 LeHISerAspPheSerLeuGlu 174
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
42 CCCATCTATATTTTCTCTCGGAA 20

seq.name: gb_est2:BF240184

seq.documentatn_block:

LOCUS BF240184 832 bp mRNA linear EST 14-NOV-2000
DEFINITION 601905704F1 NIH_MGC_54 Homo sapiens cDNA clone IMAGE:4133424 5',
mRNA sequence.

ACCESSION BF240184
VERSION BF240184.1 GI:11154107
KEYWORDS EST.
SOURCE human.
ORGANISM Homo sapiens

REFERENCE

1 (bases 1 to 832)
NIH-MGC <http://mgi.nci.nih.gov/>
National Institutes of Health, Mammalian Gene Collection (MGC)

UNPUBLISHED (1999)

Contact: Robert Strausberg, Ph.D.
Email: cga@bbs-remail.nih.gov

TISSUE Procurement: ATCC

cDNA Library Preparation: CLONTECH Laboratories, Inc.
DNA sequencing by: InCyte Genomics, Inc.

Clone distribution: MGC clone distribution information can be
found through the I.M.A.G.E. Consortium/LLNL at:

<http://image.llnl.gov>
Plate: L1CMI034 row: h column: 01
High quality sequence stop: 544.

FEATURES

source

1..832
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone_image="4133424"
/clone_lib="NIH-MGC_54"
/tissue_type="from chronic myelogenous leukemia"
/lab_host="DH10B (T1 phage-resistant)"
/note="Organ: bone marrow; Vector: pDNR-LIB (Clontech);
Site_1: SfiI (ggcgccctggcc); Site_2: SfiI (ggccatagggc
5') and 3' adaptors were used in cloning as follows: 5'
adaptor sequence: 5'-ATTCGATGAGCGGAGCGGCGGACATG-dT(30)-BN-3'
(where B = A, C, or G and N = A, C, G, or T). Average
insert size 1.75 kb (range 0.9-4.0 kb). 15/15 colonies
contained inserts by PCR. This library was enriched for
full-length clones and was constructed by Clontech
Laboratories (Palo Alto, CA)."

BASE COUNT 188 a 226 c 197 g 220 t 1 others

ORIGIN

alignment_scores:
Quality: 678.00 Length: 163
Ratio: 4.612 Gaps: 3
Percent Similarity: 90.184 Percent Identity: 88.957

alignment_block:

US-10-031-904-8 x BF240184 ..

Align seg 1/1 to: BF240184 from: 1 to: 832

```

1 MetAlaProProValArgLeuGluArgProPheProSerArgArgPhePr 17
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
113 ATGGGCGCTCCGCTCGTCGAGCGTCCCTTCTCCCGGCGGCTTCC 162

```

```

17  oglyleuleuleualaialeValleuleuleuSerSerPhSerAspG 34
18  |||||
19  163  TGGGTGGCTTCGTGGCGGC. CTGGTGTTCGTCTGTCTCTCTTCTCCGATC 211
20  |||||
21  34  lncysanValProgluTlrpleuprophealaargrpotrhnasleuthr 50
22  |||||
23  212  AATGCATATGCCGGAAATGGCTTCATTCGACAGCTACCAACCTAACT 261
24  |||||
25  51  AspAspPheglupheProillelyThrTyrleuasnTyrGlucysarGrp 67
26  |||||
27  262  GATGACCTTGATGGTTTCCATTNNGACATCATCTGACATGATGAATGCCGCC 311
28  |||||
29  67  oglyTyrserglyargrpopheserilleCysleuYsaSnSerValT 84
30  |||||
31  312  TGGTATTCGCGAAGACGGTTTTCTATCATCTGTGCTTAAACATCAGTCT 361
32  |||||
33  84  rPthSerAlaIalysAspIysCysIysarGlysserCysarGAsnPropo 100
34  |||||
35  362  GGACAGTGCTAAGGCAAGTGCACCAAGCTAATCATGTGTGTAATCTCTCA 411
36  |||||
37  101  AspProValasnGlyMetAla. HisValilleYsaSpIleGlnPhe. Gly 116
38  |||||
39  412  GATTCGTGTGAATGGCATGACACCATGTGATCAACAGCATCCAGTTCCAGA 461
40  |||||
41  117  SerGlnIleIysTyrSerCysProIysGlyTyrArgleuIleGlySerSe 133
42  |||||
43  462  TCCCAATTAATATTCCTTGTCTCTTAAGGATACCGACTCATTTGGTTCTTC 511
44  |||||
45  133  rSerAlaThrCysIleIleSerGlyAsnThrValIleTyrPaasPasnIysT 150
46  |||||
47  512  GTCTGC. ACATGCATCATCTGACGCAACACTGTCAATTCCTGGCATACATA 560
48  |||||
49  150  hrProValCys..... AspserGluIleuYsaTyr 159
50  |||||
51  561  AAACACACCTGTTTGTGGACAGTGTATGATCCATTAAC 595
52  |||||
53  name: gp_est3.BM477528

```

Site 2: Sail: Cloned unidirectionally: oligo-dT primed.
Average insert size 1.867 kb. Library enriched for
full-length clones and constructed by Life Technologies
Note: this is a NIH_MGC Library."

BASE COUNT	251 a	286 c	272 g	249 t	5 others
ORIGIN					

[illegible]

alignment_block:
US-10-031-904-8 x BM477528

Align seg 1/1 to: BM477528 from: 1 to: 1063

[illegible]


```

/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone_1 IMAGE:66327"
/clone_1b="Soares fetal liver spleen INF1s"
/sex="male"
/dev_stage="20 week-post conception fetus"
/lab_host="DH10B (ampicillin resistant)"
/note="Organ: Liver and Spleen; Vector: pT713D (Pharmacia)
with a modified polylinker; Site_1: Pac I; Site_2: Eco RI;
1st strand cDNA was primed with a Pac I - oligo(dT) primer
15' AACTGGAGACATTAATTAAGATCTTTTTTTTTTTTTTTT 3'),
double-stranded cDNA was ligated to Eco RI adaptors
(Pharmacia), digested with Pac I and cloned into the Pac I
and Eco RI sites of the modified pT73 vector. Library
went through one round of normalization. Library
constructed by Bento Soares and M.Patima Bonaldo."

```

4444 Forest Park Parkway, Box 8501, St. Louis, MO 63103
Tel: 314.286.1800
Fax: 314.286.1810
Email: es@ewatson.wustl.edu
Insert Size: 791
This quality sequence stops: 300 Source: IMAGE Cons
High quality sequence stops: 300 Source: IMAGE Cons
This clone is available royalty-free through LINDA.

alignment_block:
US-10-031-904-8 x H73873

Align seg 1/1 to: H73873 from: 1 to: 440

```

4  PevAlarIeuglIarProPhaProSeArIarPhaProGlyLeuile 20
93  CCCGTCGCTCGAGAGGCCCTTCCCTTCCTCCGGCTCT 142
20  uleuAaAlaIeueAlIeuleIeueSerSerPheserApgIeCysaIv 37
143  TCTGGGGCCCTGGGTGGTGGCTGGCTCTCCCTCTCGATCATGCAATG 192
37  aIProGutIreIeueProPhaIaIarProPhrAsIeueIhrAsaPha 53
193  TCCCGGAATGGCTTCATTCCTCCAGGCGCTACCACTCATCATCTATT 242
54  GIuIreProIIeGIYhTyrIleuAsnTyrGIaIcYarPro_GIuTyrS 70
243  GAGTTTCCCATTTGGGACATATCTGAATATGATGCGCGCTGGTTATT 292
70  erGIuIarGrProPheserIleIleCysIeueIysAsnSerValTrp_Thn 86
293  CCGGAAGACCGTTTCTATCATCTGCTTAAAAAACCTCACTGGGACAA 342
86  rAlaIeAspIyScYsIyIarq_LysSerCys_ArGAsnPro_ProAsp 102
343  TGCtAAAGAGCAAGTCCAAACGTAAATCATGTCGTAAATCCCTTCAG 392
102  roValaIasn_GIuMeAlaHisValIle_....LysAspIle 113
393  CTGTGGATTGGGCATNGCCACATTTGTGATCATCAAAAGACATT 434

```

LOCUS	AA212152	601 bp	mRNA	linear	EST 31-JUN-1997
DEFINITION	clone0907.r1 Stratagene mouse melanoma (#937312) Mus musculus cDNA				
clone IMAGE:651900 5'	similar to gp:M3529 Mus musculus complement				
receptor (MUSM5)''	mRNA sequence.				

ACCESSION	AA212152	GI:18108675
VERSION	AA212152.1	
KEYWORDS	EST.	
SOURCE	house mouse.	
ORGANISM	Mus musculus	

REFERENCE	AUTHORS
Euarystola; Metazoa; Chordata; Crustacea; Vertebrata; Euteleostomi; Mammalia; Euthuria; Rodentia; Scrinotaphi; Muridae; Mus.	1 (bases 1 to 601)
Marra, M., Hillier, L., Allen, M., Bowles, M., Dietrich, N., Dubuque, T., Gessel, S., Kucaba, T., Lacy, M., Le, M., Martin, J., Morris, M., Schellenberg, K., Steptoe, M., Tan, F., Underwood, K., Moore, B., Theising, R., Wylie, T., Lennon, G., Soares, B., Wilson, R. and Waterston, R.	

TITLE	JOURNAL	COMMENT
The Washu-HHMI Mouse EST Project	Unpublished (1996)	Contact: Marra M/Mouse EST Project

Wasnu-HMI Mouse EST Project
 Washington University School of Medicine
 4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
 Tel: 314 286 1800
 Fax: 314 286 1810
 Email: mouseest@wustl.edu
 This clone is available royalty-free through LML: com-
 mune consortium (info@lml.gov) for further info.
 MGI:397748
 Seq primer: -28m13 rev1 ET from Amersham
 High quality sequence stop: 280.
 Location/Qualifiers
 1. 601
 FEATURES
 source

```

/organism="Mus musculus"
/db_xref="taxon:10090"
/clone="IMAGE:651900"
/clone_lib="Stratagene mouse melanoma (#937312)"

```

```

/tissue_type="melanoma"
/dev_stage="M2 cells"
/lab_host="SOIR (kanamycin resistant)"
/note="Organ: skin; Vector: pBluescript SK-; Site.1: EcoRI
; Site.2: XhoI; Cloned unidirectionally. Primer: oligo
dT. From M2 cells, a highly metastatic derivative of the
K-1735 (mouse) melanoma. Average insert size: 1.0 kb;
Uni-ZAP XR Vector: -5' adaptor sequence, 5' GATTGGCCAGGAG
3' -3' adaptor sequence, 5' CTCGAGTATTTTTTTTTTTT 3'"
BASE COUNT
ORIGIN
149 a 137 c 140 g 175 t

```

[illegible]

```
alignment_block:
US-10-031-904-8  x AA212152
```

Align seg 1/1 to: AA212152 from: 1 to: 601

```

13 SerTgArpHepProGlyLeuLeuLeuAlaAlaLeuValLeuLeuLeu 29
14 ||||| ||||| ||||| ||||| ||||| ||||| |||||
16 AGCCTTCGGCGGAGAGAGTCAGCTAGAGATTGCTGCTTCTTGGCT 118
17 rSerPheSer...AspGlnCysAsnValProGluTrpLeuProPheAla 45
18 ||||| ||||| ||||| ||||| ||||| ||||| |||||
19 GCACATTAACCTTGGGTGACCTGCCAGCCCATACAGACTTCCTTCGCA 168
20 rGpProThrAsnLeuThrAspAspPheGluPheProGlyThrTyrl 61
21 ||||| ||||| ||||| ||||| ||||| ||||| |||||
22 AACCTATAATCTACTACTGATGATCATCATGTTTCCATTGGACATATTG 218
23 AsnTyrGluCysArgProGlyTyrSerGlyArgProPheSerIleIle 78
24 ||||| ||||| ||||| ||||| ||||| ||||| |||||
25 TTGTATGTAATGTCTCCAGATATATACAGAGGCACTCTCTATACACT 268
26 rLeuTyrAsnSerValTrpThrSerAlaValAspGlyGlyAsnArgLys 95
27 ||||| ||||| ||||| ||||| ||||| ||||| |||||
28 CAACCAAGACTCAACCTGAGAGCTGCTGAATATAGATGATACGAAAC 318
29 erCysArgAsnProAspProValAsnGlyMetAlaHisValIleLys 111
30 ||||| ||||| ||||| ||||| ||||| ||||| |||||
31 AATATAAACCTCTTCAGATCTCAGAAAGAGGTTGTCATGATACACACA 368
32 rAspIleGlnPheGlySerGlnIleLysTyrSerCysProLysGlyTyr 128
33 ||||| ||||| ||||| ||||| ||||| ||||| |||||
34 GGCATTCACGTTTGATCCCGATATTATATTACTTTGATACAGACATACG 418
35 rGluIleGlySerSerSerAlaThrCysIleIleSerGlyAsnThrVal 145
36 ||||| ||||| ||||| ||||| ||||| ||||| |||||
37 CCGATTTGGTTCCTCCCTGCTGATGTATGCATCATGATCAAGAAGTTG 468
38 rLeuTrpAspAsnLysThrProValCysArg 154
39 ||||| ||||| ||||| ||||| ||||| ||||| |||||
40 ATTGGATCTAGCAGCACCATTGTGTGAC 457

```

seq_documentation_block:	577 bp	mRNA	linear	EST 26-JAN-2001
LOCUS	B6077250			
DEFINITION	H3013A12-5 N1A Mouse 15K cDNA Clone Set Mus musculus cDNA clone			
	H3013A12 5', mRNA sequence.			
ACCESSION	B6077250			
VERSION	B6077250.1			
KEYWORDS	EST.			
SOURCE	house mouse.			
ORGANISM	Mus musculus			
	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;			
	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.			
REFERENCE	1 (bases 1 to 577)			

140 erglyAsnThrValIleTrpAspAsnLysThrProValCysasp 154
|||||
470 CAGGTGATGATGTCATTTGGATATGAATGAACACCTATTGTGTGAC 513

seq_name: /cgn2_6/prodata/2/lna/backfile1.seq:5472939-1

seq_documentation_block:
; Patent No. 5472939
; APPLICANT: FEARON, DOUGLAS T.; KLUCKSTEIN, LLOYD B.; WONG,
; WINNIE W.; CARSON, GERALD R.; CONCINO, MICHAEL F.; IP, STEPHEN
; H.; MARRIDES, SAVVAS; MARSH, HENRY C. JR.
; TITLE OF INVENTION: METHOD OF TREATING COMPLEMENT
; MEDIATED DISORDERS
; NUMBER OF SEQUENCES: 30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/138,825
; FILING DATE: 19-OCT-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 588,128
; FILING DATE: 24-SEP-1990
; APPLICATION NUMBER: 412,745
; FILING DATE: 26-SEP-1989
; APPLICATION NUMBER: 332,865
; FILING DATE: 03-APR-1989
; APPLICATION NUMBER: 176,532
; FILING DATE: 01-APR-1988
; SEQ ID NO: 1
; LENGTH: 6951
5472939-1

alignment_scores:
Quality: 649.50 Length: 148
Ratio: 4.883 Gaps: 2
Percent Similarity: 89.865 Percent Identity: 81.757

alignment_block:
US-10-031-904-8 x 5472939-1 ..

Align seg 1/1 to: 5472939-1 from: 1 to: 6951

```
10 ProPheProSerArgArgPhe.....ProGlyLeuLeuLeuAlaLe 24
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
70 CCGGGGGGGGCTCCCTCTGCTGGGAGAGATCCCTGCTGGCGGTGT 119
24 uValLeuLeu...LeuSerSerPheSerAspGlnCysAsnValProGluT 40
:|||||: ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
120 GGTGCTGCTGCGGCTGCGGCTGCGGCTGCGGCTGCGGCTGCGGCTG 169
40 rPLeuProPheAlaArgProThrAsnLeuThrAspAspPheGluPhePro 56
||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
170 GGCTTCATTTGGCAGGCTACCACTGATGATGATGATGATGATGATG 219
57 lIleGlyThrTyrlLeuAsnTyrlGluCysArgProGlyTyrSerGlyArgPr 73
||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
220 ATTGGGACATATCTGAATGATGATGATGATGATGATGATGATGATG 269
73 oPheSerIlelleCysLeuLysAsnSerValTrpThrSerAlaLysAspL 90
||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
270 GTTTTCATTCATTCGCTAAAAAAGCTAGCTGAGCTGCTGCTGAAGG 319
90 yScyLysArgLysSerCysArgAsnProPheAspProValAsnGlyMet 106
:|||||: ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
320 GGTGAGAGCGTAAATCATGTCGTAATCCTCAATCCTGTAATGAGCATG 369
107 AlaHisValIleLysAspIleGlnPheGlySerGlnIleLysTyrSecY 123
||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
370 GTGATGATGATCAAGGATCCAGTTCGATGCCAATTAATTAATTCCTG 419
123 sProLysGlyTyrArgLeuIleGlySerSerSerAlaThrCysIleLys 140
||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
420 TACTAAAGATACGACTCATGTTCTGCTGCTGCTGCTGCTGCTGCTG 469
```

140 erglyAsnThrValIleTrpAspAsnLysThrProValCysasp 154
|||||
470 CAGGTGATGATGTCATTTGGATATGAATGAACACCTATTGTGTGAC 513

seq_name: /cgn2_6/prodata/2/lna/5B_COMB.seq:US-08-769-967A-33

seq_documentation_block:
; Sequence 33, Application US/08769967A
; Patent No. 5859223
; GENERAL INFORMATION:
; APPLICANT: Mossakowska, Danuta E.I.
; APPLICANT: Smith, Richard A.G.
; APPLICANT: Dodd, Ian
; APPLICANT: Freeman, Anne Mary
; TITLE OF INVENTION: Soluble CRI Derivatives
; NUMBER OF SEQUENCES: 33
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: SmithKline Beecham Corporate Intellectual Property
; STREET: P.O. Box 1539
; CITY: King of Prussia
; STATE: Pennsylvania
; COUNTRY: USA
; ZIP: 19406
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/769,967A
; FILING DATE:
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/440,569
; FILING DATE: 15-May-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: King, William T.
; REGISTRATION NUMBER: 30,954
; REFERENCE/DOCKET NUMBER: P30423C2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (610) 270-5364
; TELEFAX: (610) 270-5090
; INFORMATION FOR SEQ ID NO: 33:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 605 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
US-08-769-967A-33

alignment_scores:
Quality: 635.00 Length: 121
Ratio: 5.336 Gaps: 0
Percent Similarity: 98.347 Percent Identity: 90.909

alignment_block:
US-10-031-904-8 x US-08-769-967A-33 ..

Align seg 1/1 to: US-08-769-967A-33 from: 1 to: 605

```
34 GlnCysAsnValProGluTrpLeuProPheAlaArgProThrAsnLeuTh 50
||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
7 CAGTGAACGCTCCGGAATGCTGCGGCTGCGGCGCGCCGACCAACTGAC 56
50 rAspAspPheGluPheProIleGlyThrTyrlLeuAsnTyrlGluCysArgP 67
||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
57 TGATGAATTTGAGTTCGCCGATCGGTACTGACTGAACTGCAATGCCGCC 106
67 rGlyTyrSerGlyArgProPheSerIlelleCysLeuLysAsnSerVal 83
||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
```

```

28 LeuSerSerPheSerAspGlnCysAsnValProLutIrrpLeuProPheAl 44
|||||
2661 CTTTCGTGTCGTGCTGGCTACTGTAAACCCCAAGACATTTCCATTGCG 2710
|||||
44 aArgProThrAsnLeuthrAspAspPheGluPheProIleGlyThrTyrL 61
|-|||
2711 CAGTCCCTACGCATCCCAATTAAAGACTTTGAGTTCCAGTCGGGACATCTT 2760
|||||
61 euAsnTyrGlnCysArgProGlyTyrSerGlyArgProPheSerIleLe 77
|||||
2761 TGAATTAAAGAAACCGCTCCGTGGATTTTGGGAAAATGTCTCATGCC 2810
|||||
78 CysIleuLysAsnSerValTrrPThrSerAlaLysAspLysCysLysArgLy 94
|||||
2811 TGCCCTAGAAACATTGCTGTGCTCAAGTGTGAAGACAACTATGACGGA 2860
|||||
94 sSerCysArgAsnProProAspProValAsnGlyMetAlaHisValIleL 111
|||||
2861 ATCAATGAGACCTCCACCAAGAAACCTTCAATGAATGCTGCATTAAACA 2910
|||||

```


ATTORNEY/AGENT INFORMATION:

NAME: Paul T. Clark
 REGISTRATION NUMBER: 30,162
 REFERENCE/DOCKET NUMBER: 06180/005001
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (617) 542-5070
 TELEFAX: (617) 542-8906
 TELEX: 200154

INFORMATION FOR SEQ ID NO: 11:

SEQUENCE CHARACTERISTICS:
 LENGTH: 903 base pairs
 TYPE: nucleic acid
 STRANDEDNESS: double
 TOPOLOGY: linear
 MOLECULE TYPE: cDNA
 US-08-310-416A-11

Alignment scores:

Quality: 289.00 Length: 173
 Ratio: 2.890 Gaps: 6
 Percent Similarity: 57.803 Percent Identity: 39.884

alignment_block:

US-10-031-904-8 x US-08-310-416A-11 ..

Align seg 1/1 to: US-08-310-416A-11 from: 1 to: 903

```

1 MetAlaProValArgLeuGluArgProPheProSerArgPhePr 17
4 ATGGAGCTCCCGCGCGCGGAGTGTCTTCTTCTTCTTCTTCC 53
17 oGlyLeuLeuAlaLeuValLeuLeuLeuSerPheSerAspG 34
54 TGGGTCTCTTGGGCGCCATGTGTCTCTGTCTCTTCTTCCGATG 103
34 IncysAsnValProGluTrpLeuProPheAlaArgProThrAsnLeuThr 50
104 CCTGTGAGAGCA.....CCACA..... 123
51 AspaSpPheGlu.....PhePr 56
124 .....TTTGAAGCTATGAGCTCATTTGTAAACCAAAACCTACTATAGA 167
56 oLleGlyThrLeuAsnTrpGluCysArgProGlyTrpSerGlyArgP 73
168 GATGTGTACGACGATGATTAAGTGAATAAAAGATACCTTCTATATAG 217
73 ro.....PheSerLeuLeuCysLeuAsnSerValTrpThrSer 86
218 GTTCTCTTCCACCCATCTATTGTGTGATCGAATCATACATGCGTACT 267
87 ...AlaLysAspLysCysLysArgLysSerCysArgAsnProProAspPr 102
268 GTCTCAGATGAGCGCTGTATAGAGAAACATGTCCATATATAGCGGATCC 317
102 oValAsnGlyMetAlaHisValIleLys...AspLleGlnPheGlySerG 118
318 TTTAAATGGCACAAGCAGTCCCTGCAATAGGACTTACGAGTTGGTTATC 367
118 InleLysTrpSerCysProLysGlyTrpArgLeuIleGlySerSerSer 134
368 AGATGACACTTATTTGTATGAGAGGTATTTACTTATTTGTGAAGAAT 417
135 AlaThrCysIleLleSerGlyAsnThrValIleTrpAspAsnLysThr 151
418 CTATATTGTGAACCTTAAGATCAGTACGAATTTGGAGCGGTAAAGCCCC 467
151 oValCysAspSerGluLeu 157
468 AATATGTGAAAGGTTTTC 486

```

seq_name: /cgn2_6/ptodata/2/ina/5B_COMB.seq:US-08-888-171-11

seq_documentation_block:

Sequence 11, Application US/08888171

Patent No. 5851528

GENERAL INFORMATION:

APPLICANT: Jone-Long, Ko

APPLICANT: Higgins, Paul J.

APPLICANT: Yeh, C. Grace

TITLE OF INVENTION: METHODS OF INHIBITING COMPLEMENT

NUMBER OF SEQUENCES: 19

CORRESPONDENCE ADDRESS:

ADDRESS: Fish & Richardson, P.C.

STREET: 225 Franklin Street

CITY: Boston

STATE: MA

COUNTRY: US

ZIP: 02110-2804

COMPUTER READABLE FORM:

MEDIUM TYPE: Diskette

COMPUTER: IBM Compatible

OPERATING SYSTEM: Windows95

SOFTWARE: FastSeq for Windows Version 2.0

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/888,171

FILING DATE: 03-JUL-1997

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/310,416

FILING DATE: 22-SEP-1994

ATTORNEY/AGENT INFORMATION:

NAME: Freeman, John W.

REGISTRATION NUMBER: 29,066

REFERENCE/DOCKET NUMBER: 06180/005002

TELEPHONE: 617/542-507

TELEFAX: 617/542-890

TELEX: 200154

INFORMATION FOR SEQ ID NO: 11:

SEQUENCE CHARACTERISTICS:

LENGTH: 903 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: cDNA

US-08-888-171-11

alignment_scores:

Quality: 289.00 Length: 173
 Ratio: 2.890 Gaps: 6
 Percent Similarity: 57.803 Percent Identity: 39.884

alignment_block:

US-10-031-904-8 x US-08-888-171-11 ..

Align seg 1/1 to: US-08-888-171-11 from: 1 to: 903

```

1 MetAlaProValArgLeuGluArgProPheProSerArgPhePr 17
4 ATGGAGCTCCCGCGCGCGGAGTGTCTTCTTCTTCTTCTTCC 53
17 oGlyLeuLeuAlaLeuValLeuLeuLeuSerPheSerAspG 34
54 TGGGTCTCTTGGGCGCCATGTGTCTCTGTCTCTTCTTCCGATG 103
34 IncysAsnValProGluTrpLeuProPheAlaArgProThrAsnLeuThr 50
104 CCTGTGAGAGCA.....CCACA..... 123
51 AspaSpPheGlu.....PhePr 56
124 .....TTTGAAGCTATGAGCTCATTTGTAAACCAAAACCTACTATAGA 167

```

```

56 oileglyThrTyrLeuAenTyrgIuCySarGProGlyTyrSerGlyAarP 73
   |||||
168 GATGTGTAAGAGATATTAAGTGAATAAAGATACCTTATATATAC 217
73 ro.....PheserlelleCysLeuYsaSenSerValtrPfhSer 86
   |||||
218 CTCCTCTTGCCACCCATACCTATTGTCGAGATCAATACAGTGGCTACCT 267
87 ..AlaTysAspLysCysLysArgLysSerCysArgAsnProProAspPr 102
   |||||
268 GCTCAGATGACGCGCTGTATAGAGAAACATGCTCATATATACGGATCC 317
102 oValAsnGlyMetAlaHisValIleLys..AspIleGlnPheGlySerG 118
   |||||
318 TTTAAATGCGCAAGCATGCTCCTGCAGAAAGGAGACTTACAGATTGGTTATC 367
118 InileLysTyrSerCysProLysGlyTyrArgLeuIleGlySerSerSer 134
   |||||
368 AGATGCACTTATTTGTATAGAGGCTTATCTTATTTGTTGTAAGAAAT 417
135 AlaThrCysIleIleSerGlyAsnThrValIleTrpAspAsnLysThrPr 151
   |||||
418 CTATATTGTGAACCTTAAAGATCAAGTACATTTGAGCGGTAAAGCCCC 467
151 oValCysAspSerGluLeu 157
   |||||
468 AATATGTGAAAAGCTTTTG 486

```

seq_name: /cgn2_6/ptodata/2/ina/5A_COMB.seq:US-08-793-418-1

```

seq_documentation_block:
; Sequence 1, Application US/08793418C
; Patent No. 6130062
; GENERAL INFORMATION:
; APPLICANT: The Austin Research Institute
; TITLE OF INVENTION: Improvements in Production of Proteins in Host Cells
; FILE REFERENCE: CALA-100
; CURRENT APPLICATION NUMBER: US/08/793,418C
; EARLIER FILING DATE: 1997-02-25
; EARLIER APPLICATION NUMBER: PCT/AU95/00553
; EARLIER FILING DATE: 1994-08-30
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1
; LENGTH: 1134
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: CD46 CDNA
; OTHER INFORMATION: sequence with wild type scr
US-08-793-418-1

```

Alignment_scores:

Quality:	289.00	Length:	173
Ratio:	2.890	Gaps:	6
Percent Similarity:	57.803	Percent Identity:	39.884

Alignment_block:

US-10-031-904-8 x US-08-793-418-1 ..

```

Align seg 1/1 to: US-08-793-418-1 from: 1 to: 1134

1 MetaIaProProValArgLeuGluArgProPheProSerArgArgPhePr 17
   |||||
1 ATGGAGCCTCCCGCGCGCGAGGTCCCTTCCTCCGCGCCTTCC 50
17 oGlyLeuLeuLeuAlaIleValLeuLeuLeuSerSerPheSerSp 34
   |||||
51 TGGGTTCCTTCGCGCGCATGCTTCTGCTGCTACTCCTTCCTCCATG 100
34 InCysAsnValProGluTrpLeuProPheAlaArgProThrAsnLeuThr 50
   |||||

```

```

101 CCTGTGAGAGACCA.....CCACA..... 120
51 AspaPheGlu.....PhePr 56
   |||||
121 .....TTTGAAGCTATGAGACCTCATTTGTAACCAAAACCTACATATGA 164
56 oileglyThrTyrLeuAenTyrgIuCySarGProGlyTyrSerGlyAarP 73
   |||||
165 GATGTGTAAGAGATATTAAGTGAATAAAGATACCTTATATATAC 214
73 ro.....PheserlelleCysLeuYsaSenSerValtrPfhSer 86
   |||||
215 CTCCTCTTGCCACCCATACCTATTGTCGAGATCAATACAGTGGCTACCT 264
87 ..AlaTysAspLysCysLysArgLysSerCysArgAsnProProAspPr 102
   |||||
265 GCTCAGATGACGCGCTGTATAGAGAAACATGCTCATATATACGGATCC 314
102 oValAsnGlyMetAlaHisValIleLys..AspIleGlnPheGlySerG 118
   |||||
315 TTTAAATGCGCAAGCATGCTCCTGCAGAAAGGAGACTTACAGATTGGTTATC 364
118 InileLysTyrSerCysProLysGlyTyrArgLeuIleGlySerSerSer 134
   |||||
365 AGATGCACTTATTTGTATAGAGGCTTATCTTATTTGTTGTAAGAAAT 414
135 AlaThrCysIleIleSerGlyAsnThrValIleTrpAspAsnLysThrPr 151
   |||||
415 CTATATTGTGAACCTTAAAGATCAAGTACATTTGAGCGGTAAAGCCCC 464
151 oValCysAspSerGluLeu 157
   |||||
465 AATATGTGAAAAGCTTTTG 483

```

seq_name: /cgn2_6/ptodata/2/ina/5A_COMB.seq:US-08-793-418-3

```

seq_documentation_block:
; Sequence 3, Application US/08793418C
; Patent No. 6130062
; GENERAL INFORMATION:
; APPLICANT: The Austin Research Institute
; TITLE OF INVENTION: Improvements in Production of Proteins in Host Cells
; FILE REFERENCE: CALA-100
; CURRENT APPLICATION NUMBER: US/08/793,418C
; EARLIER FILING DATE: 1997-02-25
; EARLIER APPLICATION NUMBER: PCT/AU95/00553
; EARLIER FILING DATE: 1994-08-30
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 3
; LENGTH: 1134
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: CD46 CDNA
; OTHER INFORMATION: subscr3 variant
US-08-793-418-3

```

Alignment_scores:

Quality:	289.00	Length:	173
Ratio:	2.890	Gaps:	6
Percent Similarity:	57.803	Percent Identity:	39.884

Alignment_block:

US-10-031-904-8 x US-08-793-418-3 ..

```

Align seg 1/1 to: US-08-793-418-3 from: 1 to: 1134

1 MetaIaProProValArgLeuGluArgProPheProSerArgArgPhePr 17
   |||||
1 ATGGAGCCTCCCGCGCGCGAGGTCCCTTCCTCCGCGCCTTCC 50

```



```

17 oGlyLeuLeuAlaAlaLeuValLeuLeuSerPheSerAspG 34
|||||
51 TGGGTTCCTTCTGGCGCCATGGTCTTCTCTGACTCTTCTCCATG 100
|||||
34 IncysAsnValProGluTrpLeuProPheAlaArgProThrAsnLeuThr 50
|||||
101 CCTGTGAGGAGCA.....CCACA..... 120
51 AspAspPheGlu.....PhePr 56
|||||
121 .....TTTGAAGCTATGAGCTATTGTGTAACCAAAACCTTACTATGA 164
|||||
56 oIleGlyThrTyLeuAsnTyrgLysArgProGlyTyrSerGlyArgP 73
|||||
165 GATTGGTGAACGATAGATTATTAAGTATTAAGAAAGATCTTCTATATAC 214
|||||
73 ro.....PheSerIleLeuGlyLeuLysAsnSerValTrpThrSer 86
|||||
215 CTCCTCTTCCACCACTACTATTGTGATCGGAATCATATACATGGCTACT 264
|||||
87 ...AlaLysAspLysCysLysArgLysSerCysArgAsnProProAspPr 102
|||||
265 GCTGTGAGTACGCGCTGTATATAGACAACATGTCCATATATACGGATCC 314
|||||
102 oValAsnGlyMetAlaHisValIleLys...AspIleGlnPheGlySerG 118
|||||
315 TTTAAATGGCCAGACGCTCCGCAAAAGGACCTTACGAGTTGGTATAC 364
|||||
118 InIleLysTyrSerCysProLysGlyTyrArgLeuIleGlySerSerS 134
|||||
365 AGATGCACTTTATTGTATGAGGCTTATTACTTAAATGGAGAAAT 414
|||||
135 AlaThrCysIleIleSerGlyAsnThrValIleTrpAspAsnLysThrPr 151
|||||
415 CTTATATTGAAGCTTAAAGATCACTAGCAATTGGAGCGTAAGCCGCC 464
|||||
151 oValCysAspSerGluLeu 157
|||||
465 AATATGTGAAGAGTTTGG 483

```

seq_name: /cgn2_6/ptodata/2/ina/5B_COMB.seq:US-08-528-057-41

seq_documentation_block:

Sequence 41, Application US/08528057

Patent No. 5846715

GENERAL INFORMATION:

APPLICANT: RUSSELL, Damian F. J.

APPLICANT: MCKENZIE, Ian F. C.

TITLE OF INVENTION: CD46 VARIANTS

NUMBER OF SEQUENCES: 46

CORRESPONDENCE ADDRESS:

ADDRESSEE: Foley & Lardner

STREET: 3000 K Street, N.W., Suite 500

CITY: Washington

STATE: D.C.

COUNTRY: USA

ZIP: 20007-5109

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: PatentIn Release #1.0, Version #1.25

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/528,057

FILING DATE: CONCURRENTLY HEREMITH

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 07/961,686

FILING DATE: 11-JAN-1993

PRIOR APPLICATION DATA:

APPLICATION NUMBER: PCT/AU91/00199

FILING DATE: 10-MAY-1991

PRIOR APPLICATION DATA:

```

APPLICATION NUMBER: AU PK0133/90
FILING DATE: 11-MAY-1990
ATTORNEY/AGENT INFORMATION:
NAME: BENT, Stephen A.
REGISTRATION NUMBER: 29,768
REFERENCE/DOCKET NUMBER: 17227/112 DACO
TELECOMMUNICATION INFORMATION:
TELEPHONE: (202)672-5300
TELEFAX: (202)672-5399
TELEX: 904136
INFORMATION FOR SEQ ID NO: 41:
SEQUENCE CHARACTERISTICS:
LENGTH: 1247 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA
FEATURE:
NAME/KEY: CDS
LOCATION: 83..1192
FEATURE:
NAME/KEY: mat.peptide
LOCATION: 185..1192
US-08-528-057-41

```

alignment_scores:

Quality	289.00	Length	173
Ratio	2.890 <td>Gaps</td> <td>6</td>	Gaps	6
Percent Similarity	57.803 <td>Percent Identity</td> <td>39.884</td>	Percent Identity	39.884

alignment_block:

US-10-031-904-8 x US-08-528-057-41 ..

Align seg 1/1 to: US-08-528-057-41 from: 1 to: 1247

```

1 MetaIaProProValArgLeuGluArgProPheProSerArgArgPhePr 17
|||||
83 ATGAGCCTCCCGCGCGCGAGTGTCTTCTTCTGCGGCTTTC 132
|||||
17 oGlyLeuLeuAlaAlaLeuValLeuLeuSerPheSerAspG 34
|||||
133 TGGGTTCCTTCTGGCGCCATGGTCTTCTCTGACTCTTCTCCATG 182
|||||
34 IncysAsnValProGluTrpLeuProPheAlaArgProThrAsnLeuThr 50
|||||
183 CCTGTGAGGAGCA.....CCACA..... 202
51 AspAspPheGlu.....PhePr 56
|||||
203 .....TTTGAAGCTATGAGCTATTGTGTAACCAAAACCTTACTATGA 246
|||||
56 oIleGlyThrTyLeuAsnTyrgLysArgProGlyTyrSerGlyArgP 73
|||||
247 GATTGTGTAACGATAGATTATTAAGTATTAAGAAAGATCTTCTATATAC 296
|||||
73 ro.....PheSerIleLeuGlyLeuLysAsnSerValTrpThrSer 86
|||||
297 CTCCTCTTCCACCACTACTATTGTGATCGGAATCATATACGCTTACT 346
|||||
87 ...AlaLysAspLysCysLysArgLysSerCysArgAsnProProAspPr 102
|||||
347 GCTGTGAGTACGCGCTGTATATAGACAACATGTCCATATATACGGATCC 396
|||||
102 oValAsnGlyMetAlaHisValIleLys...AspIleGlnPheGlySerG 118
|||||
397 TTTAAATGGCCAGACGCTCCGCAAAAGGACCTTACGAGTTGGTATAC 446
|||||
118 InIleLysTyrSerCysProLysGlyTyrArgLeuIleGlySerSerS 134
|||||
447 AGATGCACTTTATTGTATGAGGCTTATTACTTAAATGGTGAAGAAAT 496
|||||
135 AlaThrCysIleIleSerGlyAsnThrValIleTrpAspAsnLysThrPr 151
|||||

```

497 CTATATGTGAAGTAAAGATCAGTAGCAATTGTGAGCGGTAAAGCCCC 546

151 oValcysAspSerGluLeu 157

547 AATATGTGAAAAGGTTTGG 565

seq_name: /cgn2_6/ptodata/2/lna/5A_COMB.seq:US-08-528-057-45

seq_documentation_block:

Sequence 45, Application US/08528057

Patent No. 5846715

GENERAL INFORMATION:

APPLICANT: PURCELL, Damian F. J.

APPLICANT: MCKENZIE, Ian F. C.

TITLE OF INVENTION: CDA6 VARIANTS

NUMBER OF SEQUENCES: 46

CORRESPONDENCE ADDRESS:

ADDRESSEE: Foley & Lardner

STREET: 3000 K Street, N.W., Suite 500

CITY: Washington

STATE: D.C.

COUNTRY: USA

ZIP: 20007-5109

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patentin Release #1.0, Version #1.25

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/528,057

FILING DATE: CONCURRENTLY HERewith

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 07/961,686

FILING DATE: 11-JAN-1993

PRIOR APPLICATION DATA:

APPLICATION NUMBER: PCT/AU91/00199

FILING DATE: 10-MAY-1991

PRIOR APPLICATION DATA:

APPLICATION NUMBER: AU PK0133/90

FILING DATE: 11-MAY-1990

ATTORNEY/AGENT INFORMATION:

NAME: BENT, Stephen A.

REGISTRATION NUMBER: 29,768

REFERENCE/DOCKET NUMBER: 17227/112 DACO

TELECOMMUNICATION INFORMATION:

TELEPHONE: (202)672-5300

TELEFAX: (202)672-5399

TELEX: 904136

INFORMATION FOR SEQ ID NO: 45:

SEQUENCE CHARACTERISTICS:

LENGTH: 1304 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: CDNA

FEATURE:

NAME/KEY: CDS

LOCATION: 94..1065

NAME/KEY: mat_peptide

LOCATION: 196..1065

US-08-528-057-45

alignment_scores:

Quality: 289.00 Length: 173

Ratio: 2.890 Gaps: 6

Percent similarity: 57.803 Percent identity: 39.884

alignment_block:

US-10-031-904-8 x US-08-528-057-45

Align seg 1/1 to: US-08-528-057-45 from: 1 to: 1304

1 MetaIaProProValArgLeuGluArgProPheProSerArgArgPheP 17

94 ATGAGCCCTCCCGCCGCCGCGAGTGTCTCTCCGCGCTTCC 143

17 oGlyLeuLeuAlaAlaLeuValLeuLeuSerPheSerAsp 34

144 TGGGTTCCTCTGGCGGCCCATGTCTCTCTCTCTCCGAG 193

34 IncysAsnValProGluThrProPheAlaArgProThrAsnLeuThr 50

194 CCGTGAGGAGCCA.....CCAGCA..... 213

51 AspAspPheGlu.....PheP 56

214TTGAAAGCTATGAGCTCTATGTAACCAAAACCTACTATGA 257

56 oIleGlyThrTyrlLeuAsnTyrlGlyCysArgProGlyTyrSerGlyArgP 73

258 GATGTGTAACGATGATGATTAAGTGAATAAAGATGATCTCTATATAC 307

73 ro.....PheSerIleIleCysLeuLysAsnSerValTTPThrSer 86

308 CTCCTCTGTCACCCATCTACTATTTGTGATCGAATCTATCATGCTACCT 357

87 ...AlaLysAspLysCysLysArgLysSerCysArgAsnProProAspP 102

358 GCTCGAGTACGCGCTGTATATGAGAAACATGTCATATATAGGATGC 407

102 oValAsnGlyMetAlaHisValIleLys...AspIleGlnPheGlySerG 118

408 TTTAAATGGCCAGCAAGTCCCTGCAATGGACTTACGACTTTGGTTATC 457

118 ILeuLysTyrSerCysProLysGlyTyrArgLeuIleGlySerSerSer 134

458 AGATGACCTTATTTGTATATGAGGTTTACTTAAATTTGTTGAAGAAAT 507

135 AlaThrCysAlaIleIleSerGlyAsnThrValIleTyrAspAsnLysThrP 151

508 CTATATGTGAAGCTTAAAGATCAGTAGCAATTGTGAGCGGTAAAGCCCC 557

151 oValcysAspSerGluLeu 157

558 AATATGTGAAAAGGTTTGG 576

seq_name: /cgn2_6/ptodata/2/lna/5A_COMB.seq:US-08-458-084-3

seq_documentation_block:

Sequence 3, Application US/08458084

Patent No. 5624837

GENERAL INFORMATION:

APPLICANT: FODOR, William L

APPLICANT: Rollins, Scott

APPLICANT: Squinto, Stephen P

TITLE OF INVENTION: Chimeric Complement

NUMBER OF SEQUENCES: 19

CORRESPONDENCE ADDRESS:

ADDRESSEE: Maurice M. Klee

STREET: 1951 Burr Street

CITY: Fairfield

STATE: Connecticut

COUNTRY: USA

ZIP: 06430

COMPUTER READABLE FORM:

MEDIUM TYPE: 3.5 Inch, 750 Kb storage

COMPUTER: Dell 486/50

OPERATING SYSTEM: DOS 6.2

SOFTWARE: WordPerfect 6.0

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/458,084

```

? FILING DATE:
? CLASSIFICATION: 435
? ATTORNEY/AGENT INFORMATION:
? NAME: Klee, Maurice M.
? REGISTRATION NUMBER: 30,399
? REFERENCE/DOCKET NUMBER: ALX-120
? TELECOMMUNICATION INFORMATION:
? TELEPHONE: (203) 255-1400
? TELEFAX: (203) 254-1101
? INFORMATION FOR SEQ ID NO: 3:
? SEQUENCE CHARACTERISTICS:
? LENGTH: 1530 bases
? TYPE: Nucleic Acid
? STRANDEDNESS: Double
? TOPOLOGY: Linear
? MOLECULE TYPE: cDNA to mRNA
? DESCRIPTION: MCP (CD46) full length cDNA
? HYPOTHEICAL: NO
? ANTI-SENSE: NO
? ORIGINAL SOURCE:
? ORGANISM: Homo sapiens
? PUBLICATION INFORMATION:
? AUTHORS: Lublin, D.M.
? AUTHORS: Liszewski, M.K.
? AUTHORS: Post, T.W.
? AUTHORS: Arce, M.A.
? AUTHORS: Lebeau, M.M.
? AUTHORS: Rebentisch, M.B.
? AUTHORS: Lemons, R.S.
? AUTHORS: Seya, T.
? AUTHORS: Atkinson, J.P.
? TITLE: Molecular cloning and Chromosomal
? TITLE: Localization of Membrane Cofactor
? TITLE: Protein (MCP): Evidence for Inclusion
? TITLE: in the Multi-Gene Family of
? TITLE: Complement-Regulatory Proteins.
? JOURNAL: Journal of Experimental Medicine
? VOLUME: 168
? PAGES: 181-194
? DATE: 1988
?
? US-08-458-084-3
?
? alignment_scores:
? Quality: 289.00 Length: 173
? Ratio: 2.890 Gaps: 6
? Percent Similarity: 57.803 Percent Identity: 39.884
?
? Alignment_block:
? US-10-031-904-8 x US-08-458-084-3 ..
?
? Align seg 1/1 to: US-08-458-084-3 from: 1 to: 1530
?
? 1 MetAlaProProValArgLeuGluuArgProPheProSerArgArgPhePr 17
? ||| ||||| ||| ||| ||||| ||||| |||||
? 44 ATGAGACCTCCCGCGCGCCGCGAGCTCCCTTCTCTCGCGCGTTCC 93
? ||||| ||||| ||||| ||||| ||||| |||||
? 17 oGlyLeuLeuLeuAlaLeuValLeuLeuLeuSerPheSerAspG 34
? ||||| ||||| ||||| ||||| ||||| |||||
? 94 TGGGTGCTTGGCGCGCATGCTGCTGCTGCTGCTGCTGCTGCTGATG 143
? ||||| ||||| ||||| ||||| ||||| |||||
? 34 IncysAsnValProGluTrpLeuProPheAlaArgProThrAsnLeuHr 50
? ||||| ||||| ||||| ||||| ||||| |||||
? 144 CCGTGGAGGAGCA.....CCAGCA..... 163
?
? 51 AspAspPheGlu.....PhePr 56
? |||||
? 164 .....TTGAAGCTATGAGCTCATGTGTAAACCAAAACCTACTATGA 207
? |||||
? 56 oIleGlyThrTyrlLeuAsnTyrlGluCysArgProGlyTyrSerGlyArgP 73
? ||||| ||||| ||||| ||||| ||||| |||||
? 208 GATTGGTGAACGAGTAGATTAAAGTAAAGATTAAGTAAAGATTAAGTAA 257

```

```

? 73 ro.....PheSerIleLeuLeuLysAsnSerValTrpThrSer 86
? ||| ||||| ||||| ||||| |||||
? 258 CTCCTCTTGGCACCACCACTACTATTGTGATCGGAATCATACATGGCTACT 307
? ||| ||||| ||||| ||||| |||||
? 87 ...AlaLysAspLysCysLysArgLysSerCysArgAsnProProAspPr 102
? ||| ||||| ||||| ||||| |||||
? 308 GCTCAGATGAGCGCCTGTTATGAGAAACATGCTCATATATACGGGATCC 357
? ||| ||||| ||||| ||||| |||||
? 102 oValAsnGlyMetAlaHisValIleLys...AspIleGlnPheGlySerG 118
? ||||| ||||| ||||| ||||| |||||
? 358 TTTAAATGCGCAAGCAGTCCCTGCAAAATGGACTTACAGATTTGGTTATC 407
? ||||| ||||| ||||| ||||| |||||
? 118 InleLysTyrSerCysProLysGlyTyrArgLeuIleGlySerSerSer 134
? ||||| ||||| ||||| ||||| |||||
? 408 AGATGCACTTATTGTATGAGGTTATTACTTATTATGTTGTAAGAAAT 457
? ||||| ||||| ||||| ||||| |||||
? 135 AlaThrCysIleLeuSerGlyAsnThrValIleTyrPaspAsnLysThrPr 151
? ||||| ||||| ||||| ||||| |||||
? 458 CTATATTGTGAACTTAAGATCAGTACGCAATTTGGAGCGGTAAAGCCCC 507
? ||||| ||||| ||||| ||||| |||||
? 151 oValCysAspSerGluLeu 157
? ||||| ||||| ||||| ||||| |||||
? 508 AATATGTGAAAAGTTTGTG 526
?
? seq_name: /cgn2_6/ptodata/2/ina/5A_COMB.seq.us-08-205-508-3
?
? seq_documentation_block:
? Sequence 3, Application US/08205508
? Patent No. 5627264
?
? GENERAL INFORMATION:
? APPLICANT: Fodor, William L
? APPLICANT: Rollins, Scott
? APPLICANT: Squinto, Stephen P
? TITLE OF INVENTION: Chimeric Complement
? TITLE OF INVENTION: Inhibitor Proteins
? NUMBER OF SEQUENCES: 19
? CORRESPONDENCE ADDRESS:
? ADDRESSEE: Maurice M. Klee
? STREET: 1951 Burr Street
? CITY: Fairfield
? STATE: Connecticut
? COUNTRY: USA
? ZIP: 06430
?
? COMPUTER READABLE FORM:
? MEDIUM TYPE: 3.5 inch, 750 Kb storage
? COMPUTER: Dell 486/50
? OPERATING SYSTEM: DOS 6.2
? SOFTWARE: WordPerfect 6.0
? CURRENT APPLICATION DATA:
? APPLICATION NUMBER: US/08/205,508
? FILING DATE:
?
? CLASSIFICATION: 435
? ATTORNEY/AGENT INFORMATION:
? NAME: Klee, Maurice M.
? REGISTRATION NUMBER: 30,399
? REFERENCE/DOCKET NUMBER: ALX-120
? TELECOMMUNICATION INFORMATION:
? TELEPHONE: (203) 255-1400
? TELEFAX: (203) 254-1101
? INFORMATION FOR SEQ ID NO: 3:
? SEQUENCE CHARACTERISTICS:
? LENGTH: 1530 bases
? TYPE: Nucleic Acid
? STRANDEDNESS: Double
? TOPOLOGY: Linear
? MOLECULE TYPE: cDNA to mRNA
? DESCRIPTION: MCP (CD46) full length cDNA
? HYPOTHEICAL: NO
? ANTI-SENSE: NO
? ORIGINAL SOURCE:
? ORGANISM: Homo sapiens
? PUBLICATION INFORMATION:
? AUTHORS: Lublin, D.M.

```

AUTHORS: Liszewski, M.K.
AUTHORS: Post, T.W.
AUTHORS: Arce, M.A.
AUTHORS: Lebeau, M.M.
AUTHORS: Rebentisch, M.B.
AUTHORS: Lemons, R.S.
AUTHORS: Seya, T.
AUTHORS: Atkinson, J.P.
TITLE: Molecular cloning and Chromosomal
TITLE: Localization of Membrane Cofactor
TITLE: Protein (MCP): Evidence for Inclusion
TITLE: In the Multi-Gene Family of
TITLE: Complement-Regulatory Proteins.
JOURNAL: Journal of Experimental Medicine
VOLUME: 168
PAGES: 181-194
DATE: 1988
US-08-205-508-3

alignment_scores:
Quality: 289.00 Length: 173
Ratio: 2.890 Gaps: 6
Percent Similarity: 57.803 Percent Identity: 39.884

alignment_block:
US-10-031-904-8 x US-08-205-508-3 ..

Align seg 1/1 to: US-08-205-508-3 from: 1 to: 1530

```
1 MetAlaProValArgLeuArgProPheProSerArgPhePr 17
  ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
44 ATGGAGCCTCCCGCGCGCGGAGTGTCTTCCTCTCGGCGCTTTC 93
17 oGlyLeuLeuAlaAlaLeuValLeuLeuSerPheSerSpG 34
  ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
94 TGGGTTCCTCTGCGCGCATGTGTCTCTCTCTCTCTCTCTCT 143
34 InCysAsnValProGluTrpLeuProPheAlaArgProThrAsnLeuThr 50
  ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
144 CCTGGAGGAGGCA.....CCAGCA..... 163
51 AspAspPheGlu.....PhePr 56
  ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
164 .....TTTGAAGCTATGAGCTCATTTGTAAACCAAAACCTTACTATGA 207
56 oGlyGlyThrTyLeuAsnTyGluCysArgProGlyTySerGlyArgP 73
  ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
208 GATTGTGACAGAGTATGATTAAGTGTAAAAAGATCTCTATATAC 257
73 ro.....PheSerLeuLeuCysLeuAsnSerValTrpThrSer 86
  ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
258 CTCCTCTTCCACCCATCTATTTGTGTCGGAATCATATACATGCTACT 307
87 .....AlaLysAspLysCysLysArgLysSerCysArgAsnProProAspPr 102
  ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
308 GCTCTAGATGAGCCTGTATATAGAAACATGTCATATATACGGGATCC 357
102 oValSnglyMetAlaHisValIleLys...AspLeuInPheGlySerG 118
  ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
358 TTTAAATGCGCAAGCATCTCTGCAATGGGAGTACAGATTGTGTTATC 407
118 InIleLysTySerCysProLysGlyTyArgLeuIleGlySerSerSer 134
  ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
408 AGATGCACCTTATTTGTATATGAGGTATTAATTGATGGAGAAATTT 457
135 AlaThrCysIleIleSerGlyAsnThrValIleTrpAspAsnLysThrPr 151
  ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
458 CTATATTTGGAAGCTTAAAGATCACTACCAATTTGAGAGCCGCC 507
151 oValCysAspSerGluLeu 157
  ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
508 AATATGTGAAAAAGTTTGG 526
```

seq_name: /cgn2_6/prodata/2/lna/5B_COMB.seq:US-08-482-148-8

seq_documentation_block:

Sequence 8, Application US/08482148
Patent No. 584/082

GENERAL INFORMATION:
APPLICANT: Rother, Russell

APPLICANT: Rollins, Scott
APPLICANT: Squinto, Stephen P

TITLE OF INVENTION: Terminal Complement
TITLE OF INVENTION: Inhibitor Fusion Genes and Proteins

NUMBER OF SEQUENCES: 17
CORRESPONDENCE ADDRESS:

ADDRESSEE: Seth A. Fidel
STREET: Alexion Pharmaceuticals, 25 Science Park

CITY: New Haven
STATE: Connecticut

COUNTRY: USA
ZIP: 06511

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch, 1.4 Mb storage

COMPUTER: IBM compatible (Pentium)
OPERATING SYSTEM: Windows 95 under MS DOS

SOFTWARE: Microsoft Word for Windows
CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/482,148
FILING DATE: 6/07/95

CLASSIFICATION: 530
ATTORNEY/AGENT INFORMATION:

NAME: Fidel, Seth A.
REGISTRATION NUMBER: 38,449

REFERENCE/DOCKET NUMBER: ALX-129.1 Div
TELECOMMUNICATION INFORMATION:

TELEPHONE: (203) 776 1790
TELEFAX: (203) 772 3655

INFORMATION FOR SEQ ID NO: 8:
SEQUENCE CHARACTERISTICS:

LENGTH: 1530 base pairs
TYPE: Nucleic Acid

STRANDEDNESS: Double
TOPOLOGY: Linear

MOLECULE TYPE: cDNA to mRNA
DESCRIPTION: MCP (CD46) full length cDNA

HYPOTHETICAL: NO
ANTI-SENSE: NO

ORGANISM: Homo sapiens
PUBLICATION INFORMATION:

AUTHORS: Lublin, D.M.
AUTHORS: Liszewski, M.K.

AUTHORS: Post, T.W.
AUTHORS: Arce, M.A.

AUTHORS: Lebeau, M.M.
AUTHORS: Rebentisch, M.B.

AUTHORS: Lemons, R.S.
AUTHORS: Seya, T.

AUTHORS: Atkinson, J.P.
TITLE: Molecular cloning and Chromosomal

TITLE: Localization of Membrane Cofactor
TITLE: Protein (MCP): Evidence for Inclusion

TITLE: In the Multi-Gene Family of
TITLE: Complement-Regulatory Proteins.

JOURNAL: Journal of Experimental Medicine
VOLUME: 168

PAGES: 181-194
DATE: 1988

US-08-482-148-8

alignment_scores:
Quality: 289.00 Length: 173
Ratio: 2.890 Gaps: 6

Percent Similarity: 57.803 Percent Identity: 39.884

alignment block:
US-10-031-904-8 x US-08-482-148-8 ..

Align seg 1/1 to: US-08-482-148-8 from: 1 to: 1530

```
1 MetAlaProProValArgLeuGluArgProPheProSerArgPhePr 17
  ||| ||||| ||| ||| ||||| ||||| |||||
44 ATGAGAGCTCCGCGCGCCGCGAGTGCCTTCTCTCCGCGCTTCC 93
17 oglyLeuLeuLeuAlaAlaLeuValLeuLeuSerSerPheSerAspG 34
  ||||| ||||| ||||| ||||| ||||| |||||
94 TGGGTGCTCTCTGCGGSCCATGGTGTGCTGTACTCTCTCCGATG 143
34 lncysAsnValProGluTripleuProPheAlaArgProThrAsnLeuThr 50
  ||||| ||| |||||
144 CCTGTGAGAGCCA.....CCACA..... 163
51 AspaSpPheGlu.....PhePr 56
  |||||
164 .....TTTGAAGCTATGAGCTCATGTGTAACCAAAACCTACTATGA 207
56 oilegLyThrTyrLeuAsnTyrGluCysArgProGlyTyrSerGlyArgP 73
  ||||| :|||:|||||:|||||
208 GATGTGTGAACGAGTAGTATTAAGTCTAAAGAAAGATACTTCTATATAC 257
73 ro.....PheSerilelleCysLeuLysAsnSerValTyrThrSer 86
  || ||||| ||||| :|||:|||||
258 CTCCCTGTGCCACCCATATCTTGTGATCGAATCATACATGGCTACT 307
87 ..AlaLysAspLysCysLysArgLysSerCysArgAsnProAspPr 102
  ||| :||| ||| |||:|||||
308 GTCTCAGATGACGCCCTGTATAGAAACATGTCATATATACGGATCC 357
102 ovalAsnGlyMetaLahisValileLys...AspIleGlnPheGlySerG 118
  ||:|||||:||||| :|||:|||||
358 TTTAATGGCCACAGACAGTCCCTGCAATGGAGCTTACGAGTTGGTATC 407
118 lnlleLysTyrSerCysProLysGlyTyrArgLeuIleGlySerSerSer 134
  ||||| :||| ||| :||| ||| ||||| |||||
408 AGATGCACCTTATTTTGAATGAGGGTTATTAATTTGGGAAGAAAT 457
135 AlaThrCysIleIleSerGlyAsnThrValIleThrPaspAsnLysThrPr 151
  ||| :||| :||| :||| :||| :||| :|||
458 CTATATTGTGAACCTTAAGATCACTAGCAATTGGAGCGGTAGCCCCC 507
151 ovalCysAspSerGluLeu 157
  ||:||||:||||| |||
508 AATATGTCAAAAGCTTTTG 526
```


GenCore version 4.5
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: October 9, 2002, 15:59:43 ; Search time 1838.24 Seconds
(without alignments)
7137.772 Million cell updates/sec

Title: US-10-031-904-30

Perfect score: 627

Sequence: 1 cggactcgaagagcattcc.....ataataaaccttaaccga 627

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 1797656 seqs, 10463268293 residues

Total number of hits satisfying chosen parameters: 3595312

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

GenEmbl:*
1: gb_ba:*
2: gb_htg:*
3: gb_in:*
4: gb_om:*
5: gb_ov:*
6: gb_pat:*
7: gb_ph:*
8: gb_pl:*
9: gb_pr:*
10: gb_ro:*
11: gb_sts:*
12: gb_sy:*
13: gb_un:*
14: gb_vi:*
15: em_ba:*
16: em_fun:*
17: em_hum:*
18: em_in:*
19: em_mu:*
20: em_om:*
21: em_or:*
22: em_ov:*
23: em_pal:*
24: em_ph:*
25: em_pl:*
26: em_ro:*
27: em_sts:*
28: em_un:*
29: em_vi:*
30: em_htg_hum:*
31: em_htg_inv:*
32: em_htg_other:*
33: em_htg_inv:

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Query Match	Length	DB ID	Description
1	352	56.1	627	100.0
2	346.6	55.3	627	99.1
3	346.6	55.3	627	99.1
4	346.6	55.3	627	99.1
5	343.4	54.8	627	99.1
6	343.4	54.8	627	99.1
7	328.8	52.4	627	99.1
8	320	51.0	627	99.1
9	316.8	50.5	627	99.1
10	306.4	48.9	627	99.1
11	306.4	48.9	627	99.1
12	303.2	48.4	627	99.1
13	267.4	42.6	627	99.1
14	267.4	42.6	627	99.1
15	267.4	42.6	627	99.1
16	267.4	42.6	627	99.1
17	267.4	42.6	627	99.1
18	267.4	42.6	627	99.1
19	267.4	42.6	627	99.1
20	218.6	34.9	627	99.1
21	218.6	34.9	627	99.1
22	216.6	34.5	627	99.1
23	204.2	32.6	627	99.1
24	204.2	32.6	627	99.1
25	204.2	32.6	627	99.1
26	202.2	32.2	627	99.1
27	201	32.1	627	99.1
28	199.6	31.8	627	99.1
29	197	31.4	627	99.1
30	194.8	31.1	627	99.1
31	191.4	30.5	627	99.1
32	178.2	28.4	627	99.1
33	178.2	28.4	627	99.1
34	177	28.2	627	99.1
35	174.6	27.8	627	99.1
36	156.4	24.9	627	99.1
37	156.4	24.9	627	99.1
38	156.4	24.9	627	99.1
39	156.4	24.9	627	99.1
40	156.4	24.9	627	99.1
41	156.4	24.9	627	99.1
42	156.4	24.9	627	99.1
43	156.4	24.9	627	99.1
44	155.2	24.8	627	99.1
45	153.6	24.5	627	99.1

1	627	100.0	627	6	AX078362	AX078362 Sequence
2	352	56.1	627	9	HSCRI	Y00816 Human mRNA
3	346.6	55.3	627	6	HSCRI	X14362 Human CRI m
4	346.6	55.3	627	11	G28591	G28591 human SRS S
5	343.4	54.8	627	9	CHPCRI	L24921 Pan troglod
6	343.4	54.8	627	9	CHPCRI	L24920 Chimpanzee
7	328.8	52.4	627	9	BABCORE	L77977 Papio cynoc
8	320	51.0	627	9	BABCORE	L77977 Papio hamad
9	316.8	50.5	627	9	BABCORE	L77978 Papio cynoc
10	306.4	48.9	627	11	G25967	G25967 human SRS E
11	306.4	48.9	627	11	G27827	G27827 human SRS S
12	303.2	48.4	627	9	CHPCRI	L24922 Pan troglod
13	267.4	42.6	627	6	A86593	A86593 Sequence 2
14	267.4	42.6	627	6	A86601	A86601 Sequence 10
15	267.4	42.6	627	6	A86603	A86603 Sequence 12
16	267.4	42.6	627	6	A86605	A86605 Sequence 14
17	267.4	42.6	627	6	A86607	A86607 Sequence 16
18	267.4	42.6	627	6	A86609	A86609 Sequence 18
19	267.4	42.6	627	6	AR029199	AR029199 Sequence
20	218.6	34.9	627	6	AX333690	AX333690 Sequence
21	218.6	34.9	627	6	HSCRI	X05309 Human mRNA
22	216.6	34.5	627	9	HMMCP1A	M73721 Human MCP-1
23	204.2	32.6	627	10	D42115	D42115 Rattus norv
24	204.2	32.6	627	10	RAT512	D42114 Rat 512 ant
25	204.2	32.6	627	10	RATCRRY	L36532 Rat compl
26	202.2	32.2	627	10	MUSCRYP	M34174 Mouse compl
27	201	32.1	627	10	MUSCRYL	M23529 Mus musculu
28	199.6	31.8	627	10	GPICRBP	M7760 Guinea pig
29	197	31.4	627	10	MUSXYG	M16179 Mouse X/Y P
30	194.8	31.1	627	9	AL137789	AL137789 Human DNA
31	191.4	30.5	627	9	HUMCRIL2	M31231 Human compl
32	178.2	28.4	627	9	HUMCRISF02	L17399 Human compl
33	178.2	28.4	627	2	AL160003	AL160003 Homo sapi
34	177	28.2	627	9	HUMCR102	M31239 Human compl
35	174.6	27.8	627	10	MUSCR2AB	M36470 Mouse compl
36	156.4	24.9	627	6	AR063632	AR063632 Sequence
37	156.4	24.9	627	9	HSMCP07	X59407 H.sapiens
38	156.4	24.9	627	9	HSMCP09	X59409 H.sapiens
39	156.4	24.9	627	9	HSMCP06	X59406 H.sapiens
40	156.4	24.9	627	6	A65266	A65266 Sequence 3
41	156.4	24.9	627	9	HSMCP10	X59410 H.sapiens
42	156.4	24.9	627	9	HSMCP08	X59408 H.sapiens
43	156.4	24.9	627	9	HSMCP05	X59405 H.sapiens
44	155.2	24.8	627	9	S65879	S65879 MCP-compl
45	153.6	24.5	627	2	AC084393	AC084393 Homo sapi

ALIGNMENTS

RESULT 1
LOCUS AX078362 627 bp DNA linear PAT 22-FEB-2001
DEFINITION Sequence 30 from Patent WO0107612.
ACCESSION AX078362
VERSION AX078362.1 GI:13158031
KEYWORDS
SOURCE
ORGANISM human.
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS Baughn,M.R., Lu,D.A., Hillman,J.L., Patterson,C. and Lal,P.
TITLE Receptors and associated proteins
JOURNAL Patent: WO 0107612-A 30 01-FEB-2001;
Incyle Genomics, Inc. (US)
FEATURES
source
1..627
/organism="Homo sapiens"
/db_xref="taxon:9606"
/note="Incyle ID No: 103561CB1"

BASE COUNT 142 a 173 c 128 g 184 t

Oy		66	aaggaggtctccgcgacggcctcaatggcgacctcccgttcgtctgaagcgctcccttcccttc	125
Dd		28	ATGGGCGCCCTCTTCTTCGAAGAACCCGACGCTGTCCGGCCGCCGGCCGGCTTCCC	87
Oy		126	cggcgacttccgttggtgtctcttcgcygacctgggtgtgtc--gctgtccctctcc	182
Dd		88	TTCGTCGGCGAGAGATCCCTCCTGGCGGTTGTGGTGCTGCTTGGCGCCGGGCGCTGG	147
Oy		183	gatcaatgaagaagtcccggaatggtttcatattgccagcgctaccaaacctaatgatatgc	242
Dd		148	GGTCAATGCAATGCCCCAAGAATGGCTTCATTGGCCAGGCCCTACCACCTTAAGTAGAG	207
Oy		243	ttagtgttcccatcttgagacatacttgacaatgaatgcgcgcctgtgtltaatccggaaga	302
Dd		208	TTTGAGTTTCCCATTTGGGACATATCTGAAATATGAATGCCGCCCTGGTATTCCGGAGA	267
Oy		303	ccgtttctctatctctgccttaaanaaacccaagtcctggagaagtgtctaaggacaagtcaaa	362
Dd		268	CCGTTTCTATCTACTCTGCCTAAAAAATCACTGAGACTGGTGTCTAAGAGCAAGTGTCCA	327
Oy		363	cytaaatcalgtcgtatccctccagatccctgtgaaatgycagcacatgfatcaaagac	422
Dd		328	CCTAATAATCATAGTGGTATCTCTCCAGATCTCTGGAATGSCATGGTGATGATCAAAGCG	387
Oy		423	atccagttcggatcccaaatataatctctgttcctaaagataccgactatgttcc	482
Dd		388	ATCCAGTTGGAGATCCCAATTAATTAATCTGTACTAAAGATATCCACATCATTTGGTTCC	447
Oy		483	tcgtctgcacatgacatcatctcaggaacacctgtcatcttgagataataaacactgtt	542
Dd		448	TGCGTCCGCAATGCAATCATCTCACAGTATATCTGTCATTGGGATATGAACAACCTATT	507
Oy		543	tgtgacag 550	
Dd		508	TGTGACAG 515	
RESULT	3			
HSCRTS				
LOCUS			2376 bp mRNA linear PRI 22-MAR-1995	
DEFINITION			Human CRI mRNA for C3b/C4b receptor secreted form.	
ACCESSION			X14362 Y00812	
VERSION			X14362.1 GI:30197	
KEYWORDS			alternate splicing; C3b/C4b receptor; complement receptor;	
SOURCE			human.	
ORGANISM			Homo sapiens	
REFERENCE			Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;	
AUTHORS			Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.	
TITLE			1 (bases 1 to 2376)	
JOURNAL			Hourcade,D.	
REFERENCE			Direct Submision	
AUTHORS			Submitted (29-NOV-1988) Hourcade D., Howard Hughes Medical	
TITLE			Institute, 660 S. Euclid St. Louis Mo, 63110, USA	
JOURNAL			2 (bases 1 to 2376)	
AUTHORS			Hourcade,D., Wiesner,D.R., Atkinson,J.P. and Holzer,V.M.	
TITLE			Identification of an alternative polyadenylation site in the human	
JOURNAL			C3b/C4b receptor (complement receptor type 1) transcriptional unit	
COMMENT			and prediction of a secreted form of complement receptor type 1	
MEDLINE			J. Exp. Med. 168 (4), 1255-1270 (1988)	
FEATURES			89010527	
COMMENT			The sequence overlaps with that reported by Klickstein et. al. in	
JOURNAL			J. Exp. Med. 165:1095-1112(1987) x05309 and in J. Exp. Med.	
COMMENT			168:1699-1717(1988).	
LOCATION/Qualifiers				
source			1..2376	
FEATURES			/organism="Homo sapiens"	
source			/db_xref="taxon:9606"	
FEATURES			/clone="CRI-4"	
FEATURES			/haplotypes="CRI-A"	
FEATURES			/cell_line="HL-60"	
FEATURES			<1..1682	

	/note="CRL receptor precursor (AA -16 to 543) (1 is 2nd base in codon)"
	//codon_start=3
	//protein_id="CAA32541.1"
	//db_xref="GI:736240"
	/translation="SLAIVVLLALPVAAGOCNAPBEWLFPAKPNTNLDEFEPIGYTL INECPEYGRSPFISILKNSVVTGAKDKRKRSCNPDPVANGVAHVHINKIOGSOI KYSCQIGRIILSGSSATCIIISGDYIMDETFCIRIPCGILPTTNDFTSTRENF HXSQVVTYRCNRGSGSKVEELGEISITCTSDNOVGIMSIPAOCIIPPKCRPNWF ENGLIYSNRSLPSLINEVFEPFCOPGPVKMGPARRKCAOLNMWEELPSRSVCOPPP DYLAHERORDKDNFSFGCEVFPSCBPGVDLGSAAMRCTPGCMWSPLAPCPGVSCDD DPMGOLLGRVLFPYNLIDAKYDFVCDSEFOLKSSASCTYLAMESLMASISPYCE QIFCESPPIPNGRHGTGRPLEVPFGVANVYTODPDMDGISFDLIGSTIRCSIDQ GNVWSSPAAPRGCIILGHCOAPDHFLFAKLTKLTQMSDEPIGLSLKEPREPYGRPS ITCLDNLVWSSPKDVCKRRSCKTPPDVPMGMVHTVIDIOVGSRINVSCTTG"
	<1..50
sig_peptide	51..1679
mat_peptide	/product="mature CRL receptor (AA 1-543); secreted form"
polya_site	2376
	/note="polyA site"
BASE COUNT	633 a 549 c 568 g 626 t
ORIGIN	
Query Match	55.3%; Score 346.6; DB 9; Length 2376;
Best Local Similarity	90.5%; Pred. No. 5,8e-91;
Matches 370; Conservative 0; Mismatches 39; Indels 0; Gaps 0;	
Db 142	tgccttcgacgagccctgtgttctgtcgtcgtccctctcccgataatgaatgltccgg 201
Db 7	TGCTGGCGGTTGGTGCCTGCTTCGGCGCGCCGGGCCCTGGGGGTCAATGCMAATGCCCCAG 66
Oy 202	aatggtctcatattgcagaagtaccacaacctcaactgatgaattgaattccattggga 261
Db 67	AATGGCTCATATTGGCGACCGCTACCACAACACTGAATGAGATTGGACTTCCATTGGGA 126
Oy 262	catalctgaacatgaatgcgcgccctgtttatcccgaagaacogtllctatatctgcc 321
Db 127	CATATCGAACATAVWGAAATGCCCGCTGGTTATTCGGGAAGACCGTTTTCAATCATCTGGCC 186
Oy 322	taaaaaactgaigtgcgaagaatgtctaaggacaagtgcgaacgytaaatcatactgccaalc 381
Db 187	TAAAAAACTGAGCTCGGACTGCTGCTTAAGAACAAGGTGAGACGTAATCATGTCGTATTC 246
Oy 382	ctccagaatctgtgaatgtagtgcatggtcacatatgatacaaagaatccagtlctggatccccaa 441
Db 247	CTCCAGATCCCTGGAAATGCGATGCGCATGTCATCAAAAAGCATCCAGTTGCGATGCCANA 306
Oy 442	ttaaataitcttctccaaagaagataccgaactcaatggttcttcgtctgcacacatgatca 501
Db 307	TTAAATATCTTGTTACTATAAGATACCGCATTCATGGTTCCTGCTGCGCACATGATCATCA 366
Oy 502	tctcaagcaaacatgcatcattinggtaataaaaacacctgttttggcaag 550
Db 367	TCCTAGGTGATCTGTCATCTTGGATGAATAAACAACCATATTGTGTGACAG 415
RESULT 4	
G28591	2376 bp DNA linear STS 11-JUL-1996
LOCUS	human STS SHGC-35372, sequence tagged site.
ACCESSION	G28591 GI:1408406
VERSION	STS; STS sequence; primer; sequence tagged site.
KEYWORDS	human.
SOURCE	human.
ORGANISM	Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;	
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.	
REFERENCE	1 (bases 1 to 2376)
AUTHORS	Myers R.M.
JOURNAL	unpublished
COMMENT	Contact: Richard M. Myers

100

10

Db	127	CATATCGAAGTATGATGCCGCCCGCTGTTATTAATGGAAGACCGCTTTTGTATCATCTGCG	186
Oy	322	taaaaaactgaagtcgtgacaagtgtaaggacaagtgacaagtgtaaatcaatcgtcgtaatc	381
Db	187	TAATAAACTCAGTCTGACGTGCTGCTTAAGGACAGGCGACAGCTTAATCATGTCGTAATC	246
Oy	382	ctcaagtcctcgtgaatgagcatgacacatcttgataaagaacatccagatcgcgtccaaa	441
Db	247	CTCCAGATCCGTGTAAGGACGATGGTGCATGTGATCAAGACATCCATTCGTGATCCCAA	306
Oy	442	ttaaatatctctgcctcaagaagataccagatcatcttgctcctcgtctgcacatgacaa	501
Db	307	TTAATAATCTTGTGTAAGAGATACCGACATCATTTGGTCTCGTGTCGCACATGATCATCA	366
Oy	502	tctcaagcaacacgtcatttggtgataataaacacctgttttgacag	550
Db	367	TCTCAGTGATACGTGTCATTTGGGATGAACCACTATTGTTGACAG	415

LOCUS	6	6044 bp	mRNA	linear	pri 30-Oct-1994
DEFINITION	CHPCRIWT				
ACCESSION	L24920				
VERSION	L24920.1	GI:551564			
KEYWORDS	complement receptor 1.				
SOURCE	Pan troglodytes cDNA to mRNA.				
ORGANISM	Pan troglodytes				
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Pan.				
AUTHORS	1 (bases 1 to 6044) Birmingham,D.J., Shen,X.P., Houwade,D., Nickells,M.W. and Atkinson,J.P.				
TITLE	Primary sequence of an alternatively spliced form of CRI. Candidate for the 75,000 M(r) complement receptor expressed on chimpanzee erythrocytes				
JOURNAL MEDLINE FEATURES	J. Immunol. 153 (2), 691-700 (1994)				
source	Location/Qualifiers				
gene	1..6044				
cds	/organism="Pan troglodytes" /db_xref="taxon:9598" 1..6044 /gene="CRI" <1..>6044 /codon_start=3 /product="complement receptor 1" /protein_id="AA51438.1" /db_xref="GI:557725"				

BASE COUNT		1561 a	1496 c	1462 g	1525 t
ORIGIN					
Query Match	54.8%	Score 343.4	DB 9	Length 6044	
Best Local Similarity	90.0%	Pred. No. 6.2e-90			
Matches 368	Conservative 0	Mismatches 41	Indels 0	Gaps 0	
QY 142	tgcttcggcgccctggtgtgtcgtcgtcccttcctccgataatgcaatgctcccg	201			
DB 7	tcctggccggttggtgctgctgcttgcgcgtccggggtgcattgcaatgccccag	66			
QY 202	aatggtcttcatttgcacagcgctaaccaactaatgatagtactttagtltccattgga	261			
DB 67	aatgcttcgcatttgcacagcgctaaccaactaatgatagtactttagtltccattgga	126			
QY 262	catatctgaactatgaatagcgccctgtgttttccggagaagccgtttcatactctgc	321			
DB 127	catatctgaactatgaatagcgccctgtgtgtatgatgagaacccgtttctatcatctgcc	186			
QY 322	taaaaaactcagctctgcgaacaagtgtctaagagacaagtgcnaacgtaaatcatgtcgtaac	381			
DB 187	taaaaaactcagctctgcgaacaagtgtctaagagacaagtgcnaacgtaaatcatgtcgtaac	246			
QY 382	ctcccgatcctcttgatgatagcatagtgatactgaataagacatccagttcgatcccaa	441			
DB 247	ctcccgatcctcttgatgatagcatagtgatactgaataagacatccagttcgatcccaa	306			
QY 442	ttaaatattcttgcctaaagataacagatcatttgttctcgtctgcacatgcatca	501			
DB 307	ttaaatattcttgcctaaagataacagatcatttgttctcgtctgcacatgcatca	366			
QY 502	tctcagcaacaactgtcatttggatgaataaacaaccctgtgtgacag	550			
DB 367	tctcagcaacaactgtcatttggatgaataaacaaccctgtgtgacag	415			
RESULT 7					
BABCORE	1688 bp mRNA linear PRI 07-MAY-1996				
LOCUS	BABCORE				
DEFINITION	Papio cynocephalus complement receptor mRNA, partial cds.				
ACCESSION	L77977				
VERSION	L77977.1 GI:1301608				
KEYWORDS	complement C3b; complement receptor; glycoposphatidylinositol-linked protein.				
SOURCE	Papio cynocephalus cDNA to mRNA.				
ORGANISM	Papio cynocephalus				
	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Cercopithecoidea; Cercopithecinae; Papio.				
REFERENCE	1 (Bases 1 to 1688)				
AUTHORS	Birmingham,D.J., Logar,C.M., Shen,X.-P. and Chen,W.				
TITLE	The baboon erythrocyte complement receptor is a glycoposphatidyl inositol-linked protein encoded by a homologue of the human CRI-like genetic element				
JOURNAL	unpublished (1996)				
FEATURES	Location/Qualifiers				
source	1..1688				
	/organism="Papio cynocephalus"				
	/db_xref="taxon:9556"				
	/cell_type="erythrocyte"				

Qy 202 aatgcttcatttgcagagctaccactaactgactgattgagttccattgga 261
 Db 68 AACGCTTCATTGGCCAGCCCTACTGAACTAATGAGAGCCAGTTTCATTTGGGA 127
 Qy 262 catactgaactatgataccgcccgtgtatctccggaagaccgtttctactatcgc 321
 Db 128 CACATCTGAGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 187
 Qy 322 taaaaaactgactgagcaagtgctcaaggaagaatgcaaaagtaacatgctgtaac 381
 Db 188 TAAATAAATCTAGTGTGACAGTGTGACAGTGTGACAGTGTGACAGTGTGACAGT 247
 Qy 382 ctccagatctctgtaagtgatgacatgatacaagacatccagatccgataccaa 441
 Db 248 CTAGAGATCTGTGATGATGATGATGATGATGATGATGATGATGATGATGATG 307
 Qy 442 ttaataattcttcttaagataccgactgattgcttctctgctcgcacatgacat 501
 Db 308 TTAATATCTGTGATGATGATGATGATGATGATGATGATGATGATGATGATG 367
 Qy 502 tctcaggaacactgactgagataaataaacaactgattgagca 549
 Db 368 TCTCAGCATGATGATGATGATGATGATGATGATGATGATGATGATGATG 415

RESULT 9
 BABCOREA 945 bp mRNA linear PRI 07-MAY-1996

LOCUS BABCOREA 945 bp mRNA linear PRI 07-MAY-1996
 DEFINITION Papio cynocephalus complement receptor mRNA, partial cds.
 ACCESSION L77978
 VERSION L77978.1 GI:1301610

KEYWORDS complement C3b; complement receptor; glycoposphatidylinositol-linked protein.
 SOURCE Papio cynocephalus cDNA to mRNA.

ORGANISM Papio cynocephalus
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Cercopithecoidea;
 Cercopithecinae; Papio.

REFERENCE 1 (bases 1 to 945)
 Birmingham, D.J., Logan, C.M., Shen, X.-P. and Chen, W.

AUTHORS The baboon erythrocyte complement receptor is a glycoposphatidylinositol-linked protein encoded by a homologue of the human CRI-like genetic element

TITLE Unpublished (1996)

JOURNAL Location/Qualifiers
 FEATURES 1..945

ORIGIN 1..945
 /organism="Papio cynocephalus"
 /db_xref="taxon:9556"
 /cell_type="Lymphocyte"
 /tissue_type="bone marrow"
 /dev_stage="adult"
 <1..>945
 <1..>945
 /note="homologue of human CRI-like genetic element"

BASE COUNT 252 a 224 c 228 g 239 t 2 others

Query Match 50.5%; Score 316.8; DB 9; Length 945;
 Best Local Similarity 91.5%; Pred No. 2, 9e-82;
 Matches 333; Conservative 2; Mismatches 29; Indels 0; Gaps 0;

Qy 186 caatgcaatgcccggatgacttccatttgcagagccctaccactaactgactt 245
 Db 1 CATGCAATGCCCCGAGACAGCTTCATTTGCCAGGCTACTGAACTAATATGATGAT 60
 Qy 246 gatttcccatggaatatactgaaatgaaatgaaatgaaatgaaatgaaatgaaat 305
 Db 61 GAGTTTCCATTTGGGACATCTGAAATGATGATGATGATGATGATGATGATGATG 120
 Qy 306 ttctatcatctctgtaaaactgactgagcaagtgctcaaggaagaagtgcaagct 365
 Db 121 TTTCTATCATCTGCTTAATAAATCTGATGATGATGATGATGATGATGATGATG 180
 Qy 366 aatcatgctgtaactcctccagatccctgtaagtgatgagatgagatgagatg 425
 Db 181 AATCATGCTGTAATCTGAGATCTGTAATGATGATGATGATGATGATGATGATG 240
 Qy 426 caattgagatcccaatgaaatgacttctgctcaaggaatgagatgagatgagat 485
 Db 241 GAGTTGGAATCCAAATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 300
 Qy 486 tctgcaatgcatcatctcaggaacactgacttggatgataaataaactgattgt 545
 Db 301 TCTGCAATGATGATGATGATGATGATGATGATGATGATGATGATGATG 360
 Qy 546 gaca 549
 Db 361 GAGA 364

RESULT 10
 LOCUS G25967 389 bp DNA linear STS 02-JUN-1996
 DEFINITION human STS EST126198, sequence tagged site.
 ACCESSION G25967
 VERSION G25967.1 GI:1348199

KEYWORDS STS; STS sequence; primer; sequence tagged site.
 SOURCE human STS derived from sequences in dbEST and the unigene collection.

ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.

REFERENCE 1 (bases 1 to 389)
 Hudson, T.

AUTHORS Whitehead Institute/MIT Center for Genome Research, Physically Mapped STS

TITLE Unpublished

JOURNAL COMMENT

CONTACT: Thomas Hudson
 Whitehead Institute/MIT Center for Genome Research
 Whitehead Institute for Biomedical Research
 9 Cambridge Center, Cambridge MA 02142 USA
 Tel: 617 252 1900
 Fax: 617 252 1902
 Email: thudson@genome.wi.mit.edu

PRIMER A: CCAGAGAAATTAATGATGATCGG
 PRIMER B: CTGCTGCCACATGATC
 STS size: 125
 PCR profile:

Presoak:
 Denaturation:
 Annealing: 56 degrees C
 Polymerization:
 PCR Cycles: 35
 Thermal Cycler:

Protocol:
 Template: 10 ng
 Primer: each 5 pm
 dNTPs: each 4 mM
 Tag polymerase: 0.025 units/ul
 Total Vol: 20 ul

Buffer:

MgCl2: 1.5 mM
KCl: 50 mM
Tris-HCl: 10 mM
pH: 9.3

FEATURES
source
Derived from dbEST (genbank accession T66823).

Location/Qualifiers
1..389
/organism="Homo sapiens"
/db_xref="taxon:9606"
/map="890.2 CR from top of Chr1 linkage group"
STS
primer_bind 25..149
primer_bind 25..149
BASE COUNT 114 a 67 c 92 g 112 t 4 others
ORIGIN

Query Match 48.9%; Score 306.4; DB 11; Length 389;
Best Local Similarity 95.8%; Pred. No. 2.8e-79;
Matches 345; Conservative 0; Mismatches 10; Indels 5; Gaps 3;
267 ctgaactatgaatgc---cgccctgtgtatcgcgaagaccgttt-ctatcatctg-cc 321
|||||
369 ctgaactatgaatgc---cgccctgtgtatcgcgaagaccgttt-ctatcatctg-cc 310
|||||
322 taataaactcagctctgcaagtgctgaagacaagtgcaacgttaatactatcgtgaatc 381
|||||
309 TAAAAACCTCAGTCTGAGCAAGTGTAAAGACAAGTCAAACTTAATCTATGTCGTAAAC 250
|||||
382 ctccagatccctgtgaatgcatgacatgtgataaagacatccagttcggatcccaaa 441
|||||
249 CTCGAGANCCTGTGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 190
|||||
442 ttaaatattctgtctcctaagaagatccagatcattgttctcgtctgcacatgacata 501
|||||
189 TTAATTAATCTTGTCTCTAAAGATACCGACATGATGATGATGATGATGATGATGATGAT 130
|||||
502 tctcaggaacaacatgcatcttggatgaataaacaacctgttttgacagtgagttgaat 561
|||||
129 TCTCAGGCAACACTGCTCATTTGGATATATAAACCTGTTGTGACAGTGAATGAAT 70
|||||
562 atgcattctcattcttcttaccgatacatcttaattttctcgcgataataaactctt 621
|||||
69 ATGCAATTCCTAATTTCTTTTACCGATACATCTCTAATTTTCTCTGGAATATAAATCTT 10
|||||

RESULT 11
G27827/c 389 bp DNA linear STS 29-JUN-1996

INITIATION human STS SHGC-33387, sequence tagged site.
ACCESSION G27827
VERSION G27827.1 GI:1396546
KEYWORDS STS; STS sequence; primer; sequence tagged site.
SOURCE Human.
ORGANISM Homo sapiens

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.
REFERENCE 1 (bases 1 to 389)
AUTHORS Myers, R.M.
JOURNAL Unpublished

COMMENT

Contact: Richard M. Myers
Stanford Human Genome Center (SHGC)
Stanford University School of Medicine
Department of Genetics, M-344, Stanford, CA 94305, USA
Tel: 4157259687
Fax: 4157259689
Email: myerseshgc.stanford.edu

Primer A: CCAGAGAAAATTAAGATGTATCGG
Primer B: CTGCTCTCCACATCATC
STS size: 125

PCR Profile:

Initial incubation: 94 degrees C for 90 seconds
Denaturation: 94 degrees C for 15 seconds
Annealing: 62 degrees C for 23 seconds
Polymerization: 72 degrees C for 30 seconds
PCR cycles: 30
Thermal Cycler: Perkin Elmer 9600
Protocol:
Template: 25 ng
Primer: each 1 uM
dNTPs: each 200 uM
Tag Polymerase: 0.05 units/uL
Total Vol: 10 uL

Buffer:
MgCl2: 2.5 mM
KCl: 50 mM
Tris-HCl: 20 mM
pH: 8.3

Prepared with primer pairs provided by Sandoz, derived from T66823
-- Washington University/Merck EST sequence.

FEATURES
source
Location/Qualifiers
1..389
/organism="Homo sapiens"
/db_xref="taxon:9606"
/map="1"
STS
primer_bind 25..149
primer_bind 25..149
BASE COUNT 114 a 67 c 92 g 112 t 4 others
ORIGIN

Query Match 48.9%; Score 306.4; DB 11; Length 389;
Best Local Similarity 95.8%; Pred. No. 2.8e-79;
Matches 345; Conservative 0; Mismatches 10; Indels 5; Gaps 3;
267 ctgaactatgaatgc---cgccctgtgtatcgcgaagaccgttt-ctatcatctg-cc 321
|||||
369 ctgaactatgaatgc---cgccctgtgtatcgcgaagaccgttt-ctatcatctg-cc 310
|||||
322 taataaactcagctctgcaagtgctgaagacaagtgcaacgttaatactatcgtgaatc 381
|||||
309 TAAAAACCTCAGTCTGAGCAAGTGTAAAGACAAGTCAAACTTAATCTATGTCGTAAAC 250
|||||
382 ctccagatccctgtgaatgcatgacatgtgataaagacatccagttcggatcccaaa 441
|||||
249 CTCGAGANCCTGTGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 190
|||||
442 ttaaatattctgtctcctaagaagatccagatcattgttctcgtctgcacatgacata 501
|||||
189 TTAATTAATCTTGTCTCTAAAGATACCGACATGATGATGATGATGATGATGATGATGAT 130
|||||
502 tctcaggaacaacatgcatcttggatgaataaacaacctgttttgacagtgagttgaat 561
|||||
129 TCTCAGGCAACACTGCTCATTTGGATATATAAACCTGTTGTGACAGTGAATGAAT 70
|||||
562 atgcattctcattcttcttaccgatacatcttaattttctcgcgataataaactctt 621
|||||
69 ATGCAATTCCTAATTTCTTTTACCGATACATCTCTAATTTTCTCTGGAATATAAATCTT 10
|||||

RESULT 12

CHPCR1Y 1731 bp mRNA linear PRI 12-OCT-1994
LOCUS CHPCR1Y
DEFINITION Pan troglodytes mRNA sequence, 3' end of ORF.
ACCESSION U24922
VERSION U24922.1 GI:557728
KEYWORDS Pan troglodytes CDNA to mRNA.
SOURCE Pan troglodytes
ORGANISM Pan troglodytes

REFERENCE	AUTHORS	TITLE
Enkayotia; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Pan.	1 (bases 1 to 1731)	Birmingham,D.J., Shen,X.P., Hourcade,D., Nickells,M.W. and Atkinson,J.P.
Primary sequence of an alternatively spliced form of CRI. Candidate for the 75,000 M(r) complement receptor expressed on chimpanzee erythrocytes	J Immunol. 153 (2), 691-700 (1994)	
JOURNAL	MEDLINE	FEATURES
94292799		source
		Location/Qualifiers
		1..1731
		/organism="Pan troglodytes"
		/db_xref="taxon:9598"
		/cell_type="EBV transformed"
		/cell_line="B cell"
		<1..1571
		/note="possible homologue to human CRI-like genomic element"
		/codon_start=3
		/protein_id="AA50460.1"
		/db_xref="GI:557729"
		/translation="DEEPPPTGYLYNECPAGYGRPFSTIICLKNSWTSAEDECKRRK SCRRPDPVNGMVAHVIDIOPGSDIKRSCIKGRRLISSSTATCISGNYIMPNKPPV CDRIIGLPTLIANGDFTSISRETFHIAVYTHICNLGSGKVFELVGEPSYICISK DDVGIVSGPAQOCIIIPNKCTPPVVEGAILVSDNRSLFSLNEVWFRCQGFVWKGPR HVIHQALKNKEPELSPCSRVCQPPDVLHGERIORDNDSPEEYVSCDEPYDLNG SYTHACFPQDMSPEARCEVKSDDDLPGNRVLPPLNLQIAGVDFVCDGFEQDL KGSVAHCVIAGMSKLNSSVPCVRCSCPEPPVNGMVAHVIDIHGASINSCITL GPRKGRSASHCVIAGKMLALMNSVSPKCEPFCGNPAIINGRHTGPLDIPYKGEVY SYTDPHEDHDKMTFNLIGESTIKRTPDHNGVWSPAPRCLEPVGAGSHDALIVGTL LGTIFIIIIIFLT"
		1572..>1731
BASE COUNT	3'UTR	ORIGIN
469 a	395 c	403 g 463 t 1 others
Query Match	48.48;	Score 303.2; DB 9; Length 1731;
Best Local Similarity	97.58;	Prod. No. 3.3e-78;
Matches 308;	Conservative	0; Mismatches 8; Indels 0; Gaps 0;
QY	235	ctgatgacttgaagttccattccattggagacatctcaatgatgaatgcgcgcgtgtatt 294
Db	1	CTGATGAGTTTGAGTTTCCCATGTGGGACATATCTAACTATGAATGCGCCCTGGTTATT 60
QY	295	ccggaagacgcgtttctatcatcctctgctaanaaacatcagttcgagaagttgctaagaca 354
	61	ATGGAAGACCAATTTCTATCATCTCCTTAATAAAACCTCAAGTCGACAAAGTCTGAGACAA 120
QY	355	atgtgaacacgtataatcatgctgaatccctccagatccctgtagaattgcagacatgtga 414
Db	121	AGTGCACACGTAAATCATATGTCTTAATCCCTCCAGATCTGTGAATGGCATGGTCAATGTGA 180
QY	415	tcaaaagacatccagttcgatgcccaatatatctctgtgctctaaaggatatacagactca 474
Db	181	TCAAAAGACATCCAGTTCCGATGCCCAATTAATATTCTTGTACTAAAGATACCGCATCA 240
QY	475	tgtgttctctgctctgcacatgatcatcttcaggcaacacgttcatctttgggtataataaa 534
Db	241	TGTGTTCCTCGCTCGCCACATCATCATCTCAGGCAACACGTCTCATTTTGGATTAATAAAA 300
QY	535	caactgtttgtacag 550
Db	301	CACCTCTTTGTGACAG 316
RESULT	13	
LOCUS	AB6593	591 bp DNA linear PAT 21-JAN-2000
DEFINITION	Sequence 2 from Patent WO9839433.	
ACCESSION	AB6593	
VERSION	AB6593.1	GI:6735168
KEYWORDS	.	

SOURCE	unidentified.
ORGANISM	unclassified.
REFERENCE	1 (bases 1 to 591)
AUTHORS	Smith,R.A. and Cox,V.F.
TITLE	COMPLEMENT RECEPTOR TYPE 1 (CR1)-LIKE SEQUENCES
JOURNAL	Patent: WO 9839433-A 2 11-SEP-1998; SMITH RICHARD ANTONY GODWIN (GB); ADPROTECH PLC (GB) Location/Qualifiers
FEATURES	source 1..591 /organism="unidentified" /db_xref="taxon:32644"
BASE COUNT	132 a 159 c 148 g 152 t
ORIGIN	
Query Match	Best Local Similarity 42.6%; Score 267.4; DB 6; Length 591; Matches 304; Conservative 0; Mismatches 61; Indels 0; Gaps 0;
Qy	186 caatgcaatgtccggaaatgagcttcacattggccaaggcctaaccataactgatgactt 245
Db	4 CAGTCAACGCTCCGGATGGCTGCCGTTCGCCGCCGCAGCAACCTGCATCGATGAATT 63
Qy	246 gaattccccattggacaatatcgaataaagaacgcgccgttgatttacccggaaagcg 305
Db	64 GAGTCCCGCATGGACTACCTGACTACGAAAGCACC GCCGGTTAAGGCGCCGCCG 123
Qy	306 ttctcatcatcgtcctaanaaactcagtcctgacaagtgtctaaggacaagtgcnaact 365
Db	124 TTTTTCATCATCTGCTTGAAAACCTCTGTCGAGACTGTGCTTAAGACCGTTGCCGACGT 183
Qy	366 aaatcatctcgtaatccctccagatcctctgtaatgacagtcgaactgtgataaagaact 425
Db	184 AAATCTTGTCGTAACCCGCCAGATCCGGTTAAAGGCAATGAGTATGATCAAAGGCATC 243
Qy	426 caattccgatacccgaattaatatctctgtccctaaggataaccgaactattgctcctcg 485
Db	244 CAGTTCGGTCCCAATTAAATTTCTTGTAAGGTAAAGGTAAOCGCTGATGGTCCGCC 303
Qy	486 tcgtccaatcatcatcattcaggaacaacctgtcaatttgggataataaacacactgtttgt 545
Db	304 AGCGCTACATCATCATCTGCTGATGATCTGTCATTTGGGATTAATGAACAACCGATTGT 363
Qy	546 gccag 550
Db	364 GACCG 368
RESULT 14	
LOCUS	AB6601 591 bp DNA linear PAT 21-JAN-2000
DEFINITION	Sequence 10 from Patent WO9839433.
ACCESSION	AB6601
VERSION	AB6601.1 GI:6735175
KEYWORDS	.
SOURCE	unidentified. unclassified.
ORGANISM	unclassified.
REFERENCE	1 (bases 1 to 591)
AUTHORS	Smith,R.A. and Cox,V.F.
TITLE	COMPLEMENT RECEPTOR TYPE 1 (CR1)-LIKE SEQUENCES
JOURNAL	Patent: WO 9839433-A 10 11-SEP-1998; SMITH RICHARD ANTONY GODWIN (GB); ADPROTECH PLC (GB) Location/Qualifiers
FEATURES	source 1..591 /organism="unidentified" /db_xref="taxon:32644"
BASE COUNT	127 a 159 c 151 g 154 t
ORIGIN	
Query Match	42.6%; Score 267.4; DB 6; Length 591;

Db 184 AATCTTTCGTAATCCGCCAGATCCGGTTAACGGCATGTGCATGTGATCAAAGGCATC 243

Db 244 CAGTTCGGTCCCAATTAAATATTCTTGACTAAAGGTTACCGCTCTGATTGGTTCCTCC 303

Db 304 AGCGTACATGCATCTCTGGTGA TCTGTCA TTTGGGATATGAACACCCATTGT 363

D_b 364 GACCG 368

Search completed: October 9, 2002, 17:10:18
Job time: 4235 sec

```
Search completed: October 9, 2002, 17:10:18
Job time: 4235 sec
```

GenCore version 4.5
Copyright (c) 1993 - 2000 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: October 9, 2002, 16:37:29 ; Search time 176.28 Seconds
(without alignments)
6106.792 Million cell updates/sec

Title: US-10-031-904-30

Perfect score: 627
Sequence: 1 cggactcagaagaggtctcc.....ataataaaacttaacgca 627

Scoring table: IDENTITY NUC
Gapop 10.0 , Gapext 1.0

Searched: 1736436 seqs, 858457221 residues

3472872

total number of hits satisfying chosen parameters:

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database :

N_Geneseq_032802:*

1: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1980.DAT:*

2: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1981.DAT:*

3: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1982.DAT:*

4: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1983.DAT:*

5: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1984.DAT:*

6: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1985.DAT:*

7: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1986.DAT:*

8: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1987.DAT:*

9: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1988.DAT:*

10: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1989.DAT:*

11: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1990.DAT:*

12: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1991.DAT:*

13: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1992.DAT:*

14: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1993.DAT:*

15: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1994.DAT:*

16: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1995.DAT:*

17: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1996.DAT:*

18: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1997.DAT:*

19: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1998.DAT:*

20: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1999.DAT:*

21: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA2000.DAT:*

22: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA2001A.DAT:*

23: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA2001B.DAT:*

24: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA2002.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	627	100.0	627	22	AAFS8602
2	352	56.1	6951	10	AAAG91477
3	352	56.1	6951	12	AAQ11642
4	352	56.1	6951	20	AAZ38150
5	352	56.1	7313	22	AAI58380
6	351.8	56.1	7821	23	AA564474
7	348	55.5	6951	14	AAQ41867
8	341	54.4	7028	22	ABA09026
9	341	54.4	7028	22	AAI60166

10	273.2	43.6	9038	23	AA564290
11	269.4	43.0	2796	23	AA564473
12	267.4	42.6	591	19	AAV53262
13	267.4	42.6	591	19	AAV53269
14	267.4	42.6	591	19	AAV53270
15	267.4	42.6	591	19	AAV53271
16	267.4	42.6	591	19	AAV53272
17	267.4	42.6	591	19	AAV53273
18	247.8	39.5	2798	23	AA564289
19	218.6	34.9	5420	12	AAQ11643
20	218.6	34.9	5420	20	AAZ38151
21	156.4	24.9	1477	18	AAH90306
22	156.4	24.9	3302	22	AAH34933
23	156.4	24.9	3308	21	AAH18275
24	153.6	24.5	396	21	AAAC04275
25	153.6	24.5	125	19	AAH11827
26	120	19.1	1437	23	AA564286
27	120	19.1	1437	23	AA564470
28	117.6	18.8	1530	16	AAO99106
29	117.6	18.8	1530	16	AAO3339
30	117.6	18.8	1546	12	AAQ10864
31	116.6	18.6	1878	17	AAH6065
32	103.4	16.5	1244	12	AAQ14919
33	103.4	16.5	1659	12	AAQ14915
34	103.4	16.5	1991	12	AAO14916
35	103.4	16.5	9888	24	ABL33241
36	88.8	14.2	1848	22	AAAD0355
37	88.8	14.2	1848	22	AAAD08170
38	88	14.0	7821	23	AA564474
39	87.4	13.9	945	17	AAH17599
40	87.4	13.9	1134	17	AAH17598
41	87.4	13.9	1134	17	AAH17595
42	87.4	13.9	1134	17	AAH17596
43	87.4	13.9	1134	17	AAH17597
44	84.8	13.5	9888	24	ABL33240
45	79.4	12.7	1104	15	AAO58894

ALIGNMENTS

RESULT 1	AAFS8602	standard; cDNA; 627 BP.
ID	AAFS8602:	
AC	AAFS8602:	
XX		
XX		
XX	24-APR-2001 (first entry)	
DE	Human RECAP polynucleotide, SEQ ID NO: 30.	
XX		
XX	Human; RECAP; receptors and associated proteins; cerebroprotective;	
KW	neurotrophic; neuroprotective; anticonvulsant; antiparkinsonian; anti-HIV;	
KW	antidiabetic; immunostimulant; immunomodulator; antinflammatory;	
KW	antihypertoid; immunosuppressive; nephrotoxic; antipruritic; thymoleptic;	
KW	cytostatic; antibacterial; virucide; fungicide; proteoglycan;	
KW	antiartherosclerotic; hepatotropic; gene therapy; infection; cancer; ss.	
XX		
OS	Homo sapiens.	
XX		
PN	WO200107612-A2.	
XX		
PD	01-FEB-2001.	
XX		
PF	21-JUL-2000; 2000MO-US20035.	
XX		
XX	21-JUL-1999; 99US-0145232.	
PR	07-OCT-1999; 99US-0158578.	
XX		
PR	12-NOV-1999; 99US-0165192.	
XX		
PA	(INCY -) INCYTE GENOMICS INC.	
XX		
PI	Au-Young J, Bandman O, Tang YT, Yue H, Azimzai Y, Burford N;	

DNA encoding novel
DNA encoding novel
Complement recepto
Complement recepto
Complement recepto
Complement recepto
Complement recepto
Complement recepto
DNA encoding novel
Partial human comp
Human C3b/C4b rece
Human MCP cDNA. H
Human colon cancer
Lung cancer associ
Human secreted pro
Human diallelic po
DNA encoding novel
DNA encoding novel
Human MCP (CD46) f
Human CD46 cDNA.
Sequence encoding
Membrane co-factor
CD46 clone pms.8.
CD46 clone pms.1.
CD46 clone pms.6.
Human immune syste
CD46 protein encod
CD46 construct del
CD46 construct sub
CD46 wild-type cDN
CD46 construct sub
CD46 construct sub
Human immune syste
Sequence encoding

DE Human C3b/C4b receptor (CRI) protein encoding DNA.
 XX C3b/C4b receptor; CRI protein; cell-surface protein; erythrocyte; human;
 KM complement regulatory activity; complement pathway enzyme; tissue damage;
 KM reperfusion injury; Arthus reaction; myocardial infarct; inflammation;
 XX heart condition; autoimmune disorder; diagnostic; ss.
 OS Homo sapiens.
 XX US981481-A.
 PN 09-NOV-1999.
 PD 09-NOV-1999.
 XX 06-JUN-1995; 95US-0470652.
 PF 03-APR-1989; 89US-0332865.
 PR 06-DEC-1974; 74US-0350238.
 PR 24-FEB-1993; 93US-0026134.
 PR 01-APR-1988; 88US-0176532.
 XX (UYTO) UNIV JOHNS HOPKINS.
 PA (BGHM) BRIGHAM & WOMENS HOSPITAL.
 PA (AVAN-) AVANT IMMUNOTHERAPEUTICS INC.
 PI Conclno MF, Wong MW, Makrides SC, Klickstein LB, Fearon DT, Ip SH;
 PI Marsh HC, Carson GR;
 XX WPI; 1999-633357/54.
 DR P-PSDB; AAI5751.
 XX A human C3b/C4b receptor (CRI) protein having antiinflammatory and
 PT cardiant activity -
 XX Disclosure: Fig 1A-P; 87pp; English.
 XX The invention relates to a human C3b/C4b receptor (CRI) protein. The CRI
 CC protein or fragment is expressed as a cell-surface protein on the surface
 CC of a non-human cell and exhibits a complement regulatory activity of full
 CC -length human CRI as expressed on erythrocytes. The CRI function in vivo
 CC may be mediated through the inhibition of complement pathway enzymes. The
 CC soluble CRI protein exhibits a complement regulatory activity, and this
 CC may be used to prevent reperfusion injury, inhibit Arthus reaction, and
 CC neutrophil mediated tissue damage, and reduce myocardial infarct size,
 CC and inflammation. The CRI protein and its fragments can also be used in
 CC the treatment of conditions which involve unwanted complement activity,
 CC e.g. shock lung, tissue damage due to burn, or ischemic heart conditions,
 CC and autoimmune disorders. CRI proteins, analogues, derivatives, and anti
 CC -CRI antibodies are used in assays, and diagnostics. The present sequence
 CC represents a DNA encoding the human CRI protein.
 XX Sequence 6951 BP; 1802 A; 1680 C; 1661 G; 1808 T; 0 other;
 XX
 Query Match 56.1%; Score 352; DB 20; Length 6951;
 Best Local Similarity 84.0%; Pred. No. 1.3e-96;
 Matches 410; Conservative 0; Mismatches 75; Indels 3; Gaps 1;
 QY 66 acggaggtcccgccgagctatgagcctccgctccgctcgcgagcgtcccttctcc 125
 DB 28 atgggggctctctcccaagaagccggagcctcggcgccggcgccgtctcc 87
 QY 126 cggcgcttccgtggtctctcgcgagcctcgtgtgtgtc--gctgctctctctcc 182
 DB 88 ttctgtcggagagatccctgtcgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgt 147
 QY 183 gatcaatgaatgctccggagatgctcattgcccagagcctaccacaaactatgatgac 242
 DB 148 ggtcaatgaatgctccggagatgctcattgcccagagcctaccacaaactatgatgac 207
 QY 243 ttggaattcccatcggagacatattgaaatgaatgacgagcctgtgtttccggaaga 302
 DB 208 ttggaattcccatcggagacatattgaaatgaatgacgagcctgtgtttccggaaga 267

QY 303 ccgtttctatcatctgcctcaaaaaactcagctcggacaagtgtctaaggacaagtgcaga 362
 DB 268 ccgtttctatcatcctgcctcaaaaaactcagctcggacaagtgtctaaggacaagtgcaga 327
 QY 363 cgttaatcagctgtatcctccagatcctcgtgaatgacgagcactgtatataaac 422
 DB 328 cgttaatcagctgtatcctccagatcctcgtgaatgacgagcactgtatataaac 387
 QY 423 atccagctcggatcccaaatataattcttcttccaaaggataccagactatgtgtcc 482
 DB 388 atccagctcggatcccaaatataattcttcttccaaaggataccagactatgtgtcc 447
 QY 483 tgcgtcgcacatgacatattcgaagcaacatgctgtgtgtgtgtgtgtgtgtgtgtgt 542
 DB 448 tgcgtcgcacatgacatattcgaagcaacatgctgtgtgtgtgtgtgtgtgtgtgtgt 507
 QY 543 tgtgacag 550
 DB 508 tgtgacag 515
 RESULT 5
 ID AAI58380 standard; CDNA; 7313 BP.
 XX AAI58380;
 AC AAI58380;
 XX 22-OCT-2001 (first entry)
 XX Human polynucleotide SEQ ID NO 583.
 DE Human; neurotropic; immunosuppressant; cytostatic; gene therapy; cancer;
 KW peripheral nervous system; neuropathy; central nervous system; CNS;
 KW Alzheimer's; Parkinson's disease; Huntington's disease; haemostatic;
 KW amyotrophic lateral sclerosis; Shy-Drager Syndrome; chemotactic;
 KW chemokinetic; thrombolytic; drug screening; arthritis; inflammation;
 KW Leukaemia; ss.
 XX Homo sapiens.
 XX MO200153312-A1.
 XX 26-JUL-2001.
 XX 26-DEC-2000; 2000MO-US34263.
 XX 21-JAN-2000; 2000US-0488725.
 XX 25-APR-2000; 2000US-0552317.
 XX 09-JUL-2000; 2000US-0598042.
 XX 19-JUL-2000; 2000US-0620312.
 XX 03-AUG-2000; 2000US-0653450.
 XX 14-SEP-2000; 2000US-0662191.
 XX 19-OCT-2000; 2000US-0693036.
 XX 29-NOV-2000; 2000US-0727344.
 XX (HYSE-) HYSEQ INC.
 XX Tang YT, Liu C, Asundi V, Chen R, Ma Y, Qian XB, Ren F, Wang D;
 PI Wang Z, Wang Z, Weinman T, Xu C, Xue AD, Yang Y, Zhang J;
 PI Zhao QA, Zhou P, Goodrich R, Drmanac RT;
 XX WPI; 2001-442253/47.
 XX P-PSDB; AAM39224.
 XX Novel nucleic acids and polypeptides, useful for treating disorders
 PT such as central nervous system injuries -
 XX Claim 1; SEQ ID NO 583; 10078pp; English.
 XX The invention relates to human nucleic acids (AAI57798-AAI61369) and
 CC the encoded polypeptides (AAM38642-AAM42213) with neurotropic,
 CC immunosuppressant and cytostatic activity. The polynucleotides are useful
 CC in gene therapy. A composition containing a polypeptide or polynucleotide


```
Db 731 tggactgtgtcgaagcagcgtgcagacgacgaacatcatctgtaatccctccagatcctgtg 790
QY 396 aatgcatgtgcaatgtgatacaagaacatccagttcgatcccaatataattctt 455
Db 791 aatgcatgtgcaatgtgatacaagaacatccagttcgatcccaatataattctt 850
QY 456 cctaaaggaacacgactatgttctcgtctgcacatgatactcgaagcaact 515
Db 851 actaaaggaacacgactatgttctcgtctgcacatgatactcgaagcaact 910
QY 516 gtcaattgggataataaacaacctgttggacag 550
Db 911 gtcaattgggataataaacaacctatttggacag 945

RESULT 7
AA041867
ID AA041867 standard; DNA; 6951 BP.
XX AA041867;

14-SEP-1993 (first entry)

CRI coding region.

C3b/C4b receptor; CRI; erythrocyte; monocyte; macrophage; granulocyte;
1C3b; T cell; splenic follicular dendritic cell; soluble; complement;
glomerular podocyte; B cell; C3b; C4b; inactivated C3b; phagocytosis;
plasma; ligand binding activity; immune complex; activator; allotype;
C3/C5 convertase; lymphocyte; classical; alternative; pathway; cofactor; F;
C3/C5 convertase; liver; cleavage; factor I; regulation; glycoprotein;
S; A; B; glycosylation; duplication; repetitive intervening sequence;
endoglycosidase F; ss.

XX OS Homo sapiens.
XX FH
XX CD5
XX Key Location/Qualifiers
XX CDS 28..6147
XX FT /*tag= a
XX FT 28..150
XX FT /*tag= b
XX FT 151..6144
XX FT /*tag= c
XX FT 1534..6147
XX FT /*tag= d
XX FT /*note= "CRI cDNA"
XX FT misc_difference 509..512
XX FT /*tag= e
XX FT /*note= "Unclear in the specification"

US5212071-A.
XX 18-MAY-1993.
XX PD
XX PF 01-APR-1988; 88US-0176532.
XX PR 01-APR-1988; 88US-0176532.
XX PR 03-APR-1989; 89US-0332865.
XX PA (BGM ) BRIGHAM & WOMENS HOSPITAL.
XX PA (TCEL-) T CELL SCI INC.
XX PA (UYJO ) UNIV JOHNS HOPKINS.
XX PI Carson GR, Conclino MF, Fearon DF, Ip SH, Klickstein LB;
XX Makrides SC, Wong WM;
XX WPI: 1993-175454/21.
XX P-PSDB: AAR36743.
XX DR
XX Nucleic acid encoding polypeptide having complement regulatory
XX activity - used to prevent reperfusion injury, inhibit Arthus
XX reaction and neutrophil mediated tissue damage and reduce
XX myocardial infarct size and inflammation
XX PT
```

```
XX PS Claim 1; Fig 1; 90pp; English.
XX XX
CC This sequence represents the entire coding region for the C3b/C4b
CC receptor (CRI). CRI is present on erythrocytes, monocytes/macro-
CC phages, granulocytes, B cells, some T cells, splenic follicular
CC dendritic cells and glomerular podocytes. CRI specifically binds
CC C3b, C4b and inactivated C3b (iC3b). A soluble form of the receptor
CC is found in plasma which has ligand binding activity and the same
CC molecular weight as membrane-associated CRI. CRI binds C3b and C4b
CC that have covalently attached to immune complexes and other complement
CC activators. The consequences of these interactions depends on the
CC type of bearing the receptor. Erythrocyte CRI binds immune complexes
CC for transport to the liver. CRI on neutrophils and monocytes
CC internalises bound complexes, either by adsorptive endocytosis
CC or by phagocytosis. The function of CRI on B lymphocytes is less
CC well defined. CRI can inhibit the classical and alternative pathway
CC C3/C5 convertases and act as a cofactor for the cleavage of C3b and
CC C4b by factor I, therefore CRI has a complement regulatory function
CC as well as acting as a receptor. CRI is a glycoprotein composed of
CC a single polypeptide chain. Four allotypic forms of CRI have been
CC identified, differing by increments of approx. 40-50 kD. The two most
CC common forms, the F and S allotypes, also termed A and B allotypes,
CC have molecular weights of 250 and 290 kD respectively. The two rarer
CC forms have molecular weights of 210 and 290 kD. These differences
CC represent differences in the polypeptide chain of CRI, rather than
CC glycosylation state because they are not abolished by treatment of
CC purified receptor protein with endoglycosidase F. The CRI gene has
CC been shown to have repetitive intervening sequences which may have
CC been duplicated in the formation of the larger allotypes.
XX XX
SQ Sequence 6951 BP; 1799 A; 1692 C; 1648 G; 1807 T; 5 other;

Query Match 55.5%; Score 348; DB 14; Length 6951;
Best Local Similarity 83.2%; Pred. No. 2,2e-95;
Matches 406; Conservative 0; Mismatches 79; Indels 3; Gaps 1;

QY 66 acggggtctccgcgcgcacatgagcgccctccgctcgtctgagcgctccctctcc 125
Db 28 atggggcctctctcccaagaagccggagcctggtggcgccggtccggtctcc 87
QY 126 cggcgcttctcgtgtgtctcgtgcgcgcctgtgtgtct--gctgtccctctcc 182
Db 88 ttctcgtcggagagatccctcgtcgtgtgtgtgtgtctgtcgtcgtcgtgtgtgt 147
QY 183 gatcaatgcaatgtcccggaatgttccattgtccagcgctacaaactaatatgatgac 242
Db 148 gttcaatgcaatgtcccggaatgttccattgtccagcgctacaaactaatatgatgac 207
QY 243 ttgagattccattggagacatctggaactatgaaatgcgcctgtgtattccggaaga 302
Db 208 ttgagattccattggagacatctggaactatgaaatgcgcctgtgtattccggaaga 267
QY 303 cgglttctatcatctgcttaaaaaactcagtcgtgcaatgtgtaaggaagaatgcaaa 362
Db 268 ccgtttctatcatctgcttaaaaaactcagtcgtgcaatgtgtaaggaagaatgcaaa 327
QY 363 cgtaaatcatgtgtatactctcagatctcgtgaaatgtgcaatgtgtaaggaagaac 422
Db 328 cgttaaatcatgtgtatactctcagatctcgtgaaatgtgcaatgtgtaaggaagaac 387
QY 423 atcgaatcgaatcccaataataattcttctcgaaggaatccgactatgtttcc 482
Db 388 atcgaatcgaatcccaataataattcttctcgaaggaatccgactatgtttcc 447
QY 483 tgcgtcgaatcatgatactcgaaggaacactgtcatttgggataataaacaacctgt 542
Db 448 tgcgtcgaatcatgatactcgaaggaacactgtcatttgggataataaacaacctatt 507
QY 543 tggagacag 550
Db 508 tnnnncag 515
```

RESULT 8
 ID ABA09026
 AC ABA09026; standard; cDNA: 7028 BP.
 XX
 DT 11-JAN-2002 (first entry)
 DE Human CRI protein homologue-encoding cDNA, SEQ ID NO:802.
 XX
 KM Human; cytokine; cell proliferation; cell differentiation; growth factor;
 KM haematopoiesis regulation; tissue growth; immunomodulator; activin;
 KM inhibin; chemokinesis; chemokinesis; thrombolysis; oncogenesis;
 KM proliferation; metastasis; cancer; tumour; haematopoietic disorder;
 KM myeloid cell disorder; lymphoid cell disorder; asthma; arthritis;
 KM chronic inflammatory condition; proliferative retinopathy;
 KM atherosclerosis; coronary heart disease; arterial ischaemia;
 KM bone disorder; osteoporosis; vascular growth disorder;
 KM tissue regeneration; wound healing; infection; immune disorder;
 KM cell culture; drug screening; gene therapy; antiinflammatory;
 KM antirheumatic; antiarthritis; haemostatic; antiarteriosclerotic;
 KM cytosstatic; osteopathic; vasotropic; cardiant; virucide; antibacterial;
 KM antifungal; vulnerary; antituber; ss.
 OS Homo sapiens.
 XX
 PN WO200157188-A2.
 XX
 PD 09-AUG-2001.
 XX
 PF 05-FEB-2001; 2001WO-US03800.
 XX
 PR 03-FEB-2000; 2000US-0496914.
 PR 27-APR-2000; 2000US-0560875.
 PA (HYSE-) HYSEQ INC.
 PI Tang YT, Liu C, Drmanac RT;
 XX
 DR WPI: 2001-457740/49.
 P-PSDB: ABB11782.
 PT Human proteins and DNA encoding sequences useful for preventing,
 PT treating or ameliorating a medical condition in a mammalian subject
 PT e.g. arthritis and cancer -
 XX
 CI Claim 1; Page 707-709; 1963pp; English.
 CC Sequences ABB10981-ABB1230 represent 1350 novel human polypeptides, and
 CC sequences ABA08223-ABA09574 represent nucleic acids encoding them. The
 CC invention also relates to vectors and recombinant host cells comprising a
 CC nucleotide of the invention, methods of producing the novel polypeptides,
 CC antibodies against the polypeptides, methods of detecting the nucleotides
 CC and polypeptides in a sample, and methods of identifying compounds which
 CC bind to polypeptides of the invention. Although novel, many of the
 CC polypeptides of the invention have homology to known proteins, thereby
 CC giving an insight into their probable biological activities; and hence
 CC potential therapeutic applications. The polypeptides of the invention may
 CC have various activities, including cytokine, cell proliferation or cell
 CC differentiation activities; stem cell growth factor activity;
 CC haematopoiesis regulatory activity; tissue growth activity;
 CC immunomodulatory activity; activin- or inhibin-related activities;
 CC chemotactic or chemokinetic activities; haemostatic, thrombotic or
 CC thrombolytic activities; receptor or ligand activities; or may be
 CC involved in oncogenesis, cancer cell proliferation or metastasis.
 CC Depending on their biological activities, polypeptides and nucleotides of
 CC the invention are useful for preventing, treating or ameliorating medical
 CC conditions, e.g., by protein or gene therapy. Such conditions include
 CC cancers, haematopoietic disorders (e.g., myeloid or lymphoid cell
 CC disorders), chronic inflammatory conditions (e.g., asthma or arthritis),
 CC proliferative retinopathy, atherosclerosis, coronary heart disease,

AAV53262
 ID AAV53262 standard; DNA; 591 BP.
 XX
 AC AAV53262;
 XX
 DT 18-JAN-1999 (first entry)
 XX
 DE Complement receptor type 1-like sequence CM7 DNA.
 XX
 KW Complement receptor type-1; CRI; CM7; complement; inhibitor;
 KW anti-haemolytic; multiple sclerosis; Parkinson's disease;
 KW xenograft rejection; inflammation; Crohn's disease; asthma;
 KW pancreatitis; post-ischaemic reperfusion; infection; sepsis;
 KW autoimmune disease; rheumatoid arthritis; proliferative nephritis;
 KW myasthenia gravis; reproductive disorder; therapy; ss.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO9839433-A1.
 XX
 PF 11-SEP-1998.
 XX
 PF 05-MAR-1998; 98WO-GB00727.
 XX
 PR 05-MAR-1997; 97GB-0004519.
 XX
 PA (ADPR-) ADPROTECH PLC.
 XX
 PI Cox VF, Mossakowska DEL, Smith RAG;
 XX
 DR WPI: 1998-506358/43.
 DR P-PSDB; AAW79236.
 XX
 PT Soluble polypeptide comprising short consensus repeats from IHR-A -
 PT used to treat disorders and diseases associated with inflammation or
 PT inappropriate complement activation
 XX
 PS Claim 22; Page 42-43; 67pp; English.
 XX
 CC This DNA sequence encodes CM7 (see AAW79236), a protein that consists
 CC of the short consensus repeats (SCR) 1 and 2 from the complement
 CC receptor type 1 (CRI) fused to the SCR3 of CRI-like pseudogene (see
 CC AAW79242). CM7 DNA was constructed using plasmid pBI1013-5, which
 CC codes for SCR1-3 of CRI, by site-directed mutagenesis using 3 pairs
 CC of oligonucleotides (see AAV53263-65) that introduced 10 amino acid
 CC changes to the native SCR3 sequence corresponding to changes
 CC observed in the CRI-like pseudogene (Crlpse). proCS-CRI-3CM7
 CC carrying the CM7 DNA construct was used to transform *Escherichia*
 CC coli BL21(DE3), and CM7 was purified from solubilised inclusion
 CC bodies. The invention provides DNA sequences (see AAV53262 and
 CC AAV53269-79) encoding novel soluble engineered CRI polypeptides (see
 CC AAV53236-47) such as CM7 that act as complement inhibitors with
 CC functional complement inhibitory, including anti-haemolytic,
 CC activity. These can be used to treat a disease or disorder,
 CC associated with inflammation or inappropriate complement activation,
 CC such as neurological disorders (e.g. multiple sclerosis and
 CC Parkinson's disease), disorders of inappropriate or undesirable
 CC complement activation (e.g. xenograft rejection), inflammatory
 CC disorders (e.g. Crohn's disease, asthma, and acute pancreatitis),
 CC post-ischaemic reperfusion conditions, infection or sepsis,
 CC immune complex disorders and autoimmune diseases (e.g. rheumatoid
 CC arthritis, proliferative nephritis and myasthenia gravis), and
 CC reproductive disorders.
 CC
 XX Sequence 591 BP; 132 A; 159 C; 148 G; 152 T; 0 other:
 SO

Query Match 42.6%; Score 267.4; DB 19; Length 591;
 Best Local Similarity 83.3%; Pred. No. 2.5e-71;
 Matches 304; Conservative 0; Mismatches 61; Indels 0; Gaps 0;
 186 caatgcaatgtccggaatggtcatttgcagcctcaccactaactgatgactt 245

DB 4 caatgcaacgctccggaatggtcgcgctccgcccgaaccaactgactgatatt 63
 QY 246 gaatttcccatgtggaacatctgaactatgaatgcgcgcctgttattccggaacccg 305
 DB 64 gaattcccgatcgttacctctcgaactaagaatgcgcgcgggtatgatgcgcgcgcg 123
 QY 306 ttcttcatcattcgtcctaaanaactcagtcctggaacagtgttaaggacaagtgcacgt 365
 DB 124 ttcttcatcattcgtcctaaanaactcgtctgactcgtgtgtaaggacgcgttgcgcagct 183
 QY 366 aatcatgtctgatactcctcgaatcctctggaatggaatggaatggaatggaatggaatc 425
 DB 184 aactctgtctgatactcctcgaatcctcgttaacggaatggaatggaatggaatggaatc 243
 QY 426 caattcgatcccaatataattctctgctcctaaaggataggaactatgttctccg 485
 DB 244 cagttcggttcccaatataattctctgactcctaaaggataggaactatgttctccg 303
 QY 486 tctgcacatgcatcatctcgaagaacactgtcatttggatataaanaacactgttgt 545
 DB 304 agcgcatacatcatcctctgtgtactgtcatttggatataaanaacactgttgt 363
 QY 546 gacag 550
 DB 364 gaccg 368

RESULT 13
 AAV53269
 ID AAV53269 standard; DNA; 591 BP.
 XX
 AC AAV53269;
 XX
 DT 18-JAN-1999 (first entry)
 XX
 DE Complement receptor type 1-like sequence CM1 DNA.
 XX
 KW Complement receptor type-1; CRI; CM1; complement; inhibitor;
 KW anti-haemolytic; multiple sclerosis; Parkinson's disease;
 KW xenograft rejection; inflammation; Crohn's disease; asthma;
 KW pancreatitis; post-ischaemic reperfusion; infection; sepsis;
 KW autoimmune disease; rheumatoid arthritis; proliferative nephritis;
 KW myasthenia gravis; reproductive disorder; therapy; ss.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO9839433-A1.
 XX
 PF 11-SEP-1998.
 XX
 PF 05-MAR-1998; 98WO-GB00727.
 XX
 PR 05-MAR-1997; 97GB-0004519.
 XX
 PA (ADPR-) ADPROTECH PLC.
 XX
 PI Cox VF, Mossakowska DEL, Smith RAG;
 XX
 DR WPI: 1998-506358/43.
 DR P-PSDB; AAW79237.
 XX
 PT Soluble polypeptide comprising short consensus repeats from IHR-A -
 PT used to treat disorders and diseases associated with inflammation or
 PT inappropriate complement activation
 XX
 PS Claim 22; Page 44; 67pp; English.
 XX
 CC This DNA sequence encodes CM1 (see AAW79237), a protein that consists
 CC of the short consensus repeats (SCR) 1 and 2 from complement
 CC receptor type 1 (CRI) fused to an SCR3 (see AAW79242) in which 5 amino
 CC acids were altered to those found in the SCR3 of the CRI-like

CC pseudogene (Gripse) putative product. CM1 DNA was constructed by
CC site-directed mutagenesis (see AAV53263) of plasmid pDB1013-5, which
CC codes for SCRI-3 of CRI. pProcSCRI-3CM1 carrying CM1 DNA was used
CC to transform *Escherichia coli* BL21(DE3), and CM1 was purified from
CC solubilised inclusion bodies. The invention provides engineered CRI
CC (see AAV53262 and AAV53269-79) encoding novel soluble engineered CRI
CC polypeptides (see AAV53236-47) such as CM1 that act as complement
CC inhibitors with functional complement inhibitory, including
CC anti-haemolytic, activity. These can be used to treat a disease or
CC disorder associated with inflammation or inappropriate complement
CC activation, such as neurological disorders (e.g. multiple sclerosis
CC and Parkinson's disease), disorders of inappropriate or unstable
CC complement activation (e.g. xenograft rejection), inflammatory
CC disorders (e.g. Crohn's disease, asthma, and acute pancreatitis),
CC post-ischaemic reperfusion conditions, infection or sepsis,
CC immune complex disorders and autoimmune diseases (e.g. Rheumatoid
CC arthritis, proliferative nephritis and myasthenia gravis), and
CC reproductive disorders.

XX Sequence 591 BP; 127 A; 159 C; 151 G; 154 T; 0 other;

Query Match 42.6%; Score 267.4; DB 19; Length 591;
Best Local Similarity 83.3%; Pred. No. 2,5e-71;
Matches 304; Conservative 0; Mismatches 61; Indels 0; Gaps 0;

```
OY 186 caatgcaatgcccgaatggtcttcattgcagcgctaccacctaactgacttt 245
DB 4 cagtgcaacgctccggaatggtcttcattgcagcgctaccacctaactgacttt 63
OY 246 gagttcccatggtacatctgaactgaatgacgcccctgtttatccggaacgc 305
DB 64 gagttcccatggtacatctgaactgaatgacgcccctgtttatgagcgccgc 123
OY 306 ttcttatcatctgcctctctctctctctctctctctctctctctctctct 365
DB 124 ttcttatcatctgcctctctctctctctctctctctctctctctctctct 183
OY 366 aatcatgctgaatcccccagatctctgtaatgacgacgtgataaagaacatc 425
DB 184 aatcatgctgaatcccccagatctctgtaatgacgacgtgataaagaacatc 243
OY 426 cagttcgatcccaataataatctctgtctcctaagaagataccagctatgtctc 485
DB 244 cagttcgatcccaataataatctctgtctcctaagaagataccagctatgtctc 303
OY 486 tctgccaatgcatcatctcagcaacactgcatcttggtgataataaacaactgtt 545
DB 304 agcgctacatgcatcatctcagcaacactgcatcttggtgataataaacaactgtt 363
OY 546 gacag 550
DB 364 gacgc 368
```

RESULT 14
AAV53270
ID AAV53270 standard; DNA; 591 BP.

AC AAV53270;

XX 18-JAN-1999 (first entry)

DE Complement receptor type 1-like sequence CM2 DNA.

XX Complement receptor type-1; CRI; CM2; complement; inhibitor;
KW anti-haemolytic; multiple sclerosis; Parkinson's disease;
KW xenograft rejection; inflammation; Crohn's disease; asthma;
KW pancreatitis; post-ischaemic reperfusion; infection; sepsis;
KW autoimmune disease; rheumatoid arthritis; proliferative nephritis;
KW myasthenia gravis; reproductive disorder; therapy; ss.
XX Homo sapiens.

OS Synthetic.

XX WO9839433-A1.

XX 11-SEP-1998.

XX 05-MAR-1998; 98WO-GH00727.

XX 05-MAR-1997; 97GB-0004519.

XX (ADPR-) ADPROTECH PLC.

XX Cox VF, Mossakowska DEI, Smith RMG;

XX WPI, 1998-506358/43.

XX P-PSDB; AAW79238.

PT Soluble polypeptide comprising short consensus repeats from LHR-A -
PT used to treat disorders and diseases associated with inflammation or
PT inappropriate complement activation

XX Claim 22; Page 45; 67pp; English.

XX This DNA sequence encodes CM2 (see AAW79238), a protein that consists
CC of the short consensus repeats (SCR) 1 and 2 from complement
CC receptor type 1 (CRI) fused to an SCR3 (see AAW79243) in which 4 amino
CC acids were altered to those found in the SCR3 of the CRI-like
CC pseudogene (Gripse) putative product. CM2 DNA was constructed by
CC site-directed mutagenesis (see AAV53264) of plasmid pDB1013-5, which
CC codes for SCRI-3 of CRI. pProcSCRI-3CM2 carrying CM2 DNA was used
CC to transform *Escherichia coli* BL21(DE3), and CM2 was purified from
CC solubilised inclusion bodies. The invention provides DNA sequences
CC (see AAV53262 and AAV53269-79) encoding novel soluble engineered CRI
CC polypeptides (see AAV53236-47) such as CM2 that act as complement
CC inhibitors with functional complement inhibitory, including
CC anti-haemolytic, activity. These can be used to treat a disease or
CC disorder associated with inflammation or inappropriate complement
CC activation, such as neurological disorders (e.g. multiple sclerosis
CC and Parkinson's disease), disorders of inappropriate or unstable
CC complement activation (e.g. xenograft rejection), inflammatory
CC disorders (e.g. Crohn's disease, asthma, and acute pancreatitis),
CC post-ischaemic reperfusion conditions, infection or sepsis,
CC immune complex disorders and autoimmune diseases (e.g. Rheumatoid
CC arthritis, proliferative nephritis and myasthenia gravis), and
CC reproductive disorders.

XX Sequence 591 BP; 134 A; 158 C; 146 G; 153 T; 0 other;

Query Match 42.6%; Score 267.4; DB 19; Length 591;
Best Local Similarity 83.3%; Pred. No. 2,5e-71;
Matches 304; Conservative 0; Mismatches 61; Indels 0; Gaps 0;

```
OY 186 caatgcaatgcccgaatggtcttcattgcagcgctaccacctaactgacttt 245
DB 4 cagtgcaacgctccggaatggtcttcattgcagcgctaccacctaactgacttt 63
OY 246 gagttcccatggtacatctgaactgaatgacgcccctgtttatccggaacgc 305
DB 64 gagttcccatggtacatctgaactgaatgacgcccctgtttatgagcgccgc 123
OY 306 ttcttatcatctgcctctctctctctctctctctctctctctctctctct 365
DB 124 ttcttatcatctgcctctctctctctctctctctctctctctctctctct 183
OY 366 aatcatgctgaatcccccagatctctgtaatgacgacgtgataaagaacatc 425
DB 184 aatcatgctgaatcccccagatctctgtaatgacgacgtgataaagaacatc 243
OY 426 cagttcgatcccaataataatctctgtctcctaagaagataccagctatgtctc 485
DB 244 cagttcgatcccaataataatctctgtctcctaagaagataccagctatgtctc 303
```

QY 486 tctgccacatgcatcatctcaggaacactgttattgttgataataaacactgtttgt 545
DB 304 agcgctacatgcatcatctcgtgtgtaactgttggataatgaacacgatttgt 363
OY 546 gacag 550
DB 364 gaccg 368

RESULT 15
AAV53271
ID AAV53271 standard; DNA; 591 BP.
AC AAV53271;
XX
DT 18-JAN-1999 (first entry)
XX
DE Complement receptor type 1-like sequence CM3 DNA.

CM3 Complement receptor type-1; CRI; CM3; complement; inhibitor;
anti-haemolytic; multiple sclerosis; Parkinson's disease;
xenograft rejection; inflammation; Crohn's disease; asthma;
pancreatitis; post-ischaemic reperfusion; infection; sepsis;
autoimmune disease; rheumatoid arthritis; proliferative nephritis;
myasthenia gravis; reproductive disorder; therapy; ss.
XX
OS Homo sapiens.
XX Synthetic.
XX
PN WO9839433-A1.
XX
PD 11-SEP-1998.
XX
PF 05-MAR-1998; 98WO-GB00727.
XX
PR 05-MAR-1997; 97GB-0004519.
XX
PA (ADPR-) ADPROTECH PLC.
XX
PI Cox VF, Mossakowska DEI, Smith RAG;
XX
DR WPI: 1998-506358/43.
XX
DR P-PSDB; AAV79239.
XX
PT Soluble polypeptide comprising short consensus repeats from LHR-A -
XX used to treat disorders and diseases associated with inflammation or
XX inappropriate complement activation

Claim 22: Page 46; 67pp; English.

This DNA sequence encodes CM2 (see AAV79239), a protein that consists
of the short consensus repeats (SCR) 1 and 2 from complement
receptor type 1 (CRI) fused to an SCR3 (see AAV79244) in which 1 amino
acid was altered to that found in the SCR3 of the CRI-like
pseudogene (Cripse) putative product. CM3 DNA was constructed by
site-directed mutagenesis (see AAV53265) of plasmid pB1013-5, which
codes for SCR1-3 of CRI. pBiosCR1-3CM3 carrying CM3 DNA was used
to transform Escherichia coli BL21(DE3), and CM3 was purified from
solubilised inclusion bodies. The invention provides DNA sequences
(see AAV53262 and AAV53269-79) encoding novel soluble engineered CRI
polypeptides (see AAV53236-47) such as CM3 that act as complement
inhibitors with functional complement inhibitory, including
anti-haemolytic, activity. These can be used to treat a disease or
disorder associated with inflammation or inappropriate complement
activation, such as neurological disorders (e.g. multiple sclerosis
and Parkinson's disease), disorders of inappropriate or undesirable
complement activation (e.g. xenograft rejection), inflammatory
disorders (e.g. Crohn's disease, asthma, and acute pancreatitis),
post-ischaemic reperfusion conditions, infection or sepsis,
immune complex disorders and autoimmune diseases (e.g. rheumatoid
arthritis, proliferative nephritis and myasthenia gravis), and
reproductive disorders.

SQ Sequence 591 BP; 131 A; 160 C; 149 G; 151 T; 0 other:
Query Match 42.6%; Score 267.4; DB 19; Length 591;
Best Local Similarity 83.3%; Pred. No. 2,5e-71;
Matches 304; Conservative 0; Mismatches 61; Indels 0; Gaps 0;

OY 186 caatgcaatgtccggaatgagcttcacattgccaagcctaccacctaactgatgactt 245
DB 4 cagtgcaacgctccggaatgagcttcacattgccaagcctaccacctaactgatgactt 63
OY 246 gagttcccatgtggaactatctgaactatgaatgacgcccctgtttattccgaaagccg 305
DB 64 gagtcccgatcgtgtaactctgaactaactgaatgacgcccctgtttattccgaaagccg 123
OY 306 ttctcatcatcgtcgttaaaaaactcaagctcgtgaacagtgctaaagcaagtgcaacgt 365
DB 124 ttctcatcatcgtcgttctgttaaaaaactcgtcgtgactgtgtgtaagacgttgcgcagtc 183
OY 366 aaatcatgtcgttaactcctccagatcctgtgtgaatgcatgacatgtgataaagacatc 425
DB 184 aaacttgcgttaactcgcgcagatcctgtgtgaatgcatgacatgtgataaagacatc 243
OY 426 cagttcggatcccaaatatattctgtcttaagagataccgacccattggttctctc 485
DB 244 cagttcggatcccaaatatattctgtcttaagagataccgacccattggttctctc 303
OY 486 tctgccacatgcatcatctcaggaacactgttattgttgataataaacacactgtttgt 545
DB 304 agcgctacatgcatcatctcgtgtgtaactgttggataatgaacacgatttgt 363
OY 546 gacag 550
DB 364 gaccg 368

Search completed: October 9, 2002, 17:40:21
Job time: 3772 sec

GenCore version 4.5
Copyright (c) 1993 - 2000 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: October 9, 2002, 16:04:33 ; Search time 1594.28 Seconds
(without alignments)
5308.096 Million cell updates/sec

Title: US-10-031-904-30

Perfect score: 627

Sequence: 1 cggactcagaagagacttc.....ataataaaatttaaccga 627

Scoring table: IDENTITY_NDC
Gapop 10.0 , Gapext 1.0

Searched: 13736207 seqs, 6748477542 residues
Total number of hits satisfying chosen parameters: 27472414

Minimum DB seq length: 0
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : EST:*

1: em_estbta:*
2: em_esthum:*
3: em_estlin:*
4: em_estlun:*
5: em_estlov:*
6: em_estlpl:*
7: em_estro:*
8: em_hic:*
9: gb_estl:*
10: gb_estl2:*
11: gb_hic:*
12: gb_gss:*
13: em_gss_hum:*
14: em_gss_inv:*
15: em_gss_pln:*
16: em_gss_vrtl:*

pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	445	71.0	465	10	BE552138
2	443.6	70.7	832	10	BE240184
3	435	69.4	443	10	BE240184
4	393.6	62.8	444	9	AT171858
5	352	56.1	1063	10	BM477528
6	344.8	55.0	356	9	AT173545
7	326.8	52.1	440	10	H73873
8	307	49.0	346	10	T66823
9	306.4	48.9	389	10	T66823
10	270.4	43.1	541	10	T63269
11	268.6	42.8	433	9	AT1735085
12	212.8	33.9	577	10	BE077250
13	212.8	33.9	614	9	AA107525
14	212.8	33.9	658	10	BI697900
15	212.8	33.9	795	10	BI455761
16	212.8	33.9	807	10	BI078162
17	211.2	33.7	601	9	AA212152

18	208	33.2	773	10	BI556660
19	206.8	33.0	722	10	BI696340
20	205	32.7	488	10	BE023537
21	205	32.7	569	10	BI693880
22	205	32.7	684	9	BB613937
23	204.8	32.7	643	9	AW912091
24	203.4	32.4	525	9	AA286570
25	203.4	32.4	650	9	AW610808
26	201.8	32.2	1646	11	AK004825
27	199.6	31.8	335	10	T27695
28	195	31.1	739	10	BE243080
29	194.6	31.0	861	10	BF178335
30	194	30.9	388	10	BG146321
31	194	30.9	403	9	AW610947
32	194	30.9	409	9	AW012541
33	192.8	30.7	441	9	AW825298
34	189.2	30.2	469	9	AA261275
35	184.6	29.4	353	10	BE917021
36	184.6	29.4	981	10	BF166939
37	184.2	29.4	889	10	BF166939
38	182.6	29.1	387	9	AW211552
39	180	28.7	519	10	BF159845
40	170.2	27.1	431	10	BF015454
41	166	26.5	770	10	BF124847
42	164.4	26.2	3859	11	AK017702
43	159.4	25.4	419	9	AA756782
44	157	25.0	397	9	AA314773
45	156.4	24.9	300	9	AA100130

ALIGNMENTS

RESULT 1
BE552138/c
LOCUS
DEFINITION
BE552138
LOCUS
hw29d02.x1 NCI_CGAP_Kid11 Homo sapiens CDNA clone IMAGE:3184323 3'
similar to gb:Y00816.cdsl COMPLEMENT RECEPTOR TYPE 1 PRECURSOR
(HUMAN); mRNA sequence.

ACCESSION
BE552138
VERSION
BE552138.1
KEYWORDS
EST.
SOURCE
human.
ORGANISM
Homo sapiens

REFERENCE
1 (bases 1 to 465)
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
NCI-CGAP <http://www.ncbi.nlm.nih.gov/ncicgap>.
National Cancer Institute, Cancer Genome Anatomy Project (CGAP),
Tumor Gene Index
Unpublished (1997)

JOURNAL
COMMENT
Contact: Robert Strausberg, Ph.D.
Email: cgaps-remail.nih.gov
Tissue Procurement: Christopher Moskaluk, M.D., Ph.D., Michael R.
Emmert-Buck, M.D., Ph.D.
CDNA Library Preparation: M. Bento Soares, Ph.D.
CDNA Library Arrayed by: Greg Lennon, Ph.D.
DNA Sequencing by: Washington University Genome Sequencing Center
clone distribution: NCI-CGAP clone distribution information can be
found through the I.M.A.G.E. Consortium/LINL, send email to:
info@image.lnl.gov
Seq primer: -40UP from GIBCO
High quality sequence stop: 456.

FEATURES
source
Location/Qualifiers
1..465
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone="IMAGE:3184323"
/clone_id="NCI_CGAP_Kid11"
/lab_host="DH10B"
/note="Organ: kidney; Vector: pT73D-Pac (pharmacia) with
a modified polylinker; Site_1: Not I; Site_2: Eco RI;
Plasmid DNA from the normalized library NCI_CGAP_Kid3 was

	DEFINITION						
		994e04.x1 NCI_CGAP_Kid3 Homo sapiens CDNA clone IMAGE:1867134 3'					
		similar to gb Y00816.cds1 COMPLEMENT RECEPTOR TYPE 1 PRECURSOR (HUMAN); mRNA sequence.					
	ACCESSION	AF240881.1 GI:3836278					
	VERSION	EST.					
	KEYWORDS	human.					
	SOURCE	Human.					
	ORGANISM	Homo sapiens					
		Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.					
	REFERENCE	NCI-CGAP http://www.ncbi.nlm.nih.gov/ncicgap .					
	AUTHORS	National Cancer Institute, Cancer Genome Anatomy Project (CGAP), Tumor Gene Index					
	TITLE	Unpublished (1997)					
	JOURNAL	Contact: Robert Strausberg, Ph.D. Email: cgaabs-r@mail.nih.gov Tissue Procurement: Christopher Moskaluk, M.D., Ph.D., Michael R. Emmer-Buck, M.D., Ph.D.					
	COMMENT	CDNA library Preparation: M. Bento Soares, Ph.D. DNA library Arrayed by: Greg Lennon, Ph.D. DNA Sequencing by: Washington University Genome Sequencing Center Clone distribution: NCI-CGAP clone distribution Information can be found through the I.M.A.G.E. Consortium/LNL at: www.bio.lnl.gov/db/rp/image/image.html Insert length: 625 Std Error: 0.00 Seq primer: -40UP from Gibco High quality sequence stop: 373. Location/Qualifiers					
FEATURES	SOURCE	1..443					
		/organism="Homo saplens"					
		/db_xref="taxon:9606"					
		/clone_image="IMAGE:1867134"					
		/clone_lib="NCI_CGAP_Kid3"					
		/lab_host="DH10B"					
		/note="Organ: Kidney; Vector: pT773D-Pac (Pharmacia) with a modified polylinker; Site:1; Not I; Site:2: Eco RI; 1st strand cDNA was primed with a Not I - oligo(dT) primer, double-stranded cDNA was ligated to Eco RI adaptors (Pharmacia), digested with Not I and cloned into the Not I and Eco RI sites of the modified pT73 vector. mRNA source: 2 pooled kidneys. Library went through one round of normalization. Library constructed by Bento Soares and M. Fatima Bonaldo."					
BASE COUNT		131 a	80 c	104 g	128 t		
ORIGIN							
	Query Match	69.4%;	Score 435;	DB 9;	Length 443;		
	Best Local Similarity	98.9%;	Pred. No. 5.6e-110;	Mismatches 5;	Indels 0;	Gaps 0;	
	Matches 438;	Conservative					
Oy	185	tcaatgcaaatgccgaatgtcttccattttgcaggcctcaaacctaactgatgacct	244				
Dob	443	TCATGCAATAGTCGGAAATGGGCTTCATTGCCAGGCCTACCAACTTAATGTATGCTC	384				
Oy	245	tgaattccatttggaacatactcgaactatgaatggcccttggtattcccggaagacc	304				
Db	383	TGAATTCCCATTTGGACATATCTGAAACATGAAGAAGCCGCCCTGGTATTCCGGAAGACC	324				
Oy	305	gtttctcatcatgttgtctaaanaaacacagtcgtgcagaagtgtctaaagacaagtccaag	364				
Db	323	GTTTTCATATATCTGGCTTAATAAATCACTCAAGTCGAGCAAGTCTTAAGGACAAGTCCAAGC	264				
Oy	365	taaatcatgtcgttaactctccagatctctgtgaatgcatgtgcacatgtgatcaagaacat	424				
Db	263	TAAATCATGTGCGTAATATCTCCAGATCTCTGTGATGAGCATGTGCACATGTGATCAAGACAT	204				
Oy	425	cgaattcgatcccaaattaatatctctgttcctlaaagaataccgactcatgtttctc	484				
Db	203	CCAATTGCGATCCCAAATTAAATATCTTGTCCTTAAGAAGATACGACATGTGGTCTCTC	144				
Oy	485	gtctgcacaatgatcatatctcaggaacaacgtgtcaattggagataataaacaacctgtttg	544				

Db	143	CTGTGCCACATGCATCATCTCAGGACAACACGTCATTGTGGATAAATAAACACCCTGTTTG	
OY	545	tgcacgttgatgtaaatatgatcattcccttctttctttaccgaatacatcctaatttcctt	604
Db	83	TGACAGTGGATGTAATAATGCAATTCCTATTTCTTTTACCGACATTCATTAATTTTCTCT	24
OY	605	ggaataaaactcaacca	627
Db	23	GGAATAATAAAAAATCTTAACGA	1
RESULT	4	A1718588	444 bp mRNA linear EST 10-JUN-1999
A1718588/c		as46H01.x1 Barstead aorta HPLRB6 Homo sapiens cDNA clone	
DEFINITION		IMAGE:2320273 3' similar to gb:Y00816_cds1 COMPLEMENT RECEPTOR TYPE	
LOCUS		1 PRECURSOR (HUMAN);, mRNA sequence.	
ACCESSION		A1718588	
VERSION		A1718588.1	GI:5035844
KEYWORDS		EST.	
SOURCE		human.	
ORGANISM		Homo sapiens	
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;		Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.	
REFERENCE		1 (bases 1 to 444)	
AUTHORS		Hillier,L., Allen,M., Bowles,L., Dubucque,T., Geisler,G., Jost,S., Krisman,D., Kucaba,T., Lacy,M., Le,N., Lennon,G., Marra,M., Martin .J., Moore,B., Schellenberg,K., Steptoe,M., Tan,F., Theising,B., White,Y., Wyllie,T., Waterston,R. and Wilson.R. Washington University School of Medicine 4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108 Tel: 314 286 1800 Fax: 314 286 1810 Email: estewatson.wustl.edu WashU-MCf Human EST Project Unpublished (1997) Contact: Wilson RK	
TITLE		This clone is available royalty-free through UNL ; contact the	
JOURNAL		IMAGE Consortium (info@image.llnl.gov) for further information.	
COMMENT		Seq primer: -40Up from Glenco.	
FEATURES		Location/Qualifiers	
source		1..444	
/organism="Homo sapiens"			
/db_xref="taxon:9606"			
/clone IMAGE:2320273"			
/clone_lib="Barstead aorta HPLRB6"			
/sex="male"			
/dev_stage="adult, age 64"			
/lab_host="DH10B (phage resistant)"			
/note="Organ: aorta; Vector: pTR73D-Pac (Pharmacia) with a			
modified polylinker; Site_1: EcoRI; Site_2: NotI; 1st			
strand cDNA was primed with a Not I - oligo(dT) primer [5'			
TGTTTCGAATCGAATGCCAGATGGCTCCATTCATTTGCCAGACTTACCAACTTAATGATG			
3']; double-stranded cDNA was ligated to Eco RI adaptors			
[5': AATTGCGATCGAC 3' and 5' GTTGGATCG 3']; digested			
with Not I and cloned into the Not I and Eco RI sites of			
the modified pTR73 vector. Library constructed by Bob			
Barstead."			
BASE COUNT		134 a	87 c 103 g 120 t
ORIGIN			
Query Match		62.8%; Score 393.6; DB: 9; Length 444;	
Best Local Similarity		94.4%; Fred. No. 1.7e-98;	
Matches 419; Conservative		0; Mismatches 24; Indels 1; Gaps 1;	
OY	183	gataatgcaatgtcccggaatgagttccattgcccaggacctaaccaactgaatgac	242
Db	444	GTCGAATGCAATGCCAGATGGCTCCATTCATTTGCCAGACTTACCAACTTAATGATG	385
OY	243	tttagagtcccatctggagcacatatctgaacatgaagccgccttgttatctccgaaga	302

	Query Match	49.0%;	Score 307;	DB 10;	Length 346;
	Best Local Similarity	96.3%;	Pred. No. 1.7e-74;		
	Matches 340;	Conservative	0;	Mismatches 3;	Indels 3;
QY	72	tctccgcgcccgcctatgagcgctccgcctgcgtctgtgagcgtgcccttctccgcggcgc	131		
Db	1	TTCTCCCGCGCCGCTCATGCGC-CNTTCCGCTCGTCCAGCGTCCCTTCTTCCCGCGCC	59		
QY	132	ttctctgggtgtgtctctctgcgcgccttggtgtgtctgtcgtgcctctctccgcataatgc	191		
Db	60	TTTCTCGGGTTGCTTTCGCGCGCCCTGTTGCTGCTGTCTCTCTTCCATCAATGC	119		
QY	192	aatgtccgcgaaatggtctcaatttgcgaagcgctcacaacctaactatgaattgaatt	251		
Db	120	AATGTCCCGGAATGGCTTCATTTTGCCAGGCGTACCAACCTAACTATGACTTTAGTTT	179		
QY	252	cccatitggacaatatcttgaactatgaatgcgcgcct-aggltatcccgagaacgcttttc	310		
Db	180	CCCAATGGGACATATCTGAACTAATGAATGCCGCGCTTGGGTTATTCCGGAAGACGTTTTC	239		
QY	311	tatcatcgcctaaaaaaccccaatcagtcctgagaaagtgtctaagagacaagtgcnaacgt-aaat	369		
Db	240	TATCATCTGCTTAAAAAACCTACGTCTGGACAAATGCTTAAGACCAAGTCAAAAT	299		
QY	370	catctgcgaatcctccagatcctgtgaatgagcattgccaattgat	415		

	Query Match	48.9%;	Score 306.4;	DB 10;	Length 389;
	Best Local Similarity	95.8%;	Pred. No. 2.6e-74;		
	Matches 345;	Conservative 0;	Mismatches 10;	Indels 5;	Gaps 3;
QY	267	cgcgaactatgatgc---cgccctggtatttcgggaagccglttt-ctatactcy-cc	321		
Db	369	CTGAAGACTGATGATGCCGCCCCCTGGTTANTCGCCGAAGACCGTTTCATCATCTGCC	310		
QY	322	ttaaaactcgtcttgcgaacagtctcgaagacaagtgcgaacgtaaacatctcgtaac	381		
Db	309	TAAAAAATCTCAGTCTGGACAAGTGTCTTAAGGACAAGTGCAAACCTAATCATGTCTGTA	250		
QY	382	ctccagatccctggtgaatgycatgycacaatgtgatcaagaagatccagttcggatccca	441		
Db	249	CTCCAGAACCTGTGTAATGGCATGTGCATCATGTGATCAAGAAGACATCCAGTTCCGATCCCAA	190		

Oy	442	ttaaattcttcgtccaaagatacgcactcatlgttcccgctcgtcgcaatgatcalca	501
Db	189	TTAAATANTTCCTCCTAAGAAGATACCGACCATGTGGTCCGTGCTGCACATGATCA	130
Oy	502	tctcaaggcaaacctgycatcttggtggataataaacacctgttttgyacagtgagttaaat	561
Db	129	TCTCAGGCCAACACTGTCATTGGGTAATAATAAACCCGTGTGGACAAGTAATTAAT	70
Oy	562	atgattctcatttctttaaaccgaatacattctaattttctcbynaataaaaaactt	621
Db	69	ATGCATTCCTAATTTCTTTACCGAATACATCTCAATTTTTCTCTGGAAATATAAAAATCTT	10

RESULT	10
7833269	541 bp
LOCUS	mRNA
DEFINITION	linear EST 16-MAR-1995
	y441a11.r1 Soares fetal liver spleen INFIS Homo sapiens CDNA clone
	IMAGE:110780 5' similar to gb:Y00816_cds1 COMPLEMENT RECEPTOR TYPE
	1 PRECURSOR (HUMAN)"; mRNA sequence.

ACCESSION T83269
SERIES T83269.1 GI:711557
KEYWORDS EST.
SOURCE human.

ORGANISM	Homo sapiens
...	...

REFERENCE

HILLIER, L., CLARK, N., DUBUQUE, T., ELLISTON, K., HAWKINS, M., HOLMANN,
EUKARYOTA; METAZOA; CHORDATA; CRANIALA; VERTEBRATA; EUCELEOSTOMI;
MAMMALIA; EUTHERIA; PRIMATES; CATARRHINI; HOMINIDAE; HOMO.

AUTHORS

L. Hillier, N. Clark, T. Dubuque, K. Elliston, M. Hawkins, M. Holmann,

TITLE	The Washu-Merck EST Project
JOURNAL	Unpublished (1995)
COMMENT	Contact: Wilson RK

4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
 Tel: 314 286 1800
 Fax: 314 286 1810
 Email: est@watson.wustl.edu
 Insert Size: 791
 High quality sequence stops: 300 Source: IMAGE Consortium, LNLN
 This clone is available royalty-free through LNLN ; contact the
 IMAGE Consortium (info@image.llnl.gov) for further information.
 Insert length: 791 Std Error: 0.00
 Seq primer: M13Rpr1
 High quality sequence stop: 300.

FEATURES	Location/Qualifiers
source	1. .541

```

/organism="Homo sapiens"
/db_xref="CDB:466397"
/db_xref="taxon:9606"
/clone="IMAGE:110780"
/clone_1ib="Soares fetal liver spleen 1NPLS"
/sex="male"
/dev_stage="20 week-post conception fetus"
/lab_host="DH10B (ampicillin resistant)"
/note="Organ: Liver and Splein; Vector: pT73d (Pharmacia)
with a modified polylinker, Site_1: Pac I; site_2: Eco RI;
1st strand cDNA was primed with a Pac I - oligo(dT) primer
[5' AACTGGAGAAATTAATTAAAGATCTTTTCTTTTCTTTT 3'] ,
double-stranded cDNA was ligated to Eco RI adaptors
(Pharmacia), digested with Pac I and cloned into the Pac I
and Eco RI sites of the modified pT73 vector. Library
went through one round of normalization. Library
constructed by Bento Soares and M.Patima Bonaldo."

```

Query Match	43.1%	Score 270.4	DB 10	Length 541
Best Local Similarity	93.9%	Pred. No. 2.9e-64		
Matches 336; Conservative	0	Mismatches 13	Indels 9	Gaps 5

[illegible]

	RESULT	11
A1735085/c	LOCUS	
DEFINITION		
A1735085	433 bp	mRNA linear EST 14-JUN-1995
aas44f69.xl Barstead aorta HPLRB6 Homo sapiens cDNA clone IMAGE:2320073.3'	similar to gp:y00816_cds1 COMPLEMENT RECEPTOR TYPE I PRECURSOR (HUMAN); mRNA sequence.	

ACCESSION	AI735085	
VERSION	AI735085.1	GI:5056545
KEYWORDS	EST.	
SOURCE	human.	
ORGANISM	Homo sapiens	

ORGANISM	Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;	
Mammalia; Eutheria; Primates; Catarrhini; Hominoidea; Homo.	
1 (bases 1 to 433)	
REFERENCE	Hillier,L., Allen,M., Bowles,L., Dubouque,T., Geisels,G., Jost,S., Mortensen,A., Pearson,W., Sanger,F., Schrempf,D., Smith,R., Staden,R., Young,I.
AUTHORS	

TITLE WashU-NCI human EST project
JOURNAL Unpublished (1997)
COMMENT Contact: Wilson RK

Washington University School of Medicine
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
Tel: 314 286 1800
Fax: 314 286 1810
Email: est@wustl.wustl.edu
This clone is available royalty-free through NIND, contact the
IMAGE Consortium (image@nind.nih.gov) for further information.
Seq primer: -40UP from Gldco
High quality sequence, stop: 60.

FEATURES	Location/Qualifiers
source	1. .433

```

/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone="IMAGE:2320073"
/clone_lib="Barstead aorta HPLRB6"
/sex="male"
/dev_stage="adult, age 64"
/lab_host="DH10B (phage resistant)"
/note="Organ: aorta; Vector: pT73D-Pac (Pharmacia) with a
modified polylinker; Site_1: EcoRI; Site_2: NotI; 1st
strand cDNA was primed with the Not I - oligo(dT) primer [5'
TGTTCAGCATCTCAATGCGACGCGCCGCCCCCTTTTTTTTTTTTTTTTTTTT
3']; double-stranded cDNA was ligated to Eco RI adaptors
[5' AATTCGATCGAAC 3' and 5' GTTGGATCGG 3'], digested
with Not I and cloned into the Not I and Eco RI sites of
the modified pT73 vector. Library constructed by Bob
Barstead."

```


[illegible][illegible]

Query Match	Best Local Similarity	56.1%	Score 352;	DB 6;	Length 6951;
Matches 410;	Conservative 0;	Mismatches 75;	Indels 3;	Gaps 1;	
QY 66	acgggggtcccgccgagcgcgtacatgagcgcgcgcgtcgtctgtagcgcgtccctccctcc	125			
DB 28	atgggggacctcttccccaagaagcccgagcgtctgagcgccgagccgagccgctccccc	87			
QY 126	cggcgcttcccggtgtgtcttctggcgcccggtgtgtc---gcttccctctcc	182			
DB 88	tctctcgtcggagatccctcgtcgcgtgtgtgtgtcgtctgacgtcgcgttgagcgttg	147			
QY 183	gatacatgcaatgctccggaatgcttccatcttgcagcgccctacaactaactatgatgc	242			
DB 148	ggtcaatgcaatgcccagaatgcttccatcttgcagcgccctacaactaactatgatgc	207			
QY 243	tttggtttcccatgtgggaacatactgaactgaatgcgcctcgtgtattccggaaga	302			
DB 208	tttggtttcccatgtgggaacatactgaactgaatgcgcgcctcgtgtattccggaaga	267			
QY 303	ccgtttctatcatctgctctaaanaaccagctcgtgacaagtgcgaagacaatggaaga	362			
DB 268	ccgtttctatcatctgctctaaanaaccagctcgtgacaagtgcgaagacaatggaaga	327			
QY 363	cgtaaatcatgtcgtaatcctccagacccctgtgaatggtcgaatggtgacatgtgacaaagac	422			
DB 328	cgtaaatcatgtcgtaatcctccagacccctgtgaatggtcgaatggtgacatgtgacaaagac	387			
QY 423	atccagtcgcgaatccccaattaaatatctgtcctaaagataccagactaatgttcc	482			
DB 388	atccagtcgcgaatccccaattaaatatctgtcctaaagataccagactaatgttcc	447			
QY 483	tcgttcgcacatgacatctctcagcgaacacgttatttggatataataaacacttgt	542			
DB 448	tcgttcgcacatgacatctctcagcgaacacgttatttggatataataaacacttgt	507			
QY 543	tgtagacag 550				
DB 508	tgtagacag 515				
<p>RESULT 2</p> <p>5472939-1</p> <p>Patent No. 5472939</p> <p>APPLICANT: FEARON, DOUGLAS T.; KLICKSTEIN, LLOYD B.; WONG, NINTE W.; CARSON, GERALD R.; CONCINO, MICHAEL F.; IP, STEPHEN ;; MAKREDES, SAVVAS; MARSH, HENRY C. JR.</p> <p>TITLE OF INVENTION: METHOD OF TREATING COMPLEMENT MEDIATED DISORDERS</p> <p>NUMBER OF SEQUENCES: 30</p> <p>CURRENT APPLICATION DATA:</p> <p>APPLICATION NUMBER: US/08/138,825</p> <p>FILING DATE: 19-OCT-1993</p> <p>PRIOR APPLICATION DATA:</p> <p>APPLICATION NUMBER: 588,128</p> <p>FILING DATE: 24-SEP-1990</p> <p>APPLICATION NUMBER: 412,745</p> <p>FILING DATE: 26-SEP-1989</p> <p>APPLICATION NUMBER: 332,865</p> <p>FILING DATE: 03-APR-1989</p> <p>APPLICATION NUMBER: 176,532</p> <p>FILING DATE: 01-APR-1988</p> <p>SEQ ID NO:1:</p> <p>5472939-1</p> <p>LENGTH: 6951</p>					

[illegible]

:
:
: AUTHORS: Lemons, R.S.
:
: AUTHORS: Seva, T.
:
: AUTHORS: Atkinson, J.P.
:
: TITLE: Molecular cloning and Chromosomal
: TITLE: Localization of Membrane Cofactor
: TITLE: Protein (MCP): Evidence for Inclusion
: TITLE: in the Multi-gene Family of
: TITLE: Complement-Regulatory Proteins.
:
: JOURNAL: Journal of Experimental Medicine
:
: VOLUME: 168
:
: PAGES: 181-194
:
: DATE: 1988
:
US-08-482-148-8

Query Match	18.8%	Score 117.6	DB 2	Length 1530
Best Local Similarity	84.6%	Pred. No. 4.5e-28		
Matches 132; Conservative	0;	Mismatches 24;	Indels 0;	Gaps 0;

QY	Db	QY	Db
44	1	104	61
tcctcctcaacccctcgcgaataaatacaagaggtctcccgccgcctcatgtagcctccgcgcg	TCCTGTTTCTCCCGAGAAATACAGAGGTCTTCGCGCCGCGGCAATGAGGCTCCCGGCG	tctcgaagctcccttccttcctcccgagccttcctcgcggttctctcagcgagccctgagtgt	CCGCGAGTGTCTCTTCTCTTCTTGCGGTTCCTCGGGTGTGTTCTGGCGGCATGTGTT
164	121	164	121
gctgctcgtcctcctctctccgcgaatacaatgcaatgctcc	gctgctcgtcctcctctctccgcgaatacaatgcaatgctcc	gctgctcgtcctcctctctccgcgaatacaatgcaatgctcc	gctgctcgtcctcctctctccgcgaatacaatgcaatgctcc

RESULT 12
PCT-US95-02944-8

```

? GENERAL INFORMATION:
? APPLICANT: Rother, Russell
? APPLICANT: Rollins, Scott
? APPLICANT: Squinco, Stephen P
? TITLE OF INVENTION: Terminal Complement
? TITLE OF INVENTION: Inhibitor Fusion Genes and Proteins
? NUMBER OF SPOUSNCES: 14
? CORRESPONDENCE ADDRESS:
? ADDRESSEE: Maurice M. Klee
? STREET: 1951 Burr Street
? CITY: Fairfield
? STATE: Connecticut
? COUNTRY: USA

```

STRADENESS: Double
TOPOLOGY: Linear
MOLECULE TYPE: cDNA to mRNA
DESCRIPTION: MCP (CD46) full length cDNA
HYPOTHEICAL: No
ANTI-SENSE: No
ORIGINAL SOURCE:
ORGANISM: Homo sapiens
PUBLICATION INFORMATION:
AUTHORS: Lublin, D.M.
AUTHORS: Liszewski, M.K.
AUTHORS: Post, T.W.
AUTHORS: Arce, M.A.
AUTHORS: Lebeau, M.M.
AUTHORS: Rebentisch, M.B.
AUTHORS: Lemons, R.S.
AUTHORS: Seya, T.
AUTHORS: Atkinson, J.P.
TITLE: Molecular cloning and Chromosomal
TITLE: Localization of Membrane Cofactor
TITLE: Protein (MCP): Evidence for
TITLE: Inclusion in the Multi-Gene Family
JOURNAL: Journal of Experimental Medicine
VOLUME: 168
PAGES: 181-194
DATE: 1988
PCT-US95-02944-8

Query Match	18.8%;	Score 117.6;	DB 5;	Length 1530;
Best Local Similarity	84.6%;	Pred. NO. 4.5e-28;		
Matches 132; Conservative	0;	Mismatches 24;	Indels 0;	Gaps 0

QY	44	tctgcgcaccttcgcgaataacacagggatctccgcgcgcgcacaaatggcgcctccgcgtccg	103
Db	1	TGTGTTTCTCTCGGAGAAATACAGGGTCTTCGGCGCGCATGGAGGCTCCCGGGCGC	60
QY	104	tctgcgagtcctctctctctctccgcgcgccttccttggtatgtctctcggcggcgcgcgtgtc	165
Db	61	CGCGGAGTGTCCCTTCTCTCTCTCGCCCTTTCCTCGGGGTGGTCTTCTGCGCGCATGGTGT	120
QY	164	gctcgtctctctctctctcgcataatgcaatgtccc	199
Db	121	GCATGCTGTACTCTTCTCCGATGTGCTCTGGAGAGCC	156

COUNTRY: USA
ZIP: 06430
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch, 720 Kb storage
COMPUTER: Dell 486/50
OPERATING SYSTEM: DOS 6.2
SOFTWARE: Word Perfect 6.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US95/02944
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/205,720
FILING DATE: 3-MAR-1994
CLASSIFICATION:
ATTORNEY/AGENT INFORMATION:
NAME: Klee, Maurice M.
REGISTRATION NUMBER: 30,399
REFERENCE/DOCKET NUMBER: ALX-199PCT
TELECOMMUNICATION INFORMATION:
TELEPHONE: (203) 255 1400
TELEFAX: (203) 254 1101
INFORMATION FOR SEQ ID NO: 8:
SEQUENCE CHARACTERISTICS:
LENGTH: 1530 base pairs
TYPE: Nucleic Acid

RESULT 13
PCT-US95-02945-3
Sequence 3, Application PC/TUS9502945
GENERAL INFORMATION:
APPLICANT: Fodor, William L
APPLICANT: Rollins, Scott
APPLICANT: Squinto, Stephen P
TITLE OF INVENTION: Chimeric Complement
TITLE OF INVENTION: Inhibitor Proteins
NUMBER OF SEQUENCES: 19
CORRESPONDENCE ADDRESS:
ADDRESSEE: Maurice M. Klee
STREET: 1951 Burr Street
CITY: Fairfield
STATE: Connecticut
COUNTRY: USA
ZIP: 06430
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch, 750 Kb storage
COMPUTER: Dell 486/50
OPERATING SYSTEM: DOS 6.2
SOFTWARE: WordPerfect 6.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US95/02945
FILING DATE:
CLASSIFICATION:

```

? PRIOR APPLICATION DATA:
? APPLICATION NUMBER: 08/205,508
? FILING DATE: 3-MAR-1994
? CLASSIFICATION:
? ATTORNEY/AGENT INFORMATION:
? NAME: Klee, Maurice M.
? REGISTRATION NUMBER: 30,399
? REFERENCE/DOCKET NUMBER: ALX-120PCT
? TELECOMMUNICATION INFORMATION:
? TELEPHONE: (203) 255-1400
? TELEFAX: (203) 254-1101
? INFORMATION FOR SEQ ID NO: 3:
? SEQUENCE CHARACTERISTICS:
? LENGTH: 1530 bases
? TYPE: Nucleic Acid
? STRADEDNESS: Double
? TOPOLOGY: Linear
? MOLECULE TYPE: cDNA to mRNA
? DESCRIPTION: MCP (CD46) full length cDNA
? HYPOTHEICAL: NO
? ANTI-SENSE: NO
? ORIGINAL SOURCE:
? ORGANISM: Homo sapiens
? PUBLICATION INFORMATION:
? AUTHORS: Lublin, D.M.
? AUTHORS: Liszewski, M.K.
? AUTHORS: Post, T.W.
? AUTHORS: Arce, M.A.
? AUTHORS: LeBeau, M.M.
? AUTHORS: Rebentisch, M.B.
? AUTHORS: Lemons, R.S.
? AUTHORS: Seya, T.
? AUTHORS: Atkinson, J.P.
? TITLE: Molecular cloning and Chromosomal
? TITLE: Localization of Membrane cofactor
? TITLE: Protein (MCP): Evidence for
? TITLE: Inclusion in the Multi-Gene Family
? TITLE: of Complement-Regulatory Proteins.
? JOURNAL: Journal of Experimental Medicine
? VOLUME: 168
? PAGES: 181-194
? DATE: 1988
? PCT-US95-02945-3
?
? Query Match 18.8%; Score 117.6; DB 5; Length 1530;
? Best Local Similarity 84.6%; Pred. No. 4.5e-28;
? Matches 132; Conservative 0; Mismatches 24; Indels 0; Gaps 0;
?
? 44 tctgtcaacttcgcgataatactacgagggtctccgcgcgcgtcatcattgagcctccgctccg 103
? ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
? Db 1 tctgttttccttcgcgagaataatcagccgttcctccgcgcgcacatcgaacccctccggcg 60
?
? QY 104 tctcgaagctcccttccttcctccgcgcgcgtcttcctggttgccttcggcgagccctgagt 163
? ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
? Db 61 ccgcgaagtgcccttctctctccctgctgacgcttctcctgggttcgttcgagggccatggtgt 120
?
? QY 164 gctcgtctcctctccttcctccgatcaatgcagtcc 199
? ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
? Db 121 gctgctgacgttccttcgcgattgcctgtgagagacc 156
?
? RESULT 14
? 5514787-1
? Patent No. 5514787
? APPLICANT: ATKINSON, JOHN P.
? TITLE OF INVENTION: DNA SEQUENCES ENCODING HUMAN MEMBRANE
? COFACTOR PROTEIN (MCP)
? NUMBER OF SEQUENCES: 2
? CURRENT APPLICATION DATA:
? APPLICATION NUMBER: US/07/948,350
? FILING DATE: 21-SEP-1992
? PRIOR APPLICATION DATA:
?

```

```

: APPLICATION NUMBER: 384,210
: FILING DATE: 21-JUL-1989
: SEQ ID NO:1
: LENGTH: 1546
514787-1

Query Match      18.8%; Score 117.6; DB 6; Length 1546;
Best Local Similarity 84.6%; Pred. NO. 4.5e-28;
Matches 132; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

OY 44 tctgtcacctccgataatcacggggtctcccgccgcgtcatgagcctcccgctcg 103
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 1 tctgttctccctccggagataaacgagctcttcgcgcgcgcatgagagctcccgcg 60
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

OY 104 tctgagcgtcccttctcctcccgcgcttctcgtgtgtctcttgaggccctgtgt 163
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 61 ccgcgaggtctcccttctcctcccgcgcttctcgtgtgtctcttgaggccatgtgt 120
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

OY 164 gctgtctccctctcccgatcatgcatgtccc 199
||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 121 gctgtctactcctctccgatgctgtcgaggagcc 156
||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

RESULT 15
US-08-435-149-17
: Sequence 17, Application US/08435149
: Patent No 5866402
: GENERAL INFORMATION:
: APPLICANT: INNIS, MICHAEL A.
: APPLICANT: ZAROR, ISABEL
: APPLICANT: CREASEY, ABILA A.
: TITLE OF INVENTION: CHIMERIC MCP AND DAF PROTEINS WITH CELL
: TITLE OF INVENTION: SURFACE LOCALIZING DOMAIN
: NUMBER OF SEQUENCES: 26
: CORRESPONDENCE ADDRESS:
: ADDRESSEE: CITRON CORPORATION
: STREET: INTELLECTUAL PROPERTY - R440, P.O. BOX 8097
: CITY: EMERYVILLE
: STATE: CALIFORNIA
: COUNTRY: U.S.A.
: ZIP: 94662-8097
: COMPUTER READABLE FORM:
: MEDIUM TYPE: Floppy disk
: COMPUTER: IBM PC compatible
: OPERATING SYSTEM: PC-DOS/MS-DOS
: SOFTWARE: Patent Release #1.0, Version #1.25
: CURRENT APPLICATION DATA:
: APPLICATION NUMBER: US/08/435,149
: FILING DATE: 05-MAY-1995
: CLASSIFICATION: 530
: ATTORNEY/AGENT INFORMATION:
: NAME: SAVEREIDE, PAUL B.
: REGISTRATION NUMBER: 36,914
: REFERENCE/DOCKET NUMBER: 0989,001
: TELECOMMUNICATION INFORMATION:
: TELEPHONE: (510) 601-2565
: TELEFAX: (510) 655-3542
: TELEX: N/A
: INFORMATION FOR SEQ ID NO: 17:
: SEQUENCE CHARACTERISTICS:
: LENGTH: 1878 base pairs
: TYPE: nucleic acid
: STRANDEDNESS: single
: TOPOLOGY: linear
: MOLECULE TYPE: DNA (genomic)
US-08-435-149-17

Query Match      18.6%; Score 116.6; DB 2; Length 1878;
Best Local Similarity 84.5%; Pred. NO. 1.1e-27;
Matches 131; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

```


